Company

About

199 Biotechnologies

199 Biotechnologies

London, England, United Kingdom

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

1ST Biotherapeutics

1ST Biotherapeutics

Yongin-si, Gyeonggi-do, South Korea

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

20/20 Gene Systems

20/20 Gene Systems

Rockville, Maryland, United States

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

3billion

3billion

Seoul, South Korea

3billion is revolutionizing the existing methods and procedures to enable more people to benefit from faster and much accurate diagnosis at an affordable cost. [Who is 3billion?] - 3billion provides an AI-driven clinical diagnostic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases for patients and physicians in need. - 3billion reanalyzes the undiagnosed patients’ genomic data every day without any additional charge. About 10% of undiagnosed patients can receive diagnosis by reanalysis. - More than 40,000 rare diseases patients from more than 60 countries have been tested. - More than 93% of acceptance rate on the 3billion’s test report by physicians. - 3billion has been collaborating with 100 medical institutions across 33 countries to make a diagnosis for rare disease patients. [Core Technology Features] - 3billion has expertise in medical genetics. We have streamlined the analysis pipeline using an automated variant prioritization system and are currently leading diagnostic technology by developing a pathogenicity prediction model of human variants. - 3billion devised a variant interpretation system, EVIDENCE, to automate the process. With the help of EVIDENCE, the variant interpretation takes less than 5 minutes per patient on average. - The EVIDENCE produces consistent variant interpretation according to the current medical guideline, ACMG-AMP interpretation guideline. 3billion's medical geneticist gives the diagnosis and confirms reported variants by Sanger validation (Richards S et al, 2015). - The analysis reflects the latest updates on diseases and genetic variants on daily basis. If any diagnosed case is identified through reanalysis, 3billion provides a report without any additional charge. - We offer Whole Exome Sequencing (WES) & Whole Genome Sequencing (WGS) for rare disease diagnosis. - Web-based portal service – easy access from all over the world. For any inquires, please contact us at support@3billion.io

3CPM

3CPM

Sparks, Maryland, United States

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

3Z Pharmaceuticals

3Z Pharmaceuticals

Reykjavík, Iceland

3Z uses advanced disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.

4D Lifetec

4D Lifetec

Cham, Switzerland

About 4D Lifetec AG 4D Lifetec is a pioneer on a mission to revolutionize early cancer detection. Our easy and powerful blood tests can detect cancer at its earliest stages (I and II), offering you peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment.

4P-Pharma

4P-Pharma

Lille, France

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

908 Devices

908 Devices

Boston, Massachusetts, US

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

A2A Pharma

A2A Pharma

New York, United States

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

A-Alpha Bio

A-Alpha Bio

Seattle, Washington, United States

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Abalone Bio

Abalone Bio

Emeryville, California, United States of America

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Ability Biologics

Ability Biologics

Montreal, Quebec

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Abiologics

Abiologics

Cambridge, Massachusetts, US

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

Absci

Absci

Vancouver, Washington, United States

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Abterra Biosciences

Abterra Biosciences

San Diego, California, United States

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

Accel Diagnostics, LLC

Accel Diagnostics, LLC

Houston, Texas, United States

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

AccuPulse Medical Inc

AccuPulse Medical Inc

9 West Suhong Road, 201, West wing, Building 6, Suzhou, Jiangsu, CN

Founded in November 2020, AccuPulse is dedicated to become a globally leading innovator in cardiac electrophysiology industry. The core team members come from companies such as J&J, GE, Acutus Medical and Abbott with in-depth experience in R&D, registration and commercialization of cardiac electrophysiological medical devices. The company has built R&D centers in both China and the United States, and the company is backed by top scientists, physicians and famous venture capital firms.

Accutar Biotech

Accutar Biotech

Shanghai, Shanghai, China

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

AcelaBio

AcelaBio

San Diego, California, United States

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Acellera Therapeutics

Acellera Therapeutics

Dr. Trueta 183, 7th floor, #5, Barcelona, Barcelona 08005, ES

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

Acelot

Acelot

329 Oyster Point Blvd, South San Francisco, California 94080, US

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

Achilles Therapeutics

Achilles Therapeutics

London, England, United Kingdom

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Achira

Achira

New York, New York, United States

Achira is building atomistic foundation simulation models to power the future of drug discovery.

Acorai

Acorai

Helsingborg, Sweden

Acorai is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. Our product can monitor cardiac and pulmonary pressure sensing non-invasively through a machine-learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement, and a fast track to commercialization.

AcroViz Inc.

AcroViz Inc.

AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health span with state-of-art technologies. Comprising eminent academia researchers and experienced industrial professionals, the team is devoted to advancing scientific research, maximizing its clinical significance and application, as well as commercialization to achieve extended positive impact. The first product: AcroViz Axonal Brain Age – Brain Health Report, is the first to the market that adopting diffusion Magnetic Resonance Imaging (dMRI) and Machine Learning techniques to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk and prognosis of dementia, such as Alzheimer's Disease (AD). Web acroviz.com/en/ FB www.facebook.com/acroviz IG www.instagram.com/acroviz_brainhealth YT www.youtube.com/@acroviz LINE https://lin.ee/T2Ttyyj

Activ Surgical

Activ Surgical

Boston, Massachusetts, United States

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Actnova

Actnova

South Korea

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

AcuraStem

AcuraStem

Monrovia, California, United States

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Adaptive Clinical Systems

Adaptive Clinical Systems

2875 Ashton Rd. Unit 20322 , Sarasota, Florida 34231, US

Adaptive Clinical Systems, a global life sciences technology company, offers a simple, secure, validated, compliant and cost-effective solution for data interoperability as well as reporting and visualization for clinical trials. Adaptive Clinical offers the Adaptive eClinical Bus and Adaptive DataVIEW. The Adaptive eClinical Bus®, a cloud-based hosted service, will integrate with any EDC, eCOA, CTMS, ePRO/IWRS, Medical Imaging, IRT, Analytics, Data Acquisition Systems as well as RWD, EHR/EMR to reduce error and speed data management for any size study. With the Adaptive eClinical Bus, patient- centric clinical trials can ensure interoperability and full compliance from the many diverse eSources generated from the explosion of data from Digital Health Technologies (DHTs), such as wearables and remote patient monitoring (RPM) solutions. Key benefits of the Adaptive eClinical Bus include: ✔️ Fully-validated Platform with Detailed Audit Logs and Reports ✔️ Fully compliant with HHS 45 CFR Part 64, FDA 21 CFR Part 11, GxP and other regulatory guidelines ✔️ Standards-based for Interoperability ✔️ Easily Implement an eSource Data Capture Workflow ✔️ Adaptive Rules Engine offers Built-in Clinical Intelligence ✔️ Reusable components for Quick Installation ✔️ Full training and 24/7 support Adaptive DataVIEW provides a robust solution for visualizing and analyzing data from disparate sources quickly and efficiently. It provides real-time, bi-directional data from many disparate sources into comprehensive dashboards. Purpose built for clinical trial operational key performance indicators and dashboards. Reports can be created at the patient, site, study or program level, including across studies. Adaptive DataVIEW enables "single click-back" from any widget or dashlet to the data source regardless of eClinical tool.

Adaptive Phage Therapeutics

Adaptive Phage Therapeutics

Gaithersburg, Maryland, United States

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

Ad Astra Diagnostics

Ad Astra Diagnostics

Morrisville, North Carolina, United States

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Adimab

Adimab

Lebanon, New Hampshire, United States

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

Adjuvant Partners

Adjuvant Partners

1340 Smith Ave, Suite 200, Baltimore, MD 21209, US

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

Admetsys

Admetsys

21 dry dock avenue, boston, massachusetts, united states, 02210

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

AeroFarms

AeroFarms

Newark, New Jersey, United States

AeroFarmsis an indoor vertical farming company. They usea patented aeroponic growing system to grow produce.

Aether Bio

Aether Bio

Menlo Park, California, United States

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

Afecta Pharmaceuticals

Afecta Pharmaceuticals

Irvine, California, United States

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Affinia Therapeutics

Affinia Therapeutics

Waltham, Massachusetts

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

AgBiome

AgBiome

Research Triangle Park,, North Carolina, United States

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

AgeCurve

AgeCurve

IDEASPACE CITY, 3 LAUNDRESS LN, CAMBRIDGE, CB2 1SD, GB

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Age Labs

Age Labs

Oslo, Norway

Aging is the main cause behind most illnesses that eventually kill us. Your chance of dying doubles every 8 years. By the time you turn 80, half of your peers are dead. However, it turns out aging is a biological process, amenable to treatment. Research has demonstrated that we can postpone the onset of age-related disease. Lab mice know this already. Experiments with caloric restriction, senolytics and metabolic inhibitors have extended life and reversed aging - in mice. But how do we know these treatments will work in humans? We can wait and see if patients receiving these new treatments die later. Or see if onset of age-related disease is postponed. But this is slow. It takes many, many years to know for sure if the treatments work. Wouldn’t it be great if we had a faster way? Thanks to the discovery of the epigenetic clock, we can now accurately describe changes to gene regulation caused by aging. By turning this discovery into a blood test, we can measure the exact aging status inside human cells. This will be incredibly useful to researchers involved in aging research. They would know if a treatment works, much earlier than before. So that’s what we’re making: A biomarker for aging which is accurate, affordable and quick.

Agilis Robotics

Agilis Robotics

hong kong, new territories, hong kong

Agilis Robotics is a spin-off company from The University of Hong Kong that develops flexible robotic instruments for endoscopic surgery. We aim to provide clinicians with enhanced robotic dexterity and precision while leveraging current clinical workflows.

a:head bio

a:head bio

Vienna, Austria

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

AI2 Incubator

AI2 Incubator

Seattle, Washington, United States

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis

A.I. Analysis

Seattle, Washington, United States

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry

Aiberry

Bellevue, Washington, United States

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

Ai-biopharma

Ai-biopharma

104, Rue de la Galera, Montpellier, Occitanie 34090, FR

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

Aiforia Technologies

Aiforia Technologies

Pursimiehenkatu 29-31, Helsinki, 00150, FI

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

Aigen

Aigen

Kirkland, Washington, United States

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

AIGEN Sciences Inc.

AIGEN Sciences Inc.

Office 507, 25 Ttukseom-ro 1-gil, Seongdong, Seoul Teugbyeolsi, KR, 04778

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Aignostics

Aignostics

Berlin, Germany

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

AILIS Care

AILIS Care

ul. Grabowa, 8, Kraków, Małopolska 30-227, PL

AILIS is a pioneering technology. It combines Dynamic Parametric Imaging, artificial intelligence, and telemedicine to immediately detect symptoms of breast cancer and estimate the risk of developing the illness. Our mission is to provide women with dense breasts with access to efficient and comfortable testing based on imaging that detects early symptoms of breast cancer, and to guarantee them with comprehensive care in terms of monitoring their health. Technologies that change the world are always a result of long and hard work of a team of non-accidental people. At AILIS, everyone has a purpose. We are a team of experts and specialists in a number of fields and we share common values. At AILIS, we share common values and principles that we follow in everyday work. To protect the health of millions of women in an honest, responsible, and respectful way. Never to lose our passion for science. And to develop a technology that is authentic in terms of its mission, as well as a service that will become a synonym for protectiveness.

Ainnocence

Ainnocence

San Jose, California, US

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos

Ainos

San Diego, California

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Aiosyn

Aiosyn

Nijmegen, Netherlands

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

AI Proteins, Inc.

AI Proteins, Inc.

Boston, Massachusetts, United States

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

aitiologic

aitiologic

Karl-Farkas Gasse 18, Vienna, 1030, AT

aitiologic is an Austrian precision medicine startup developing ai-powered solutions for early disease detection and targeted therapy.

Aizen Therapeutics

Aizen Therapeutics

9276 Scranton Rd, San Diego, California 92121, US

We are creating a new category of medicines with the application of spatial biology and AI.

Aizon

Aizon

San Francisco, California

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Alabama A&M University

Alabama A&M University

Huntsville, Alabama, United States

Alabama Agricultural and Mechanical University(AAMU) is a historic, student-friendly and community-focused institution of higher learning. Reflecting on its heritage as a historical black college and university (HBCU) and a traditional 1890 land-grant institution, AAMU functions as a teaching, research and public service institution, including extension.

Alcedis - a HUMA company

Alcedis - a HUMA company

2 winchesterstrasse, giessen, hesse, germany

With over 30 years of experience, Alcedis combines medical expertise with ground-breaking technologies to pioneer data-driven clinical research. Our module-based service concept and flexible data capture systems adapt seamlessly to any project structure and accompany your entire research process - from Phase I to drug approval and beyond market access into real-world evidence.

Alexion Pharmaceuticals

Alexion Pharmaceuticals

Boston, Massachusetts, United States

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Alex Therapeutics

Alex Therapeutics

Stockholm, Sweden

At Alex Therapeutics we provide digital health solutions that enable pharmaceutical companies to better support their products, and their patients. Leveraging our proven modular technology platform allows partners to reduce time-to-market and enables frictionless deployment of safe, secure and effective digital health products. Over 100,000 patients have used our products globally, with our best-in-class user experience design ensuring better health engagement and outcomes.

Algorithmic Biologics

Algorithmic Biologics

Bangalore, Karnataka, India

Algorithmic Biologic's vision is to create a bountiful and healthy world by bringing scale efficiencies to molecular discovery and diagnostics. Our transdisciplinary team has a deep modeling-based understanding of the chemistry and mechanics of molecular technologies. Our first product, Tapestry, is award-winning, regulatory approved algorithmic solution to provide affordable large-scale COVID-19 testing.

Alife

Alife

South San Francisco, California, United States

Building a modern operating system for IVF, powered by artificial intelligence.

Aliri Bioanalysis

Aliri Bioanalysis

4720 forge road, suite 108, Colorado springs, CO 80907, US

Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions.

AliveCor

AliveCor

San Francisco, California, United States

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

Alkermes plc

Alkermes plc

Dublin, Ireland

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Alli Connect

Alli Connect

Seattle, Washington, United States

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Alltrna

Alltrna

Cambridge, Massachusetts

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Allurion Technologies

Allurion Technologies

Natick, Massachusetts, United States

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

Alphatec Spine

Alphatec Spine

Carlsbad, California, United States

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Alpinion Medical Systems

Alpinion Medical Systems

15, Magokjungang 14-ro, Seoul, Gangseo-gu 07789, KR

Technology that leverages customer value. ALPINION's an innovative and recognized ultrasound brand ‘E-CUBE' principles (‘Extreme Clarity', ‘Efficient Workflow', ‘Ergonomic Design') reflect ALPINION's technological philosophy that provides customers with uniform image quality throughout the product lifetime. ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted attention to the front-end with a focus on the signal quality sent to system processors. ALPINION focuses on continuous innovation in acoustic technology. ALPINION has developed a range of transducer array types and applied them to ALPINION's innovative E-CUBE series of ultrasound systems. Based upon proprietary superior acoustic technology, ALPINION continuously strives to expand the medical business from diagnostic ultrasound to therapeutic ultrasound.

Altoida

Altoida

Washington, District of Columbia, United States

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Alto Neuroscience

Alto Neuroscience

Los Altos, California, United States

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Aluna

Aluna

345 CALIFORNIA ST, SAN FRANCISCO, Ca 94104, US

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

Amadix

Amadix

2 Acera de Recoletos St, 1B, Valladolid, Castilla y León 47004, ES

AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.

Amai proteins

Amai proteins

Rehovot, Israel

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

Amberstone Biosciences

Amberstone Biosciences

Laguna Hills, California, United States

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Amgen

Amgen

Thousand Oaks, California, United States of America

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Ampersand Biomedicines

Ampersand Biomedicines

Ampersand Biomedicines, 245 First Street, Suite 1800, Cambridge, MA 02142

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Amphista Therapeutics

Amphista Therapeutics

Cambridge, Cambridgeshire, United Kingdom

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Amplified Sciences

Amplified Sciences

West Lafayette, Indiana, United States

Imagine a world in which devastating disease such as cancer is detected sooner; thus, providing doctors the ability to treat patients earlier with better outcomes. Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases. The company leverages IP licensed from Purdue University and has developed a platform that can scale to point of care. The lead assay is an ultra-sensitive molecular sensing technology revolutionizing #pancreaticcancer. Enabling early detection of debilitating diseases across oncology and chronic kidney disease.

Amplitude Venture Capital

Amplitude Venture Capital

Montreal, Canada

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

AMPLY Discovery

AMPLY Discovery

63 University Road, Belfast BT7 1NF, Northern Ireland, United Kingdom

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

AMRA Medical

AMRA Medical

Badhusgatan 5, Linköping, 58222, SE

AMRA Medical is a health informatics company founded in 2010, originating from Linköping University in Sweden. With a team of over 30 employees and a global presence, AMRA specializes in AI-driven medical imaging and precision medicine, particularly in advanced MRI analytics for body composition assessment. The company has achieved regulatory clearances, including CE-Marked medical device status, and collaborates with major industry players like Pfizer Inc. AMRA offers next-generation phenotyping that utilizes AI to analyze whole-body MRI scans, providing precise fat and muscle biomarkers for personalized health insights. Their cloud-based platform ensures secure, quality-controlled results with a quick turnaround and is compatible with various MRI scanners. The company also develops imaging biomarkers and disease phenotypes through partnerships, aiming to create a global representative database. Under the leadership of CEO Eric Converse and co-founders Magnus Borga and Olof Dahlqvist Leinhard, AMRA focuses on equipping clinicians and researchers with actionable data to manage conditions such as obesity and metabolic disorders.

Amsterdam UMC

Amsterdam UMC

New Hampshire, US

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care. For the generations of today and tomorrow. The two medical university centers in Amsterdam, AMC and VUmc, are working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites - AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

Amyl Therapeutics

Amyl Therapeutics

Ougrée, Walloon Region, Belgium

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Anatomise Biostats

Anatomise Biostats

71-75 Shelton Street, London, England WC2H 9JQ, GB

Welcome to Anatomise Biostats. Our biostatistics services are designed to support Biopharma and Medtech/Medical Device SMEs and start-ups in their R&D and clinical trials projects throughout the regulatory approval process and beyond. 💡 Our Mission: We aim to facilitate innovation in the life sciences sector while assuring patient benefit and safety, offering unwavering support throughout your journey. 🌐 Who We Serve: Our services cater exclusively to Biopharma and Medtech/Medical Device SMEs and start-ups, and are fine-tuned to address unique industry challenges as they arise. 📈 Specialized Expertise: Our team of biostatistics and bioinformatics experts ensures data-driven precision in your R&D and clinical trials. 🔍 Navigating Regulatory Waters: We guide you through evolving regulatory requirements with confidence. 🤝 Dedicated Partnership: We're not just consultants; we're committed to the success of your project and longer-term pipeline. 🌟 Results-Focused: Our focus is on delivering accurate insights for informed decision-making. Ready to embark on your life sciences journey? Connect with Anatomise Biostats today, and let's chart a course to success together. #Biostatistics #Bioinformatics #LifeSciences #Medtech #Biopharma #BiometricsConsulting #RegulatoryApproval #ClinicalTrials #FunctionalServiceProvider

AngioInsight

AngioInsight

601 Carlson Parkway, Suite 1290, Minnetonka, Minnesota 55305, US

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

Anivive Lifesciences

Anivive Lifesciences

Long Beach, California, United States

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Antiverse

Antiverse

34 Roath Court Road, Cardiff, Wales, GB, CF24 3SD

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Anumana

Anumana

Cambridge, Massachusetts, United States

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana recently acquired NeuTrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With nference's proprietary nSights real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making. Anumana's 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.

Anx Robotica

Anx Robotica

Plano, Texas, United States

Are you ready for a transformative leap in small bowel capsule endoscopy? Meet ProScan, our cutting-edge AI Assisted Reading Tool meticulously designed to revolutionize the diagnostic process for patients suspected of small bowel bleeding. ProScan leverages advanced artificial intelligence algorithms to significantly reduce the time required for reviewing capsule endoscopy studies, enabling quicker and more precise diagnoses. It is meticulously engineered to expedite the evaluation of capsule endoscopy images, enhancing the timeliness of a diagnosis and initiation of therapy. Headquartered in Plano, Texas, AnX Robotica brings versatility in development and integration of multi-discipline technologies such as precise magnetic, robotic control, in house ASIC design, artificial intelligence, micro-optical imaging, image processing, and wireless transmission. With more than 200 patents granted or applications pending, and dozens of clinical papers published in major international journals, AnX Robotica, together with its sister companies, have become the leading companies in robotic capsule technology.

Apertura Gene Therapy

Apertura Gene Therapy

New York, New York

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

Apis Assay Technologies

Apis Assay Technologies

Manchester, United Kingdom

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

AppHarvest

AppHarvest

Morehead, Kentucky, United States

AppHarvest is a sustainable food company in Appalachia developing and operating some of the world’s largest high-tech indoor farms with robotics and artificial intelligence to build a reliable, climate-resilient food system. AppHarvest’s farms are designed to grow produce using sunshine, rainwater and up to 90% less water than open-field growing, all while producing yields up to 30 times that of traditional agriculture and preventing pollution from agricultural runoff. AppHarvest currently operates its 60-acre flagship farm in Morehead, Ky., producing tomatoes, a 15-acre indoor farm for salad greens in Berea, Ky., a 30-acre farm for strawberries and cucumbers in Somerset, Ky., and a 60-acre farm in Richmond, Ky., for tomatoes. The four-farm network consists of 165 acres under glass. AppHarvest is a public benefit corporation and a Certified B Corp.

Applied Surgical Robotics

Applied Surgical Robotics

san diego, california, united states

Applied Surgical Robotics is a MedTech company focused on developing robotic technology and SaaS software solutions to improve surgical precision.

April 19

April 19

Calgary, Canada

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.

Apriori Bio

Apriori Bio

Cambridge, Massachusetts

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

AQEMIA

AQEMIA

1 Boulevard Pasteur, 75015 Paris

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia

Aquavit Pharmaceuticals, Inc

Aquavit Pharmaceuticals, Inc

145 West, 57TH Street, New York, New York, USA, 10019

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Arbor Biotechnologies

Arbor Biotechnologies

Cambridge, Massachusetts, US

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Archon Biosciences

Archon Biosciences

Seattle, WA

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arctic Therapeutics

Arctic Therapeutics

Reykjavik, Iceland

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development, as well as sharply reducing the enormous cost and time to bring effective treatments to millions of patients. AT leverages over 20 years of international genomics research, pioneering a novel approach to guide its drug development. The company collaborates closely with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia to repurpose and develop ground-breaking new medical treatments. AT-001, AT's Alzheimer‘s drug candidate, has the potential to become the first cure for dementia, not only treating the disease but preventing it. AT was founded by one of the leading minds in applied genomics, Dr. Hakon Hakonarson, who launched CAG in 2006 and established it as the largest paediatric biobank and genomic database in the world.

Arctoris

Arctoris

120E Olympic Avenue, Milton Park, Abingdon, Oxfordshire, England OX14 4SA, GB

Arctoris Ltd is a biotechnology company founded in 2016 and based in Oxford, UK, with additional locations in Singapore, Boston, and Abu Dhabi. It operates as a tech-enabled Partnership Research Organization (PRO) and utilizes its proprietary Ulysses platform, the first fully automated drug discovery platform, to enhance research and development processes for biotech, pharmaceutical, and academic partners. The company employs over 40 experts in various fields, including cellular and molecular biology, biochemistry, and machine learning. Arctoris offers services such as Experiments-as-a-Service, integrated drug discovery, and collaborative R&D, providing end-to-end support from target identification to preclinical candidate development. The Ulysses platform combines robotics and advanced data science to deliver high-quality datasets, reducing human error and accelerating project timelines. Arctoris collaborates with biotech startups, large pharmaceutical companies, and AI-driven drug discovery firms, focusing on oncology, neurology, and other therapeutic areas.

Arda Therapeutics

Arda Therapeutics

San Francisco Bay Area, California, United States

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Ardigen

Ardigen

San Bruno, California, United States

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

Argon AI

Argon AI

318 Grand Street, Brooklyn, New York, NY 11211

Argon AI is a platform that allows biopharmacy and life sciences experts to conduct complicated, data-driven operations. They help life sciences companies automate their data-intensive workflows with unprecedented AI.

Ariana Pharma

Ariana Pharma

Boston, Massachusetts, United States

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

AriBio

AriBio

Seongnam-si, Gyeonggi-do, South Korea

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

Aromarc Therapeutics

Aromarc Therapeutics

ArrePath

ArrePath

303a College Rd E, Princeton, New Jersey 08540, US

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Arrow Dx

Arrow Dx

Boston, Massachusetts, United States

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

Arsenal Biosciences

Arsenal Biosciences

South San Francisco , CA

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Artera

Artera

1025 Chapala Street

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Arterys

Arterys

San Francisco, California, United States

Arterys was founded to facilitate the global advancement of medicine through data, artificial intelligence and technology. Because a significant proportion of the world's medical data resides in medical images, Arterys set out to tackle several issues around the space, including the enormous workloads radiologists face, the lack of accuracy with many of today's tools, and the need for increased consistency across practices. The company was the first to receive FDA clearance for a cloud-based product with Artificial Intelligence, and currently has 8 FDA clearances, and is active in 118 countries. Arterys continues to focus on solving some of radiology's most pressing needs. We deliver the most comprehensive set of clinical AI solutions in the industry, built off a single platform and user interface that focuses on users with seamless workflow integration and a unified and optimized UI for every one of our applications. By making imaging diagnostics quantitative, intelligent and available, we empower healthcare organizations to improve physicians' experience, patient outcomes, efficiency, and reduce costs with cloud and AI. Arterys has offices in San Francisco, Calgary and Paris. For more information, please visit www.arterys.com. Follow Arterys on Twitter at @ArterysInc at https://twitter.com/ArterysInc.

Artificial

Artificial

Austin, Texas, United States

Artificial accelerates the pace of life science discoveries by making connecting and orchestrating labs easy with its cloud-based software platform, the Artificial Product Suite. As a vendor-agnostic platform, the Artificial connects with any native instruments, devices, databases, and informatics to provide a single, easy-to-use orchestration layer for the entire lab. Using Artificial, scientific labs can control and monitor their processes in real-time while capturing AI-ready data and keeping humans in the loop.

Artos

Artos

Artos HQ, Omaha, Nebraska

Artos helps clinical development and medical writing teams turn their data into regulatory submissions in days instead of weeks. Life sciences companies spend $13 billion and millions of man-hours each year on regulatory submissions for health agencies. At Artos, we build AI and software tools to shrink those timelines so that life-saving treatments can get to patients sooner.

ARUP Laboratories

ARUP Laboratories

Salt Lake City, Utah, United States

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

Arxspan

Arxspan

5a Crystal Pond Road, Southborough, MA 01772, US

Arxspan provides cloud-based solutions to meet the scientific data management needs of leading life sciences, chemicals, and scientific companies globally. Arxspan offers ArxLab®, a suite of web-based scientific informatics applications, allowing scientists to record, manage, and share their research data​: * Notebook - Intuitive electronic laboratory notebook (ELN) optimized for collaborative models in current research environments * BioReg/ChemReg Registration - Configurable repository for registering unique chemical/biological entities and subsequent batches * Assay - Flexible system for registering assay protocol and result data * Inventory - Comprehensive tool for defining and managing chemical and biological compounds, reagents, equipment, and other items * Search - Robust decision support platform for querying, visualizing, and reporting data * Workflow - ArxLab Workflow allows users to create new work requests and to assign them to users and/or groups. The workflow management tool enables scientists to manage and prioritize all scientific projects, as well as to make procedure requests to internal colleagues and external partners. For more information, please visit our website at www.arxspan.com

Arzeda

Arzeda

Seattle, Washington, United States

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Asa Ren

Asa Ren

Jakarta, Indonesia

Established in 2016, Asa Rén is the 1st DNA data company in Indonesia with the most comprehensive bioinformatics in South East Asia. We aim to enable innovation in Indonesia's healthcare industry through utilization of longitudinal data and genomic data for drug discovery and personalized treatments.

Ascertain

Ascertain

New York, New York, United States

Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain's tech-enabled services, outsourcing entire workflows to Ascertain's team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain's AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care. Ascertain was launched by Northwell Holdings, the for-profit investment arm of Northwell Health, and Aegis Ventures.

Asensus Surgical

Asensus Surgical

1 Tw Alexander Dr, Suite 160, Durham, North Carolina 27701, US

Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.Senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: https://www.senhance.com/indications.

Asimov

Asimov

Boston, Massachusetts, US

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.

Aspen Neuroscience

Aspen Neuroscience

La Jolla, CA

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Aspira Women's Health

Aspira Women's Health

35 Nutmeg Drive, Suite 260, Trumbull, Connecticut

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Aspire Food Group

Aspire Food Group

Austin, Texas, United States

Our vision is a world transformed by insect technology. Our mission is to harness the combined powers of technology and nature to pioneer the future of sustainable farming. We are creating tomorrow's traditions through breakthrough innovations that are in harmony with our largest stakeholder: our planet. We believe in technology that unleashes, rather than replaces, the incredible treasures of our natural world. We Aspire to a world that is abundant in planet-based nutrition that is better for people, pets and plants. Every company's culture is defined by its people and their actions. Who we are is the direct product of what we do and what we value. At Aspire, our culture is defined by the following attributes which spell the name of our company: • Audacity (we are competitive, innovative, and dream big) • Skill (we are competent, data-driven, and curious) • Passion (we are impact-centered, profit-minded, and market-driven) • Integrity (we are ethical, trusting, humble and candid) • Resilience (we face adversity and setbacks with fierce determination and collaboration) • Excellence (we aim to be world class in everything we do and believe generosity is a competitive advantage)

Astarte Medical Partners

Astarte Medical Partners

Yardley, Pennsylvania, United States

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Astellas Pharma

Astellas Pharma

Northbrook, Illinois, United States

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Asterra Labs

Asterra Labs

Nashville, North Carolina, United States

At Asterra Labs, we are pharmaceutical scientists and industry veterans with a passion to innovate, develop, and manufacture a pharmaceutical-grade line of safe, beneficial wellness products and alternative medicines.

Ataraxis AI

Ataraxis AI

New York, New York, United States

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

Atgenomix

Atgenomix

Taipei, Taiwan

Atgenomix is a data and machine learning (ML) company that provides an open standard and unified platform for operationalizing biomedical data, analytics, and ML to deliver on the promise of precision medicine. The Atgenomix cloud-based biomedical informatics platform empowers clinical laboratories to design, develop, and operate GA4GH (Global Alliance for Genomics & Health) standard orchestrated multimodal workflows of data integration, tool engineering, analysis automation, workload acceleration, and regulatory compliance management. At Atgenomix, we envision a technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide industry accessible computational lab technologies that researchers need to scale data and machine learning in the future. Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, and a Google Health trusted partner in genomics research.

Athelas

Athelas

160 s whisman rd, mountain view, california, united states, 94041

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Athos Therapeutics

Athos Therapeutics

1124 West Carson Street, MRL Building, 3rd floor, Torrance, California

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Atom Bioworks

Atom Bioworks

1011 Passport Way, Cary, NC 27513, US

Atom Bioworks is a startup company that specializes in DNA nanostructures.

Atomic AI

Atomic AI

South San Francisco, California, United States

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise

Atomwise

San Francisco, California, United States

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

ATUM

ATUM

Newark, California, United States

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Augere Medical

Augere Medical

Oslo, Norway

Augere Medical is a commercial stage Norwegian medical device company founded in 2018 and is developing systems based on Artificial Intelligence (AI) to improve polyp detection rates during screening for colorectal cancer. The term "augere" is derived from Latin, meaning "to increase" or "to grow" - hence the green color in our logo. It is the root of several words in English and other languages, including "authority," which signifies the power to promote or bring about growth. Augere’s first product, the PolypAID System, is being developed in cooperation with leading colonoscopists and in close cooperation with the research group at Simula. The PolypAID System analyses the real-time video stream during colonoscopy screening and supports the physicians in making the right decision during the screening process. We pledge to implement transparent AI to physicians and patients. These are our values, mission, vision, and tagline statements: OUR VALUES Quality We are delivering high quality products through focus on details and by meeting customer expectations.   Innovation We are in the forefront of the technology development by embracing continuous improvements and investing in our employees.   Care We care about the patients who will benefit from our technologies and put real heart into our promises to our investors and customers.   Agility We move fast and are willing to adapt to changing market conditions regardless of the size of the company.   Delivering results We have grit to deliver results by defining clear objectives and by meeting deadlines. MISSION Making lives better   VISION Augere will, through partnerships with the world's leading clinical and technical research environments, develop a platform for AI-based systems that improve the detection rate and characterization of cancer and precancerous abnormalities and thereby reduce the burden on patients and the cost of cancer treatment   TAGLINE Confidence in outcomes (TM)

Augmenta Bioworks, Inc.

Augmenta Bioworks, Inc.

3475 Edison Way, Menlo Park, California 94025, US

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Aulos Bioscience

Aulos Bioscience

Larkspur, California, United States

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Auron Therapeutics

Auron Therapeutics

Newton, Massachusetts, United States

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Auxilium Health, Inc

Auxilium Health, Inc

Cleveland, Ohio, US

Auxilium Health is developing low-cost and smart biomaterials for hard-to-heal wounds. Our mission is to empower patients to take control of their healing journey by providing technology that actively heals and monitors wound infections, enabling faster recovery times and better quality of life for patients. We are providing a smarter way to heal wounds, one patient at a time.

Avellino

Avellino

Menlo Park, CA

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Avenue Biosciences

Avenue Biosciences

San Fransisco, US

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avicenna Biosciences

Avicenna Biosciences

701 W. Main St., Suite 200, Durham, NC 27701

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Avitia

Avitia

6650 Rue Saint-Urbain, 100, Montreal, Quebec H2S 3G9, CA

Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on what matters — personalized patient care. From pinpointing cancer mutations to streamlining clinical trial access, we’re here to make precision oncology accessible for every community and improve patients’ quality of life. Let’s transform cancer care together. Le cancer n’attend pas, et nous ne devrions pas non plus attendre. Chez Avitia, nous veillons à ce que les laboratoires cliniques et les oncologues du monde entier disposent des outils dont ils ont besoin pour diagnostiquer et traiter le cancer plus rapidement. Notre technologie IA/ML garantit à nos partenaires des solutions de tests moléculaires NGS rentables qui offrent des délais d’exécution rapides. Désormais, nous permettons aux équipes de soins de santé d’éviter les retards et de se concentrer sur ce qui compte : des soins personnalisés aux patients. De l’identification des mutations cancéreuses à la rationalisation de l’accès aux essais cliniques, nous sommes là pour rendre l’oncologie de précision accessible à toutes les communautés et améliorer la qualité de vie des patients. Transformons ensemble les soins contre le cancer.

Axcelead Drug Discovery Partners

Axcelead Drug Discovery Partners

Fujisawa, Japan

Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.

Axiom Bio

Axiom Bio

San Francisco, CA 94107, US

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

AxoSim

AxoSim

New Orleans, Louisiana, United States

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim®, BrainSim®, and microBrain™ deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim's platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology.

Ayasdi

Ayasdi

Menlo Park, California, United States

Symphony Ayasdi is a FinTech company that specializes in AI-driven machine learning and data analytics solutions for financial services.

Bactobio

Bactobio

Unit 408, Vox Studios 1-45 Durham Street, London, London SE11 5JH, GB

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

BAMF Health

BAMF Health

Doug Meijer Medical Innovation Building, Medical Mile

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

Basecamp Research

Basecamp Research

27 clerkenwell close, london, greater london, united kingdom

Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global genetic biodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most.

Baseimmune

Baseimmune

London, England

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

BCAL Diagnostics

BCAL Diagnostics

50 Clarence Street, Sydney, New South Wales, AU, 2000

BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.

BEKhealth

BEKhealth

Raleigh, NC, US

Purpose-built for organizations conducting clinical trials and observational studies, we leverage our AI-powered patient-matching platform and clinical expertise to optimize feasibility and speed up patient identification by extracting structured and unstructured data from electronic medical records (EMRs) that captures three times more trial criteria. Why: We believe sites are vital to the success of clinical trials. Empowering them to find the right patient for the right research at the right time is the focus of everything we do. What: We leverage our best-in-class technology and data expertise to detect more protocol-eligible candidates than traditional methods, so that site teams can focus on the parts of the job they actually love. How: We deliver an AI-powered software platform and support from clinical experts that enables our customers to find and match patients to available clinical research. With unbelievably fast and highly-accurate data extraction from electronic medical records (EMRs) we can capture three times more trial criteria - making trial participation more accessible and efficient.

BenchSci

BenchSci

Toronto, Canada

BenchSci is a biotechnology company that offers an AI-powered platform to accelerate biomedical research by providing researchers with antibody search and selection tools.

BERG

BERG

Framingham, Massachusetts, United States

BERGis aclinical-stage,AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging a proprietary intelligence platform – Interrogative Biology®, their goal is to map disease and develop new treatments for patients.COVID-19: Testing their technology in reducing COVID-19 patient mortality.

Bertis

Bertis

Seoul, South Korea

BERTIS Inc.'s proteomics technology provides diagnostic services that detect cancer and various diseases in the early stages. Proteomics is a field that studies the roles of various proteins, their relationships, and their characteristics, and that can research proteins directly involved in disease occurrence and progression, using technology simultaneously analyze hundreds of proteins as accurate and exquisite. About 10 years ago, when there was no interest in proteomics in Korea, BERTIS Inc. pursued proteomics scientific research after seeing the global scaled potential. As a result, We have secured unique technology based on 25 million protein big data and A. I. and have grown into a leading proteomics company in Korea. And now, we are working hard to go beyond the Republic of Korea into a global representative proteomics company. We constantly communicate and endeavor with experts representing each field, including physicians, chemists, biologists, and engineers.

BigHat Biosciences

BigHat Biosciences

San Mateo, California, United States

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

BillionToOne

BillionToOne

1035 O'Brien Drive

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BioAge Labs

BioAge Labs

Berkeley, California, United States

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

BioAI Health

BioAI Health

Manchester, New Hampshire, United States

At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D

BioCopy

BioCopy

Emmendingen, Germany

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

BioFlyte

BioFlyte

Albuquerque, New Mexico, United States

We are commercializing a revolutionary new class of fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats.

Biofourmis

Biofourmis

Boston, Massachusetts, United States

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

BioGeometry

BioGeometry

4343 Shallowford Road Ste E6

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

Biognosys

Biognosys

Schlieren, Switzerland

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Our Solutions We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Our Technology Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples. Our Facility From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our Data Competence Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. Global Presence Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.

Bioheaven360 Genotec

Bioheaven360 Genotec

New Delhi, India

Later part of the bygone twentieth century has witnessed a major revolution in the field of life-sciences. Researches carried out during this period, particularly in the area of molecular biology and recombinant technology, have led to emergence of 'Biotechnology'​ with a new face. Plants, animals and microorganisms being a key component of our ecosystem have always remained at centre-stage of research for different purposes as they affect the human life. Development of culture methods, better understanding about molecular biology, discovery of restriction endonucleases and their use in mapping of DNA laid the foundation stone for modern day biotechnology. Isolation of thermostable DNA polymerase along with the development of PCR technique made cloning simplified and providing way for rec-DNA technology. Further developments were generation of bar-code like DNA fragment patterns of genomic DNA. These patterns appeared useful in distinguishing individuals based on DNA sequence variations among them. Such variations of DNA among organisms were termed as fingerprints or profiles which provide a versatile tool to characterize genetic variability, genome evolution, population genetics, taxonomy, breeding and diagnostics even today! The technology to read the DNA base-by-base made it possible to identify useful genes. This information which could be cloned in suitable vectors and introduced in appropriate hosts through a variety of gene transfer methods gave an impetus to genetic improvement programmes and production of Genetically modified organisms. Today the genomic sequencing is contributing to identify the basis of pathology, providing tailored therapies. We are quickly advancing towards the in situ engineering of the genomic information to achieve designer humanity. Bioheaven ventures into this space "Turning Human Needs into Careful Solutions"​..........

BioinfoScientist

BioinfoScientist

Louisville, Kentucky, United States

BioLizard

BioLizard

Ghent, Belgium

BioLizard is a leading multi-national data analytics and data management consulting company supporting digital transformation in the life sciences industry by offering bespoke, tailored solutions. From data analytics and bioinformatics, to software development and AI, we support biopharma and biotech companies in accessing vital, data-driven insights that can be turned into actions and drive your life sciences research forward. Our team of experienced bioengineers, software engineers and computer science experts combines extensive data science expertise with deep biological knowledge to provide solutions that are tailored to your needs and in line with your unique strategic goals. We have a proven ability to support companies from discovery to pre- & early clinical phases, enabling data-driven R&D. Our expertise spans drug and biomarker discovery and development, in silico screening, target identification, development of companion diagnostics, mechanism-of-action studies, process automation, data strategy, and more. As your true data partner, we’re ready to help you leverage data to keep your competitive edge. Our expert ‘Lizards’ can support you no matter where you are in the world, and in a flexible, proactive, and agile way to drive your data-driven research forward. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝗕𝗶𝗼𝗟𝗶𝘇𝗮𝗿𝗱 𝘁𝗼𝗱𝗮𝘆 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗼 𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. More information: https://lizard.bio/home Company video: https://www.youtube.com/watch?v=q9MR126aiNo&t=1s BioLizard careers: https://lizard.bio/careers

Biolojic Design

Biolojic Design

Revohot, Israel

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

BioLoomics

BioLoomics

4665 nautilus ct s, boulder, colorado, united states

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.

BioMap

BioMap

Palo Alto, California, US

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

BioMark Diagnostics

BioMark Diagnostics

Richmond, British Columbia, Canada

BioMark is an oncology-focused company with advanced near-to- market diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites. We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory ,clinical and scientific standards.. Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

Biomeme

Biomeme

Philadelphia, Pennsylvania, United States

Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use. The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.

BiomeSense

BiomeSense

Chicago, Illinois, United States

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

Biomica

Biomica

Rehovot, HaMerkaz, Israel

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Biomonadic

Biomonadic

Berkeley, California, United States

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

BiomX

BiomX

Gaithersburg, Maryland, United States

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BioPharm International

BioPharm International

Iselin, New Jersey, US

BioPharm International® covers all aspects of biopharmaceutical development, analysis, processing, and packaging, as well as business strategies and regulatory issues. The print and digital editorial coverage provides technical and business insight and analysis for all biologic-based therapies including monoclonal antibodies, vaccines, biosimilars, protein therapeutics, cell therapies, gene therapies, antibody-drug conjugates, and other emerging therapies.

BioPhenoMA Inc.

BioPhenoMA Inc.

1-22-3 Nishiwaseda, Waseda University EntrepreneurshipCenter, Shinjuku, Tokyo 169-0051, JP

Providing high-sensitivity quantification services for ultra-trace proteins, we will support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

Bioptimus

Bioptimus

Paris, France

Bioptimus is a developer of a universal AI foundation model designed to drive advancements in scientific research and biotechnological innovations. Their mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine.

BioRaptor

BioRaptor

binyamina-giv'at ada, haifa district, israel

Biology is at a tipping point for implementing AI - thanks to rich data, tool availability, compute capacity, and measurable business impact. Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, bioraptor will make it easier, quicker and more cost-effective for scientists to discover, develop and scale processes that get much-needed food and pharma products into the hands of those who need them.

BioRealm

BioRealm

19330 rim of the world dr, monument, colorado, united states

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

Bioscibex

Bioscibex

Monthey, Switzerland

At Bioscibex, we are redefining bioprocessing with innovative single-use bioreactor solutions tailored for modern biologics and cell therapy manufacturing. Our mission is to empower researchers and manufacturers with tools that simplify processes, enhance scalability, and improve efficiency.

Biosim AI

Biosim AI

College Park, Maryland, United States

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

Biostate AI

Biostate AI

3240 Hillview Ave, Palo Alto, CA, 94304

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

BioStrand

BioStrand

Diepenbeek, Belgium

BioStrand is a biotechnology company that offers an AI-powered biotherapeutic SaaS platform revolutionizing drug discovery.

BioTherapeutics

BioTherapeutics

Blacksburg, Virginia / Philadelphia

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Biotia

Biotia

New York, New York, United States

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

BioTuring

BioTuring

San Diego, California, United States

BioTuring is an innovative bioinformatics company based in San Diego. Founded in 2016, the company has developed transformational bioinformatics platforms for sequencing data analysis, enabling scientists to gain valuable insights from biological data in an interactive, fast, and accurate approach. Its product portfolio now covers single-cell and spatial data analysis with BBrowserX, Talk2Data, Lens, BioVinci, and BioColab. BioTuring helps accelerate life sciences and nourishes computational minds.

Biotype Diagnostics

Biotype Diagnostics

Dresden, Germany

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

Biovaxys

Biovaxys

Ontario, Canada

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Biovista

Biovista

2421 Ivy Road, Charlottesville, VA, US

Biovista is a biotechnology company located in Charlottesville, Virginia, founded in 2005 by CEO Andreas Persidis. The company specializes in AI-driven drug repositioning and development services, aiming to enhance the efficiency of bringing new treatments to market. Biovista offers services that include drug repositioning, which identifies new therapeutic uses for existing drugs, and drug de-risking, which assesses and mitigates potential risks in drug development. The company also conducts disease cohort analysis to better understand specific patient populations and treatment strategies. Biovista develops its own drug repositioning programs across various therapeutic areas, including central nervous system disorders, diabetes and obesity, eye disorders, and oncology. The company employs advanced AI technologies to analyze large datasets, facilitating the discovery of novel applications for existing drugs. Biovista is actively involved in R&D projects, reflecting its commitment to advancing drug discovery through innovative approaches.

BioXcel Therapeutics Inc

BioXcel Therapeutics Inc

New Haven, Connecticut, United States of America

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Birch Biosciences

Birch Biosciences

Portland, Oregon, United States

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

bit.bio

bit.bio

The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3FH, GB

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio's trademarks, visit www.bit.bio/trademarks

BostonGene

BostonGene

Boston, Massachusetts, United States

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

Bowdoin College

Bowdoin College

Brunswick, Maine, United States

It is the mission of the College to engage students of uncommon promise in an intense full-time education of their minds, exploration of their creative faculties, and development of their social and leadership abilities in a four-year course of study and residence that concludes with a baccalaureate degree in the liberal arts.

BPGbio Inc.

BPGbio Inc.

Framingham, Massachusetts, United States

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Brainomix

Brainomix

Oxford, England, United Kingdom

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

brain.space

brain.space

Tel-Aviv, Israel

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

Brenus Pharma

Brenus Pharma

Lyon, France

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.

Briefly Bio

Briefly Bio

Ladbroke Grove, London, England, GB

Briefly helps give scientists headspace to design their experiments.  Our experiment builder helps create clear, consistent, visual experimental plans, with a copilot that takes care of the busywork.

Brightseed

Brightseed

San Francisco, California, United States

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Brightseed produces branded, proprietary, clinically proven bioactives that are sold to leading dietary supplement, food & beverage CPG, specialty nutrition and medical food companies for incorporation into health beneficial consumer products. Visit www.brightseedbio.com to learn more.

Broken String Biosciences

Broken String Biosciences

Cambridge, United Kingdom

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Buck Institute for Research on Aging

Buck Institute for Research on Aging

Novato, California, US

Buck Institute for Research on Aging is a biomedical research institute focused on studying the aging process and its effects on health.

Bug Mars

Bug Mars

Havelock, Canada

Smart, scalable, and automated insect farming. Bug Mars uses computer vision and machine learning to increase yield and profitability of insect farms for food, feed, and organic waste reduction.

BullFrog AI

BullFrog AI

Gaithersburg, Maryland 20878, US

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

Bullseye Biosciences

Bullseye Biosciences

Pagliuca Harvard Life Lab, 127 Western Ave, Allston, MA 02134, US

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

Butterfly Network

Butterfly Network

Burlington, Vermont, United States

Butterfly’s mission is to create access to valuable clinical insights using innovative ultrasound technology, made simple with artificial intelligence, to benefit all patients worldwide. Through the delivery of high-quality, affordable, easy-to-use, intelligently connected ultrasound, Butterfly Network enables better clinical decisions through better information and insight at the point of care. With Butterfly, seeing is knowing – in the hospital, community, or home.

CAI

CAI

Indianapolis, Indiana, United States

Clinical Assay Innovation (CAI) Biosciences is a consulting firm focused on providing expertise and guidance in the development of Laboratory Developed Test (LDT) and In Vitro Diagnostic (IVD) assays in the areas of Next Generation Sequencing (NGS), Real-Time Polymerase Chain Reaction (qPCR), Immunochemistry, and Clinical Chemistry. Our mission is to provide our clients with best in class assay development services and to insure successful implementations of their projects.

CAMP4 Therapeutics

CAMP4 Therapeutics

Cambridge, Massachusetts, United States

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

CAPACITÉS

CAPACITÉS

16, Rue des Marchandises, Nantes, Pays de la Loire 44200, FR

CAPACITÉS is the subsidiary of University of Nantes, dedicated to the development of research. Specialized in engineering of innovative projects, CAPACITÉS exploits the latest scientific discoveries necessary for the performance of its customers. Springboard to differentiate in the ever-changing markets, areas of activity extend to technological and engineering sciences, human and social sciences and health. The activities of CAPACITÉS have advanced expertise on specific and cross-cutting themes. From idea generation to their implementation, CAPACITÉS impulse with its customers a strong value creation process through the development of R&D of high level dedicated to nine economic sectors.

Capra Biosciences

Capra Biosciences

Manassas, Virginia, United States

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

Caption Health

Caption Health

Brisbane, California, United States

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

Caranx Medical

Caranx Medical

6000 north terminal parkway, nice, provence-alpes-cote d'azur, france

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

CaraVan Biologix

CaraVan Biologix

Princeton , NJ

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

CardioCommand, Inc.

CardioCommand, Inc.

4920 W. Cypress Street, Suite 110, Tampa, Florida 33607, US

Delivering cutting-edge cardiac medical devices to clinicians since 1994. CardioCommand Inc., headquartered in Tampa, Florida, is a pioneering medical technology company dedicated to revolutionizing cardiac care. Established in 1994, CardioCommand has established itself as a leading innovator in the field of cardiovascular health, leveraging cutting-edge advancements in medical technology to enhance patient outcomes and streamline medical procedures. At CardioCommand, our mission is to empower healthcare professionals with state-of-the-art cardiac monitoring solutions, ensuring timely and accurate diagnoses while prioritizing patient comfort and well-being. We are committed to advancing the standard of care in cardiovascular medicine through innovation, integrity, and excellence.

Cardio Diagnostics

Cardio Diagnostics

Chicago, Illinois, United States

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

Cardiosense

Cardiosense

Chicago, Illinois, United States

Contact: contact@cardiosense.com Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

Cardiotrack

Cardiotrack

1670, 18th Cross, MC Layout, Vijayanagar

Cardiotrack is a disruptive healthcare diagnostics solution that is making healthcare delivery more efficient. The mission of Cardiotrack is to reduce the cost of diagnosis by an order of magnitude through innovation in product design, and enhancements in healthcare workflow. Key challenges faced by healthcare providers include – the high cost of diagnostic equipment and lack of trained professionals, especially in semi-urban areas. Cardiotrack is addressing both these issues through the state of the art medical electronics, data analytics, cloud storage and diagnostics workflow management. Cardiotrack focuses on heart health and has consulted with some of the best medical research institutions in India like St John's Research Institute & Jayadeva Institute of Cardiovascular Science in Bangalore; brought onboard doctors and cardiologists as advisers and is collaborating researchers at the Loyola University of Chicago to deliver a comprehensive diagnostics solution for cardiovascular diseases (CVD). Cardiotrack is a multiple parameter handheld diagnostic device including 12-lead ECG monitor, pulse oximeter and blood pressure monitor integrated with mobile-based practice management solution and cloud backend. Low cost, portability and network-connectivity mean that Cardiotrack may be deployed at the primary care level and the resultant scan of the patient can be delivered instantaneously to a specialist anywhere in the world. This approach leads to efficient use of specialists'​ time, enables early diagnosis of heart patients and thus reduces the need for expensive invasive intervention. YouTube: https://www.youtube.com/watch?v=Tj3EI2iC7RE

CardioWise, Inc.

CardioWise, Inc.

535 West Research Center Boulevard Suite 135 M/S 2300, Fayetteville, Arkansas 72701, US

CardioWise's non-invasive Cardiac Computed Tomography (cCT) analysis software produces an easy-to-understand 3D image model of the human heart.

CarePoint Solutions, Inc.

CarePoint Solutions, Inc.

100 Cummings Center, Suite 434-E, Beverly, Massachusetts 01915, US

CarePoint Solutions: Elevating the IQ of Healthcare Delivery Introduction: Welcome to CarePoint Solutions, where we're committed to revolutionizing healthcare delivery through innovative technology. Our flagship product, Pro-QCP, is a cutting-edge SaaS quality management utility designed to address critical challenges in diagnostic accuracy and clinical lab regulatory compliance. The Challenge: Healthcare systems globally face significant issues with diagnostic errors, leading to adverse outcomes and unnecessary costs. Evolving regulatory requirements further complicate matters, making compliance a challenge for labs while maintaining efficiency. Our Solution: Pro-QCP not only introduces a higher standard for diagnostic quality assurance, but offers a practical and efficient means for clinicians to achieve it. Developed in collaboration with industry experts, our solution streamlines lab workflows, saves time, identifies errors, ensures compliance, and drives improved clinical outcomes and operational efficiencies throughout healthcare organizations. "Pro-QCP is like a Pac-Man that goes through a healthcare system, identifying and correcting diagnostic test errors wherever they are found." Pro-QCP's Key Features and Benefits: - Ensures compliance with challenging new international regulatory standards. - Optimizes a lab's most critical workflow: delivering accurate and timely test results. - Provides actionable information to improve diagnostic processes and mitigate errors. - Prevents needless deaths and adverse events. - Drives downstream efficiencies and economies by improving diagnostic accuracy. - Saves a typical lab hundreds of hours of staff time. - Offers value to stakeholders throughout a healthcare delivery organization. Pro-QCP is a first-to-market solution that meets a critical need in the healthcare industry. From small labs to multinational lab networks, our solution offers value to virtually every clinical setting.

Caresyntax

Caresyntax

San Francisco, CA, US

At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 3,000 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we're transforming surgical care, visit us at www.caresyntax.com.

Caris Life Sciences

Caris Life Sciences

Basel, Switzerland

Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.

Caristo Diagnostics

Caristo Diagnostics

New Barclay House, 234 Botley Road, Oxford, United Kingdom OX2 0HP, GB

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

Carta Genomics

Carta Genomics

309 ballards lane, london, greater london, united kingdom

Carta provides advanced genomic testing for IVF. We help IVF parents predict their embryo's disease risk and health outcomes in advance, resulting in improved women's health and healthier babies.

Carterra

Carterra

825 North 300 West, Suite C309, Salt Lake City, UT 84103, US

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

Castle Biosciences

Castle Biosciences

Friendswood, Texas, United States

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

CD ComputaBio

CD ComputaBio

Shirley, New York, United States

CD ComputaBio is a professional computational biology service company. Our service spans across different areas in computational biology, providing access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. We are committed to providing high-quality data and customer service to various industrial and academic customers.

Cellanyx Diagnostics

Cellanyx Diagnostics

Beverly, Massachusetts, United States

Cancer diagnostic

Cellari

Cellari

Frederiksberg, Denmark

Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari aims to provide the most precise "active learning model" for biological image segmentation combined with an intuitive and easy-to-use user interface for carrying out complex image related tasks and analytics. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities. Cellari is a proud part of the InnoFounder – Graduate incubator for Cohort 5 of September 2019.

Cellarity

Cellarity

Somerville, Massachusetts, United States

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.

CellChorus

CellChorus

Houston, Texas

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells exist in motion. CellChorus is a single-cell, visual AI company that is the leader in visual AI for single-cell analysis.

Celldom

Celldom

Durham, North Carolina, United States

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Cellestia Biotech

Cellestia Biotech

Basel, Basel-Stadt, Switzerland

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

Cellibre

Cellibre

San Diego, California, United States

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Cellinfinity Bio

Cellinfinity Bio

West Haven, Connecticut

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

Cellino

Cellino

Cambridge, Massachusetts

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Cellix Bio

Cellix Bio

Hyderabad, Telangana, India

CELLIX BIO - Founded in 2014, we are the leading drug discovery and development company. We generate our own drug design data before combining the critical power of AI with the creativity of involving proprietary platform technology, Synergix AI, and the expertise of our world-class scientists. This allows us to shorten the pre-clinical drug discovery stage and, in turn, substantially accelerate the delivery of new treatments to patients worldwide. By reducing the number of compounds analysed, we aim to vividly reduce the time and cost of discovering and developing new medicines. Cellix Bio balances Synergix AI plus human creativity in drug discovery.

CellVoyant

CellVoyant

40 Berkeley Square, Bristol, England BS8 1HP, GB

CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We're working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We're backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We're also supported by the founder/CEO of Abcam, which pioneered the antibody business.

Cell X Technologies

Cell X Technologies

Cleveland, Ohio, United States

Cell X is pioneering a revolution in cell processing. At the core of this revolution lies our transformative Celligent platform – an innovative bundling of automation, imaging, data analytics, and machine learning that enables therapeutic researchers to develop consistent, reproducible, and scalable GMP-compliant processes for stem cells and bio-fabrication. Celligent enables the development of safe and effective products by executing the necessary process development and cell manufacturing procedures in a fully documented, compliant way. Successful cellular therapies demand starting with optimized cell sources; and intrinsic variability and heterogeneity among cell sources presents a major challenge. This critical first step of control over starting materials demands the use of quantitative and reproducible standards for cell and clone selection and process management based on critical process parameters (CPPs) in order to achieve products with defined critical quality attributes (CQAs). Backed by a highly experienced team, Cell X automates cell processing in diverse cell culture applications spanning mesenchymal stromal/stem cells (MSCs) and exosomes, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), connective tissue progenitor cells (CTPs) and tumor-infiltrating lymphocytes (TILs) as well as other progenitor cell types. We are dedicated to advancing the promise of cellular therapies for innovators and patients alike, ultimately making cell therapies more accessible to millions of patients worldwide. 

Centaur Labs

Centaur Labs

50 Milk St, 16th Floor, Boston, Massachusetts 02109, US

Centaur Labs is the modern data labeling solution for AI innovators across the healthcare landscape. With an expert crowd of 50k+ labelers and a gamified app to incentivize and quality-control them, our scaleable labeling methodology ensures high-quality labels in as little as 24 hours.

Cercle

Cercle

san francisco, california, united states

Cercle is an AI technology company with the mission to advance healthcare for all women. With AI, we harness anonymized, diverse and reliable biomedical and genomics data from around the world to deliver unprecedented and secure healthcare insights. The Cercle™ Biomedical Graph is a first-of-its-kind knowledge graph. It uses AI to analyze billions of anonymized data points securely drawn from hospitals, clinics and research labs from all over the globe. We're turning raw, unstructured and disconnected biomedical and genomics data into clear insights for doctors, hospitals, research centers, pharmaceutical companies, labs and clinics so they can treat patients more effectively. That's how we support innovation and advancements in treatments and healthcare outcomes across the entire healthcare ecosystem. Women's health is the most underserved healthcare market, which is why Cercle's first focus will be fertility and IVF. We're proud to beta launch Luce, a fertility companion for women and doctors that analyzes data from thousands of treatment cycles to help people make more informed decisions for their fertility journeys. Cercle's suite of products includes: — Data access tools: Researchers and lab directors can query and visualize structured biomedical and genomics data to accelerate health innovation. — Modeling and insights products: Advanced modeling tools help healthcare providers with financial and operational strategies. — Tools for clinicians: Doctors get personalized care insights and predictive treatment outcomes based on Real World Data and Real World Evidence. — Patient companions: Patients get clear, data-driven insights that make it easier to understand their health and make informed decisions with their doctors. Cercle is built by medical professionals, molecular biologists, data scientists, engineers and business entrepreneurs dedicated to unlocking a world where everyone feels informed, empowered, and in control of their own health.

CereHealth Corp.

CereHealth Corp.

991 Southpark Dr, Suite 200, Littleton, Colorado 80120, US

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Cerillo

Cerillo

Charlottesville, Virginia, United States

Transformation. It's a word we hear a lot—the moment when a discovery leads to an innovation that fundamentally changes our world. There's a backstory to transformation—one that takes place in labs and research facilities by people who work tirelessly for years to reach that a-ha moment. Cerillo understands the passion, tenacity and investment that come before transformation. Our technology is laser-focused on helping you achieve greater efficiency and agility in your research. But more than that, it's designed to illuminate possibility by letting you view the same problem from new angles. Stratus, our portable plate reader, is helping scientists anticipate and creatively solve human challenges from the palm of their hand, giving them the freedom to take their work out into the world. And that's just the beginning. Our team is committed to constant innovation in our lab to make discovery in your lab easier. Think of us as the proactive lab partner you didn't know you needed, clearing the way for you to reach that transformational moment that changes the world for good.

Cernostics

Cernostics

Pittsburgh, Pennsylvania, United States

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Certara

Certara

Paris, France

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

Certis Oncology Solutions

Certis Oncology Solutions

5626 Oberlin Drive, Suite 110, San Diego

Certis Oncology is a life science technology company committed to realizing the promise of precision oncology. Certis was founded in 2016 with a singular purpose: to bring certainty to the fight against cancer. Their science delivers clinically relevant, predictive data and they are located in the heart of San Diego's Life Sciences center, Sorrento Valley.

CHA Bio Group

CHA Bio Group

335 pangyoro bundanggu, seongnam, korea

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CHARM Therapeutics

CHARM Therapeutics

London, United Kingdom

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.

ChemDiv

ChemDiv

San Diego, California, United States

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

Circle Pharma

Circle Pharma

South San Francisco, California, United States of America

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

CircNova

CircNova

Detroit, Michigan, United States

CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.

Citeline

Citeline

New York, US

Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.

Citius Pharmaceuticals

Citius Pharmaceuticals

Cranford, New Jersey, United States of America

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citrine Informatics

Citrine Informatics

Redwood City, California, United States

Citrine empowers product experts with vanguard AI technologies. With no background in data science, product experts apply Citrine to deliver next generation products faster than any other time in history. Citrine’s software learns easily from the knowledge of its users and their idiosyncratic data to enhance all aspects of the product lifecycle across all industries with a physical product. Citrine’s users increase supply chain efficiency, rapidly improve product quality, enhance customer experience, expand product reach and increase the velocity of product delivery. With Citrine, product experts unlock the capability to solve our society’s greatest environmental and productivity challenges. Citrine's customers include Eastman, Panasonic, Grace, LyondellBasell, LANXESS, Morrow Batteries and some of the biggest and most respected names in the materials and chemicals and CPG industries in Asia, North America, and Europe. For more information visit our website at https://citrine.io.

City Therapeutics

City Therapeutics

Cambridge, MA

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

CJ Bioscience

CJ Bioscience

14, Sejong-daero, Jung-gu, Seoul, Republic of Korea, Seoul, 06725, KR

CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness'. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform' to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform' by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.

Clarapath

Clarapath

12 Skyline Dr, Hawthorne, New York 10532, US

Clarapath is a medical robotics company automating the laboratory. Our first product is focused on automating the microtomy station in pathology. Our vision is to innovate, standardize, and digitally transform anatomic pathology through higher quality lab medicine, more robust safety standards, increased lab throughput, while lowering laboratory costs and labor related delays.

Clarity Genomics Inc

Clarity Genomics Inc

501 Broadway, Suite 800, San Diego, California 92101, US

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

Clarivate

Clarivate

London, United Kingdom

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

Clear Guide Medical

Clear Guide Medical

3600 Clipper Mill Rd, Ste. 400, Baltimore, MD 21210, US

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

Clee Medical

Clee Medical

Geneva, Switzerland

Our vision is to redefine the boundaries of neuroscience with minimally invasive technologies to enable unparalleled precision, enhance patient outcomes, and forge a new era of highly targeted neurotherapies for a healthier world.

Click Therapeutics

Click Therapeutics

New York, New York, United States

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

Clinerion

Clinerion

Elisabethenanlage 11, Basel, Basel-Town 4051, CH

Clinerion, a wholly owned subsidiary of TriNetX LLC, accelerates clinical research and medical access to treatments for patients. We use proprietary, patented technologies for analysis of live electronic health record (EHR) data from our global network of partner hospitals to generate real-world data (RWD), which can be used for investigation into disease epidemiology, the patient journey and outcomes, and patient care metrics. Clinerion's Patient Network Explorer platform radically improves the efficiency and effectiveness of clinical trials by offering data-driven protocol optimization, site feasibility evaluation, and search and identification for patient recruitment – in real-time. Among other uses, we provide solutions for increasing diversity in clinical trials and identification of rare disease patients. Clinerion's new Federated Machine Learning Platform enables the training and validation of machine learning (ML) algorithms on our global RWD network. Apart from the contributions to drug development this platform targets to develop preventive care for patients before they reach a critical stage. Clinerion operates on the principle of "privacy by design" and complies fully with international patient privacy and data security regulations. Clinerion is headquartered in Switzerland. Clinerion website: www.clinerion.com Clinerion's Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

Clinion

Clinion

5900 Balcones Dr, STE 100 Austin , TX 78731 Travis County, Austin, Texas 78731, US

Clinion is a leading global clinical trial company renowned for its award-winning solutions that drive innovation and excellence in the field of clinical research. We implement cutting edge technologies like AI/ML and GenAI to accelerate clinical trials for better outcomes. Our unparalleled expertise empower pharmaceutical, biotechnology, and medical device companies to conduct clinical trials more efficiently and effectively. Join us in revolutionizing the future of clinical trials and making a lasting impact on global healthcare. Facebook : https://www.facebook.com/clinion Twitter : https://twitter.com/clinion YouTube : https://www.youtube.com/c/Clinion Instagram : https://www.instagram.com/clinion_ai/

Clinomics

Clinomics

Ulju-gun, South Korea

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

Cloudbyz

Cloudbyz

1770 Park St, 108, Naperville, Illinois 60563, US

Cloudbyz is focused on building cloud-based products and solutions for life sciences customers, and help them innovate drug development and research to bring therapies faster to market which improve patient health and saves lives. Our innovative digital solutions for Pharmaceuticals, Contract Research Organizations (CRO) and Medical Devices companies helps to digitize research, drug and device development and commercialization. Our suite of products include: 1. Cloudbyz CTMS 2. Cloudbyz CTBM 3. Cloudbyz eTMF 4. Cloudbyz EDC, ePRO & eCOA 5. Patient Recruitment 6. Cloudbyz Safety & PV 7. ClinicalWave.ai (AI based platform for Life sciences organizations) Cloudbyz CTMS, eTMF, EDC, and Safety & Pharmacovigilance are built 100% native on Salesforce cloud platform for sponsors, clinical research organizations (CRO), and Clinical Sites. Cloudbyz Clinical Research Solutions are flexible and scalable to enable to manage and collaboration on clinical trial operations while the intuitive, straightforward design allows rapid deployment with a very intuitive and easy-to-use cloud-based solution. Cloudbyz ITPM offers 360° view and real-time visibility across IT planning, execution, and operations and helps organizations to achieve agility, velocity, innovation, and collaboration across IT and business. Cloudbyz ITPM helps CIO, PMO, and IT leaders to visualize the IT landscape, capability mapping, investment, and operational health in real-time and better align IT initiatives with business.

CloudMedx

CloudMedx

Palo Alto, California, United States

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Cloud Pharmaceuticals

Cloud Pharmaceuticals

Research Triangle Park, North Carolina, United States

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

Codexis Inc.

Codexis Inc.

Redwood City, California, United States of America

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Coding Bio

Coding Bio

oxford, oxfordshire, united kingdom

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

CogNano

CogNano

Kyoto, Japan

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

Cognivia

Cognivia

Rue Granbonpré 11, Boite 9, Mont-Saint-Guibert

Cognivia is an innovator of analytical tools to optimize and accelerate the clinical development of new medicines. The privately held company was founded in 2013 by longtime colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace. Cognivia helps lessen risk and helps increase clinical trial success. It can help reduce the variability of study data by 30 percent. This can lead to fewer patients needed in a study, equating to less cost and time. The company offers Placebell©™, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.

Cognoa

Cognoa

Palo Alto, California, United States

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics

Cognos Therapeutics

Inglewood, California, United States

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Collaborations Pharmaceuticals, Inc.

Collaborations Pharmaceuticals, Inc.

1730 Varsity Drive, Suite 360, Raleigh, NC 27606-5228, US

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Collaborative Drug Discovery - CDD Vault

Collaborative Drug Discovery - CDD Vault

1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, US

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Color Genomics

Color Genomics

Milbrae, California, United States

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Colossal Biosciences

Colossal Biosciences

1401 lavaca street, austin, tx, united states

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

ColVisTec

ColVisTec

Berlin-Adlershof, Germany

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

Compass Pathways

Compass Pathways

Cheshire, United Kingdom

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Compugen

Compugen

Richmond Hill, Canada

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Computomics

Computomics

Tubingen, Germany

Computomics was founded to bring the latest bioinformatics discoveries to industry application, facilitating global agricultural development.Crops: Parse large genomic data sets for plant breeders, deliver breeding recommendations, and provide molecular biology insight to reduce crop area requirements.Animal Health: Assemble and annotate genomic data from your species of interest, compare time-series data and visualize genomic variation in insightful ways.Metagenomics and Microbial Genomics: Analyze complex microbial communities and discover new organisms and metabolic pathways in a variety of samples.

Conceivable Life Sciences

Conceivable Life Sciences

New York, New York, United States

Conceivable has developed the world’s first fully automated IVF lab. Our end-to-end reinvention of today’s largely manual, artisanal labs delivers new levels of precision, quality, and scalability. Simultaneously, Conceivable brings the innovation of modern cell therapies to IVF. We are already exceeding the clinical benchmarks of today’s best IVF labs. Worldwide 95% of the infertile population–and 80% in the United States–don’t have access to IVF. Conceivable exists to change this. By automating the IVF lab we will vastly broaden the availability of this Nobel Prize winning therapy, improve results, and meet the demands of millions of infertile people wishing to achieve the dream of becoming parents.

ConcertAI

ConcertAI

Boston, Massachusetts, United States

Their mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, healthcare providers, and medical societies.

Concinnity Genetics

Concinnity Genetics

Edinburgh, GB

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Conduct Science

Conduct Science

Boston, Massachusetts, United States

Science has a problem. There are many suppliers and many scientists. Finding the right supply at the right price is hard, and if you're a life science company, you want to be able to get your customers the best product. We are creating a better vision for scientists to conduct science and make new discoveries. Located between two of the most prominent universities in the world, Harvard University and Massachusetts Institute of Technology, our startup has access to some of the most talented biotechnology, life sciences, and medical/health professionals in the world. https://linktr.ee/conduct_science

Congenica

Congenica

Cambridge, United Kingdom

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

Connecta Therapeutics

Connecta Therapeutics

Barcelona, Spain

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Consegna Pharma

Consegna Pharma

Pittsburgh, Pennsylvania, United States

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

ConsoneAI

ConsoneAI

10 Union Street, London, SE1 1SZ

Consone AI a disruptive technology platform targeting how decisions are made in the drug development process. Accelerating new medicines to market, reducing cost, reducing preclinical toxic trials, time and environmental footprints. The Consone AI platform will empower user decision making by successfully predicting toxicological effects and viability of new drugs.

Constantiam Biosciences

Constantiam Biosciences

Houston, Texas, United States

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

Convalife Pharmaceuticals

Convalife Pharmaceuticals

Room 41, No.780 Cailun Road, Zhangjiang Hi-Tech Park 201203, Shanghai, China

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

Converge Bio

Converge Bio

Tel Aviv, Israel

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent Beam Technology

Convergent Beam Technology

Haifa, Israel

Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.

Conversio Health

Conversio Health

720 Aerovista Place, Suite D, San Luis Obispo, CA 93401

Conversio Health is an innovative chronic condition management company focused on COPD and Asthma Disease Management. They aim to improve outcomes, prevent hospitalizations, and reduce the total cost of care for chronic respiratory conditions.

CoraVie MEDICAL

CoraVie MEDICAL

minneapolis, minnesota, united states

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Coreline Soft

Coreline Soft

Seoul, South Korea

About Coreline soft We develop AI-based imaging diagnosis package, specializing in lungs. This includes lung cancer screening(LCS), COPD quantification, and coronary artery calcification (CAC) systems, we call it B3 systems, covering the 3 big diseases in thoracic imaging. More in-depth lung diagnosis products with analysis such as texture analysis for ILD/IPF and pneumonia detection including COVID-19 are soon to be expected.   √ The Official solution provider for the nationwide lung cancer screening program in Korea (K- LUCAS) from 2017, which is the 2nd state-level-reimbursed LCS program following the US from 2015 √ The Official solution provider of 4-ITLR project by the Nelson Team (Erasmus MC and iDNA in the Netherlands), which is a large early detection LCS Trial-based on B3 system. Two hospitals in Germany, DKFZ Heidelberg and Univ Hosp of Essen, are the members of this trial and our systems will be implemented in these hospitals from 2021. √ Imminent Official solution provider for the German Trial by multi-university hospitals which is a pilot project to prove a national support necessary for LCS in Germany. √ Our COPD systems are used by European customers such as NZ Leuven Belgium, Leicester Univ UK, Parma Univ Italy obtaining the appraisal as the best of breed for early detection, phenotyping, surgery support, and etc.

Core Vista Health

Core Vista Health

Toronto, Canada

CorVista Health is transforming cardiovascular care with the CorVista System, a non-invasive point-of-care diagnostic technology, that shortens the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. The CorVista System leverages proprietary machine-learned algorithms and robust clinical data to deliver results providers can trust. For more information visit www.corvista.com

Cortechs.ai

Cortechs.ai

San Diego, California, United States

Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers. Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

Cortex - acquired by Boston Scientific

Cortex - acquired by Boston Scientific

3350 scott boulevard, santa clara, california, united states

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to See What Matters.

Cradle

Cradle

Amsterdam, Netherlands

We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world.

Crane Biosciences Inc.

Crane Biosciences Inc.

London, GB

At Crane Biosciences, we enable RNA treatments for incurable diseases. We are based at Imperial College London and backed by Norrsken, InnovateUK, Entrepreneur First, and Creative Destruction Lab (University of Oxford).

Creyon Bio

Creyon Bio

San Diego, California, United States

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Cumulus Neuroscience

Cumulus Neuroscience

The Innovation Centre, Queens Rd, Belfast, BT3 9DT, GB

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and research. They collaborate with leading global pharmaceutical companies to meet the industry's complex clinical trial needs. Cumulus Neuroscience offers a unique career and is known for its innovative assessment platform for identifying brain disorders.

CUREPORT, INC

CUREPORT, INC

60Prescott St, Worcester, Massachusetts 01605, US

Curi Bio

Curi Bio

Seattle, Washington, US

CurifyLabs

CurifyLabs

Helsinki, Finland

CurifyLabs is a Finnish healthtech company developing solutions for manufacturing personalized medicines in pharmacies and hospitals. CurifyLabs is revolutionizing the way personalized medicines are created. We provide innovative technology that enables the automation of compounding—transforming a traditionally manual, time-intensive process into a streamlined, efficient, and accurate system. The CurifyLabs' Compounding System Solution (CSS) is an automated pharmaceutical compounding platform for non-sterile dosage forms, including tablets, troches, liquids, suppositories, vagitories, ointments and capsules. It enables better treatments for patients and improved efficiency for pharmacies and hospital pharmacies. In addition to cost savings, it ensures high manufacturing standards at the point of care through in-process quality control. The CSS is a user-friendly platform consisting of: GMP manufactured excipient bases, compounding robotics, integrated quality control tools, software and a comprehensive formulation library to meet versatile compounding needs of pharmacies.. CurifyLabs’ CSS technology is currently in use for patients by customers in Europe and US. The CurifyLabs Compounding System Solution offers an easy-to-use, turnkey solution for pharmacists and hospitals, making personalized medication production faster, safer, and more accessible to patients in need. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.

Cyclarity Therapeutics

Cyclarity Therapeutics

Novato, California, United States

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cycuria

Cycuria

Graz, Austria

Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering a new solution where conventional therapies have fallen short.

Cyrus Biotechnology

Cyrus Biotechnology

Seattle, Washington, United States

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

Cytonus Therapeutics

Cytonus Therapeutics

San Diego, California, United States

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

CytoReason

CytoReason

Circular Building Azrieli Center,, Tel Aviv, Tel Aviv District, IL, 6329302

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

Cytovale

Cytovale

San Francisco, California, United States

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Cytovia Therapeutics

Cytovia Therapeutics

Aventura, Florida, United States

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Dandelion Science

Dandelion Science

95 River St, Suite 5D, Hoboken, New Jersey 07030, US

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Darmiyan

Darmiyan

san francisco, california, united states

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

Dassault Systemes Biovia

Dassault Systemes Biovia

San Diego, California, United States

The BIOVIA portfolio integrates the diversity of science, experimental processes and information requirements, end-to-end, across research, development, QA/QC and manufacturing. Capabilities include Scientific Informatics, Molecular Modeling/Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality & Compliance and Manufacturing Analytics.Subsidiaries: Accelrys Ltd, Synomics Ltd, VelQuest Corporation, others.

Data MATRIX

Data MATRIX

5 kovenskiy pereulok, sankt-peterburg, russian federation

Резидент инновационного фонда Сколково, Data MATRIX предоставляет услуги по исследованию рутинной клинической практики (RWE) с использованием российских и зарубежных датасетов, обработке данных и биостатистике в клинических исследованиях и разрабатывает программные продукты для клинических исследований. В портфеле компании более 200 проектов для фармацевтических и биотехнологических компаний и CRO. Среди продуктов Data MATRIX такие приложения, как EDC, IWRS и ePRO, онлайн-инструменты для врачей по прогнозированию и оценке эффективности терапии. Компания является членом профессиональных сообществ CDISC, ACDM, SCDM.

Day Two

Day Two

Nashville, Tennessee, United States

DayTwo is leading the charge in personalized nutrition through cutting-edge microbiome analysis. Our mission is to empower individuals to take control of their health by understanding and optimizing their unique gut microbiome. About Us: We specialize in precision health through microbiome-based insights that drive personalized dietary recommendations. We decode the intricacies of the microbiome and translate it into practical solutions. Services: -Microbiome analysis for personalized nutrition optimization. -Predictive dietary recommendations based on individual microbiome composition. Why Choose Us: -Advanced technology: State-of-the-art sequencing methods (full shotgun) and proprietary algorithms -Supported by science: Microbiome insights combined with 25 years of diverse patient data, bolstered by research published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care -Largest collection of data: World's largest high-resolution sequenced data set of over 90,000 samples -Personalized approach: Recommendations based on each unique microbiome profile Join us on the journey to better health and unlock the potential of your microbiome with DayTwo. Connect with us to learn more!

Day Zero Diagnostics

Day Zero Diagnostics

Boston, Massachusetts, United States

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

D&D Pharmatech

D&D Pharmatech

Germantown, Maryland, United States

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Debiopharm

Debiopharm

Lausanne, Switzerland

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Deciphex

Deciphex

DCU Alpha Building, Innovation Campus, 11 Old Finglas Rd, Glasnevin, Co. Dublin, D11 KXN4, Ireland

Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

Deep 6 AI

Deep 6 AI

241 east colorado boulevard, pasadena, california, united states

Deep 6 AI is a clinical trials software company based in Pasadena, California, founded in 2016. The company focuses on accelerating patient recruitment and enhancing clinical research through AI-powered analysis of real-world clinical data. In March 2025, Deep 6 AI was acquired by Tempus, further integrating its capabilities into Tempus' healthcare ecosystem. The company specializes in AI-powered patient matching, which analyzes both structured and unstructured electronic medical record data to identify eligible patients for clinical trials. Its platform connects healthcare organizations, researchers, and life sciences companies, streamlining trial workflows. Deep 6 AI also generates real-world evidence to support rapid clinical trial feasibility analysis and data-driven protocol design, utilizing natural language processing and machine learning to process data from over 25 major healthcare organizations.

Deep Apple Therapeutics

Deep Apple Therapeutics

San Francisco Bay area

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

DeepCure

DeepCure

100 City Hall Plz, Boston, Massachusetts, 02108, United States

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

Deep Genomics

Deep Genomics

Toronto, Canada

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

DeepHealth

DeepHealth

Belmont, Massachusetts, United States

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

Deep Lens

Deep Lens

Columbus, Ohio, United States

Deep Lens is a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis using VIPER. Deep Lens' AI-driven cloud platform gives care teams, trial coordinators and oncologists visibility into all available trials and the ability to collaborate on groundbreaking cancer research across all cancer types.

DeepLife

DeepLife

Paris, Ile-de-France 75013, FR

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform's features and data.

DeepMatter

DeepMatter

Glasgow, United Kingdom

We are a big-data and analysis company focused on enabling reproducibility and predictability in chemistry. With machine learning (ML) and AI powered products, SmartChemistry® empowers the chemist to design, experiment and understand their chemistry on an unprecedented scale. Utilising an advanced knowledge base that combines reaction data, real time sensor data and outcomes, SmartChemistry® enables access to a higher level of experimentation in the chemistry laboratory.

Delfi Diagnostics

Delfi Diagnostics

Baltimore, Maryland, United States

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Delphinus Medical Technologies, Inc.

Delphinus Medical Technologies, Inc.

Novi, Michigan, United States

Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

DermaDetect

DermaDetect

4 Oppenheimer St, Rehovot, Rehovot, Israel 7670104, IL

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

DermaSensor, Inc.

DermaSensor, Inc.

950 brickell bay dr, miami, florida, united states

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

Detect

Detect

Guilford, Connecticut, United States

Detect builds tools that empower people to understand their health and make informed, timely decisions. Led by Founder Dr. Jonathan Rothberg, the Detect team is redesigning the future of healthcare with the power of technology. Detect wants to make fast, accurate diagnostic testing as routine as taking your temperature and as accessible as telemedicine.

Dewpoint Therapeutics

Dewpoint Therapeutics

Boston, Massachusetts, United States

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Diabeloop

Diabeloop

Grenoble, France

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

DIAGENS

DIAGENS

unavailable

DIAGENS is a Hangzhou-based biotechnology firm, providing in-vitro diagnostic (IVD) products and other medical equipment.

Diag-Nose.io

Diag-Nose.io

Melbourne, VIC 3207, AU

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Differential Bio

Differential Bio

Munich, Bavaria, Germany

Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.

Digbi Health

Digbi Health

Mountain View, California, United States

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Digi.bio

Digi.bio

Amsterdam, Netherlands

Digi.Bio is bridging the digital and biological world through microfluidic automation and AI. We develop programmable microfluidics platforms, integrated with sensor and AI, to make biology easier to engineer.

Digital Biology

Digital Biology

Watertown, Massachusetts, United States

Digital Diagnostics

Digital Diagnostics

Coralville, Iowa, United States

Digital Diagnostics is an Iowa-based AI diagnostic platform that offers solutions such as image analysis and EMR integration for the healthcare industry.

Dispatch Bio

Dispatch Bio

Harnessing the immune system to reimagine cancer therapy

DNAgo

DNAgo

Irvine, California, United States

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

DNAVisit

DNAVisit

San Diego, California, United States

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Dong-A Pharmaceutical

Dong-A Pharmaceutical

Seoul, Korea

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Doriane

Doriane

Nice, France

Pionner and leader in crop innovation software, since 1984, managing up to 250K agronomic trials per year. Doriane empowers your agronomy department in its digital transformation. Optimize your data, automate your workflows, and make agile decisions! We support innovation in agronomy—whether in the field, lab, or office—to tackle environmental, economic, and human challenges. We offer digital solutions to collect and enhance data for better decision-making. Our goal is to help agronomy teams adopt practices that are more effective, efficient, open, and resilient. Leverage our extensive experience in project management, technology complexity, cyber-security compliance, and evolving scientific knowledge. We bring our full ambition to every project, working closely with customer teams. Our Customer Success Service is fully engaged throughout the project lifecycle to ensure maximum user adoption. Choosing Doriane means more than just acquiring new software; it's embarking on a digital transformation journey with a partner who supports you at every stage to maximize your benefits. Bloomeo agro-testing software manages the evaluation of varieties, inputs, biosolutions, or practices with a systemic approach, emphasizing the environmental context of field data. Bloomeo BioSolutions evaluates the conditions under which a biosolution performs optimally. Bloomeo Product Development software supports product development activities in agronomy: aligning product design with market segments, managing multi-environment trials, standardizing data collection, and optimizing team collaboration. RnDExperience software supports all stages of the breeding process, from crossing to selection and evaluation. Our motto is “Agronomy driven by data!” and stakeholders worldwide appreciate making informed decisions based on meaningful information. Let's discuss your project: https://www.doriane.com/book-a-demo

Dotmatics

Dotmatics

Herts, United Kingdom

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. Combining a workflow and data platform with best-of-breed applications, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Trusted by more than 2 million researchers from the world's leading biopharma, chemicals and materials enterprises, and academic institutions, we are dedicated to working with the scientific community to help make the world a healthier, cleaner and safer place to live. Learn more about our platform and products, including GraphPad Prism, Geneious, SnapGene, Protein Metrics, LabArchives, and more, at https://dotmatics.com.

Draper

Draper

Cambridge, Massachusetts, United States

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

DreaMed

DreaMed

14 Kaplan St, Institute for Endocrinology and Diabetes, Suite 20. POB 3271, Petah Tikva, Mercaz 4920235, IL

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Dxcover

Dxcover

Glasgow, United Kingdom

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

DynoSense

DynoSense

Sunnyvale, California, United States

DynoSense Corp. is a medical technology founded by successful high tech veteran, with a mission to “innovate best in class products and services for better, longer, and healthy life that are integrated, accurate, secure, elegant, and simple to use”. We call it “Innovation For Life”.

Dyno Therapeutics

Dyno Therapeutics

Cambridge, Massachusetts, United States

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

EchoNous

EchoNous

Redmond, Washington, United States

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

EDDA Technology, Inc.

EDDA Technology, Inc.

5 independence way, princeton, new jersey, united states, 08540

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

Eden Genetics Ltd

Eden Genetics Ltd

Scale Space, White City, London, England W12 7RZ, GB

Eden Bio uses machine learning to improve protein yield, saving companies time and money, and helping them get their proteins to market faster.

EdeniQ

EdeniQ

Visalia, California, United States

Edeniq, Inc. is a leading biotechnology company specializing in innovative, analytical solutions for the biofuels industry. With a focus on the analysis of fiber and cellulosic ethanol, Edeniq helps its customers quantify and qualify increased yield value and reduced carbon intensity, and optimize plant operations. Founded in 2008, Edeniq’s experienced team and strong customer focus have established the company as the top analytical testing service provider for ethanol producers across North America. Learn more at www.edeniq.com.

eHealth Global Technologies, Inc

eHealth Global Technologies, Inc

West Henrietta, New York, United States

Founded in 2006, eHealth Technologies is the industry-leading provider of clinically informed referral services. We serve more than half of the nationÕs top 100 hospitals, including 16 of the top 20 U.S. News & World Report Honor Roll Hospitals for 2016-2017, and leading health information exchanges (HIEs) across the United States. The companyÕs eHealth Connect¨ solution enhances patient and physician satisfaction by streamlining referrals and intelligently aggregating patientsÕ clinical records. This assures physicians have the right healthcare information to care for their patients, right when they need it. As a critical adjunct to HIEs, eHealth Connect¨ Image Exchange enables the automated access to all types of medical images in the context of the aggregated patient record, in full diagnostic quality, and supports the ability of providers to meet Meaningful Use Stage 2 requirements.

Eigen Therapeutics

Eigen Therapeutics

740 Broadway, Redwood City, CA 94063, United States

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eikon Therapeutics

Eikon Therapeutics

Hayward, California, United States

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

Eleven Therapeutics

Eleven Therapeutics

Cambridge, United Kingdom

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

Elnora AI

Elnora AI

Tallinn, Estonia

Elnora AI is revolutionizing drug discovery by harnessing the power of AI and the academic research community. This approach accelerates the R&D process, makes it faster, more cost-effective, and more reliable by avoiding repeated mistakes.

Elsi Beauty

Elsi Beauty

San Francisco, California, United States

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

Elucid

Elucid

Boston, Massachusetts, United States

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

Elucidata

Elucidata

New Delhi, India

Recognized as the 'Most Innovative Biotech Company, 2024', by Fast Company! Even today Early R&D, Precision Diagnostics and Translational Biomarker teams spend about 80% of their time wrangling data. Elucidata's mission is to empower scientists in the life sciences field by reclaiming every valuable hour for their research endeavors. Elucidata’s data harmonization platform - Polly, helps research teams make multi-modal biomedical data Machine Learning ready. Each dataset on Polly is processed consistently using pipelines of your choice, is custom curated with granular annotations and undergoes robust QA/QC checks to ensure highest data quality standards. Polly transforms multi-modal and multi-source biomedical data (Omics, Assay, Real World Data, Clinical & EHR Data, and CRO data) into a Unified Data Model. With our 10X faster LLM-powered curation and human-in-the-loop model to achieve 99.99% accuracy, we are fast-tracking time to analysis. Today, Polly is facilitating use case like patient stratification, biomarker discovery, target ID & validation, data management, and development of clinical and commercial pipelines across Pfizer, Janssen Pharmaceuticals, NextGen Jane and IMBDx and over 35 premier biopharma companies and research labs. Head-quarted in San Francisco, we are a 120+ multi-disciplinary team of experts based across the US and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our existing investors Hyperplane and IvyCap. Write to us at info@elucidata.io for queries To talk to us, visit: https://www.elucidata.io/book-a-meeting For more information, visit: https://www.elucidata.io/ Visit Our Offices - San Francisco Head Quarters: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Boston Office: 625 Massachusetts Avenue Cambridge, MA 02139 R&D Hubs, India - Delhi and Bangalore

Elypta

Elypta

Solna, Sweden

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

e-MDs

e-MDs

Austin, Texas, United States

CompuGroup Medical is a leading provider of healthy solutions for healthy patients and healthy providers. We offer integrated electronic health records, practice management software, revenue cycle management solutions, and credentialing services for physician practices and enterprises. Founded by physicians, the company is an industry leader for usable, connected software that enables physician productivity and a superior clinical experience. eMDs software has received top rankings in physician and industry surveys including those conducted by the American Academy of Family Physicians’ Family Practice Management, AmericanEHR™ Partners, MedScape®, and Black Book®. For more information, please visit http://www.emds.com.

Emerald Clinical

Emerald Clinical

#32-01, 300 Beach Road, The Concourse, Singapore, Singapore 199555, SG

Emerald Clinical is a global clinical research organization (CRO) that specializes in end-to-end clinical trial management. Operating in over 70 countries, the company has completed more than 600 clinical trials, with a strong focus on Oncology and Cardio-Renal-Metabolic research. With over 20 years of experience, Emerald Clinical aims to mitigate clinical development risks through localized solutions and scientific leadership. The company offers comprehensive services, including protocol design, site selection, and regulatory compliance. It emphasizes predictable trial delivery and inclusive trial design, ensuring diverse patient populations are represented in research outcomes. Emerald Clinical serves over 100 biotech companies and six of the top ten pharmaceutical firms, leveraging its expertise and reputation for reliability. The leadership team, supported by an advisory committee of active researchers and clinicians, is dedicated to advancing clinical research with transparency and innovation.

Emerald Therapeutics

Emerald Therapeutics

Menlo Park, California, United States

Emerald Cloud Lab® (ECL®) provides researchers from various disciplines with access to state-of-the-art scientific labs from anywhere on earth, 24 hours a day, 365 days per year. With ECL researchers utilize a single software interface to securely design, run, and analyze experiments, allowing researchers to spend more time designing protocols and analyzing data, and less time on mundane time-intensive activities in the lab. With ECL every researcher utilizing the platform becomes more productive, and more efficient while reducing operational costs and the impact on the environment.

Emmes

Emmes

Rockville, Maryland, US

Empire Genomics

Empire Genomics

Buffalo, New York, United States

Empire Genomics is a leading biotechnology company focused on the development of advanced molecular diagnostics and genomic products. Our mission is to accelerate precision medicine by providing tools that empower researchers, clinicians, and pharmaceutical companies to better understand, diagnose, and treat complex diseases, particularly in oncology. We offer an extensive portfolio of FISH (Fluorescence In Situ Hybridization) probes, ancillary reagents, and custom assay development services. These products are essential for detecting genetic abnormalities, such as gene amplifications, deletions, and rearrangements, critical for diagnosing and monitoring various cancers and genetic disorders. Committed to quality and innovation, our products are rigorously tested to meet the highest industry standards, ensuring reliable results. Selling products globally through a network of distributors, Empire Genomics continues to advance personalized medicine, enabling healthcare providers worldwide to deliver more targeted and effective treatments to patients.

Enamine

Enamine

Kyiv, Ukraine

Enamine has developed the world's largest reputable collection of chemical compounds, carefully designed and produced for Life Science industries. Stock collections: 4M+ screening compounds, 250k+ fragments, 300k+ building blocks. Comprehensive services in lead discovery and optimization are available including integrated biomolecular and ADME/TOX screening, all on-site.

EnClear Therapies

EnClear Therapies

65 Park St, 3, Newburyport, Massachusetts 01950, US

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease. The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for: › Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression. › Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Engimmune Therapeutics

Engimmune Therapeutics

Allschwil, Basel, Switzerland

Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain. Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology. Engimmune is based in a brand new science park in Allschwill, Basel in Switzerland

Engine Biosciences

Engine Biosciences

San Francisco, California, United States

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Enpicom

Enpicom

Amsterdam, Netherlands

ENPICOM is an innovative bioinformatics software engineering company committed to accelerating biologics discovery and development through cutting-edge bioinformatics solutions. With a deep understanding of biology, software engineering, and AI, ENPICOM delivers innovative tools that empower scientists to make groundbreaking discoveries faster and more accurately. For more information visit enpicom.com.

Entact Bio

Entact Bio

Watertown, Massachusetts, United States

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Enthought

Enthought

Austin, Texas, United States

Enthought specializes in digital transformation of science-driven companies in the materials science, chemistry, semiconductor, life science, and energy industries. In today's competitive global business environment, it's imperative that R&D organizations move from the traditional human-centric model to a digital, compute-centric infrastructure. Enthought is expert in this transition. We have been providing technical consultation and implementation services for scientific R&D for over 20 years.

Entos Pharmaceuticals

Entos Pharmaceuticals

10230 Jasper Avenue, Unit 4550, Edmonton, Alberta T5J 4P6, CA

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

Envisagenics

Envisagenics

New York, New York, United States

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Envoya

Envoya

Boston, MA

Enzymit

Enzymit

Pinhas Sapir Street 3, Daren labs, Ness Ziona, Center District, IL, 7403626

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Epigenic Therapeutics

Epigenic Therapeutics

Shanghai, China

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

Epistemic AI

Epistemic AI

New York, New York, United States

At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP. We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.

Epitel

Epitel

465 south 400 east, salt lake city, utah, united states

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Erasca

Erasca

San Diego, California, United States of America

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Essenlix

Essenlix

Monmouth Junction, New Jersey, United States

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Etcembly

Etcembly

Oxfordshire, United Kingdom

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

e-Therapeutics

e-Therapeutics

London, United Kingdom

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

Evaxion Biotech

Evaxion Biotech

Copenhagen, Hovedstaden, Denmark

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.

Evergreen Therapeutics, Inc.

Evergreen Therapeutics, Inc.

10411 Motor City Dr, Bethesda, Maryland 20817, US

埃格林医药是一家高速发展的国际化生物医药公司,以“关注临床迫切需求,惠及全球广大患者”为使命,致力于在全球范围内的临床研发与商业化推广

Everlum Bio

Everlum Bio

Austin, Texas, United States

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Every Cure

Every Cure

Philadelphia, PA

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

Evia Bio

Evia Bio

2001 6th ST SE, Room 2-434, Minneapolis, Minnesota 55455, US

Evia Bio™ is a life science innovation company enabling the growing cell therapy market. We provide new non-DMSO cryopreservation solutions developed by world-leading cryobiologist, Allison Hubel, PhD. We partner with cell therapy companies looking to advance their products to clinical trials and commercialization. Our solutions unlock the full potential of emerging life-saving therapies through the use of all-natural organic compounds to protect the integrity of cells during cryopreservation and patient safety at the point of care. Please visit www.eviabio.com.

Evidation

Evidation

San Mateo, California, United States

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

Evogene

Evogene

13 Gad Feinstein Street, P.O.Box 2100, Rehovot, Tel Aviv District, IL, 7612002

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

EvolutionaryScale

EvolutionaryScale

New York, New York

EvolutionaryScale is a biotech startup focused on AI research in the field of biology. The company has developed a database of over 2 billion protein sequences to train its AI model, offering technology that can provide insights into biological processes. EvolutionaryScale has raised significant funding, including a $142 million seed round, and is known for its ESM3 Generative AI Model for biology.

Evotec

Evotec

Hamburg, DE

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Evozyne

Evozyne

330 north wabash avenue, chicago, illinois, united states

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.

Exagen

Exagen

Vista, California, United States

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio

Exai Bio

3350 W Bayshore Rd, Palo Alto, California 94303, US

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Excelra

Excelra

Excelra Inc, 200 Middlesex-Essex Tpke, #204 Iselin, NJ, 08830-2033, US

Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 Excelra's interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. 𝗙𝗿𝗼𝗺 𝗖𝗵𝗮𝗼𝘀 𝘁𝗼 𝗖𝗹𝗮𝗿𝗶𝘁𝘆: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. 𝗖𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗚𝗼𝗮𝗹𝘀 Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.

Exegenesis Bio

Exegenesis Bio

Hangzhou, Zhejiang Province, China

Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The company’s innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs. Two programs have advanced to the clinical stage: (1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China (2) neurovascular AMD (wet AMD) rAAV gene therapy in USA The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Exegenesis Bio has raised over $150 M since inception in 2019 and currently employs over 200 scientific and operations staff worldwide. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com

ExpressionEdits

ExpressionEdits

Haverhill, Suffolk, United Kingdom

Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.

Expression Manufacturing

Expression Manufacturing

4692 Brate Dr, West Chester Township, OH 45011, USA

We are a specialty CDMO for LV vector manufacture & use. Our three platforms: Expression Cassette Optimization (ECO), LentET (3rd gen system), & LentET Express (cGMP mfg.) enable GMP LV manufacture 10 months from sequence submittal. ECO increases expression up to 8 fold. LentET plasmids are ECO optimized, have improved safety, produce potent LVs & may be available royalty/licensing free depending upon the specifics. With full CMC & regulatory support, Expression is your preferred CDMO of choice.

Exscientia

Exscientia

Oxford, United Kingdom

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Eyam Vaccines and Immunotherapeutics

Eyam Vaccines and Immunotherapeutics

Surrey, British Columbia

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

Eybna

Eybna

Hod Hasharon, Israel

Eybna is a technology company and a leading terpene manufacturer. Eybna's forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna's strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel, and a US office based in California.

Fable Therapeutics

Fable Therapeutics

Boston, Massachusetts, United States

Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. ‍ Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. ‍ With this passion and vision, we’re designing the future of drug discovery.

FAR Biotech

FAR Biotech

Houston, Texas

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Fauna Bio

Fauna Bio

820 Heinz Ave, Berkeley, California 94710, US

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

FDNA

FDNA

Boston, Massachusetts, United States

FDNA uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic intelligence to improve diagnostics and therapeutics.

Fibronostics

Fibronostics

3452 Lake Lynda Dr, Suite 151, Orlando, Florida 32817, US

Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics'​ LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics'​ HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients'​ risk levels and drive better patient care.

FIOS Genomics

FIOS Genomics

Edinburgh, United Kingdom

We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 15 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

Firefly Neuroscience

Firefly Neuroscience

Buffalo, New York, United States

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

First Ascent Biomedical

First Ascent Biomedical

Miami, Florida, United States

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

Flagship Biosciences

Flagship Biosciences

11800 Ridge Pkwy. Suite 450, Broomfield, Colorado 80021, US

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Flagship Pioneering

Flagship Pioneering

Cambridge, Massachusetts, United States

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Flomics

Flomics

Carrer de Roc Boronat, 31, Barcelona, Catalonia 08005, ES

Flomics is developing novel blood-based diagnostic tools for a broad range of complex diseases. Our proprietary technology accurately identifies pattern changes in the circulating long RNA molecules of patients. With deep learning algorithms we identify RNA changes associated with disease states in a faster, cheaper and non-invasive way.

FluoroFinder

FluoroFinder

Thornton, Colorado, United States

FluoroFinder is developing innovative cloud-based research tools for the search of fluorescent reagents and the design of medical experiments: accelerating the research initiatives aimed at curing Cancer, HIV, Multiple Sclerosis, in addition to other infectious diseases. Simplifying the complexity of managing the life-cycle of reagent selection, FluoroFinder's technology solutions offers unparalleled support and resources to core facilities and labs. Members receive additional benefits and support to drive efficiencies and resource savings. FluoroFinder's technologies save thousands of days - and millions of dollars - for research institutions every year! Please contact us at info@fluorofinder.com to request a demo.

Forever Oceans

Forever Oceans

Bethesda, Maryland, United States

Forever Oceans is pioneering a new way to produce delicious, natural seafood that's good for people and the planet. We combine our expertise in off-shore aquaculture with unique innovations to ocean-raise fish that are always delicious, healthy, and sustainable.

Formation Bio

Formation Bio

16 East 34th Street Floor 10

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

Form Bio

Form Bio

Austin, Texas, United States

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

Fraunhofer Institute

Fraunhofer Institute

Munich, Germany

Fraunhofer is EuropeÕs largest application-oriented research organization. Our research efforts are geared entirely to peopleÕs needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on peopleÕs lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas. In short, we forge the future.

Freenome

Freenome

279 E Grand Ave, South San Francisco, California 94080

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Frontier Medicines

Frontier Medicines

San Francisco, California, United States

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.

Gain Therapeutics

Gain Therapeutics

Bethesda, Maryland, United States of America

Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Galactica Biotech

Galactica Biotech

Cork, Ireland

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people.

Galatea Bio Inc.

Galatea Bio Inc.

14350 Commerce Way, Miami Lakes, Florida 33016, US

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

Ganymed Robotics

Ganymed Robotics

27, Rue du Faubourg Saint-Jacques, Hôpital Cochin, Paris, Île-de-France 75014, FR

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

GATC Health

GATC Health

Irvine, California, United States

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

GC Therapeutics

GC Therapeutics

cambridge, massachusetts, united states

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

Geisinger Medical Laboratories

Geisinger Medical Laboratories

Danville, Pennsylvania, United States

Geisinger Medical Laboratories, a medical reference laboratory in Pennslyvania (PA). Dedicated to caring, laboratory excellence, patient safety, quality assurance, and service excellence.

GEn1E Lifesciences

GEn1E Lifesciences

Palo Alto, California, United States

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.

Genedata

Genedata

Basel, Switzerland

Founded in 1997, Genedata delivers enterprise solutions to enable Biopharma R&D globally to discover, develop, and manufacture innovative biotherapeutics faster and more efficiently. Genedata combines computational, scientific, and technical expertise with extensive biopharma R&D domain knowledge to deliver user-friendly solutions that are scalable, open, and aligned with industry processes. Today, most of the leading pharmaceutical, biotechnology, and agrichemical companies, as well as innovative life science research institutions rely on Genedata. Genedata is proud to be part of Danaher. Danaher’s science and technology leadership puts Genedata’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Genemod

Genemod

Edmonds, Washington, United States

Genemod helps scientists maximize productivity in their research to drive the next generation of medicines. Genemod helps solve problems of data sharing and data archiving for research labs by providing inventory, experiment management, applications, and data, all in one collaborative workspace.

GenePlanet

GenePlanet

Ljubljana, Slovenia

GenePlanet is the leading European provider of preventive genetic tests, specialising in NIPT, cancer screening, and lifestyle DNA tests.   With over 15 years of experience in the market, GenePlanet collaborates with over 1000 medical centres, doctors, and insurance companies to provide top-quality tests based on the latest scientific discoveries. The company’s tests are designed to empower individuals to take control of their and their baby’s health, as well as assist doctors with therapeutic procedures. GenePlanet adheres to the highest standards of quality and is constantly striving for new discoveries through its research and development efforts. With a presence in more than 35 countries worldwide and over 100,000 satisfied customers, GenePlanet has been recognised as one of the 1000 fastest-growing companies in the EU by the Financial Times and one of the Top 35 EU Unicorns by the European Commission.

General Probiotics

General Probiotics

St. Paul, Minnesota, United States

The company offers products and services in:advanced probiotics and feed additivesgenetically engineered probioticsassays and screens of probiotics, andcustom probiotic fermentation.

Generate:Biomedicines

Generate:Biomedicines

Somerville, Massachusetts, United States

Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.

Geneseeq

Geneseeq

Toronto, Canada

Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.

Genesis Drug Discovery & Development (GD³)

Genesis Drug Discovery & Development (GD³)

2439 Kuser Rd, Hamilton, New Jersey 08690, US

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Genesis Therapeutics

Genesis Therapeutics

South San Francisco, California, United States

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

Genestack

Genestack

St. Petersburg, Russia

We are a global player in life-science R&D informatics, providing customers with cutting-edge multi-omics data management and integration software. We develop innovative off-the-shelf and custom solutions for clients in pharma, biotech, agriscience, consumer goods, and research centers. Omics Data Manager (ODM), our flagship product, helps organisations create a FAIR catalogue of multi-omics investigations (studies, samples, omics data), with powerful tools for curating rich and standardised metadata in bulk, as well as optimised RESTful APIs for scalable cross-study, cross-omics integrative search. We complement this product with a complete range of professional services including technology consulting, product implementation, managed service and co-development models. We are based in Cambridge, United Kingdom.

Généthon

Généthon

Every, France

Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases. At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.

Genetika+

Genetika+

Jerusalem, Israel

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Geneyx

Geneyx

Wilmington, Delaware, United States

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.

GENFIT

GENFIT

Cambridge, Massachusetts, United States of America

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.

Genialis

Genialis

177 Huntington Ave, Ste 1703 PMB 29417, Boston, MA 02115-3153, US

Genialis is a precision oncology company based in Houston, USA, founded in 2013. The company is dedicated to advancing drug programs from the lab to the clinic through its data science platform. Genialis aims to enhance cancer treatment effectiveness by utilizing advanced AI models and deep biological expertise to provide insights into patient responses and drug mechanisms. The company offers several key services, including therapeutic intelligence and biomarker discovery, which help pharmaceutical companies identify therapeutic targets and understand disease mechanisms. Genialis also provides digital disease models that uncover drug targets and biomarkers related to treatment efficacy and outcomes. Additionally, its precision medicine solutions leverage diverse datasets and AI to improve patient stratification and clinical success. Genialis primarily serves clients in the pharmaceutical industry, including biopharmaceutical firms, diagnostics companies, and clinical researchers, focusing on areas such as oncology, neurodegenerative disorders, and immunology.

GENinCode

GENinCode

Oxford, United Kingdom

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

Genix Cure

Genix Cure

Karachi, Sindh 05444, PK

At Genix Cure, we're on a mission to redefine well-being through the power of nature. We craft innovative, natural remedies that promote health and vitality, utilizing the genesis of nature's ingredients. Our commitment to authenticity and purity ensures that our products can be consumed daily, fostering wellness without compromise. Join us on our journey to a healthier, more rejuvenated life, where we believe that the path to well-being begins with nature's own genesis.

Gennova Biopharmaceuticals

Gennova Biopharmaceuticals

Plot P1 - P2, ITBT Park, Phase II, MIDC - Hinjawadi, Pune, Maharashtra 411057, IN

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

GenomeKey

GenomeKey

Bristol, United Kingdom

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

Genomenon

Genomenon

Ann Arbor, Michigan, United States

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Clinical Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.

GenomOncology

GenomOncology

Cleveland, Ohio, United States

GenomOncology enables real-time clinical decision-making at the point-of-care for Molecular Pathologists, Clinical Oncologists and Cancer Informaticists in their research of cancer treatments and therapies for cancer patients.

Genovac

Genovac

Fargo, North Dakota, United States

A One-Stop-Shop Gene to Antibody Partner Genovac is a contract research and manufacturing organization committed to positioning our clients for the successful development of new transformative drugs and diagnostics. Genovac specializes in antibody discovery and production against challenging targets. Our unique combination of genetic immunization, multiple host species, multiple single B cell platforms, and state-of-the-art production facilities enables us to serve as your one-stop-shop Gene to Antibody partner.

GenScript

GenScript

860 Centennial Ave, Piscataway, NJ 08854, US

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Gense Technologies

Gense Technologies

20/F, Devon House, Taikoo Place, 979 King's Road

Gense Technologies is a healthtech startup offering an affordable and portable health screening device for preventive care and chronic disease monitoring at elderly services, clinics and home care, specifically for liver, lungs, kidney and more. The company has secured investments from Alibaba Entrepreneurs Fund, Gobi Partners, HKUST, Cyberport, and HKSAR Government’s ITVF. The proprietary technology is developed by a team of PhDs and top talents in Hong Kong. Gense is also the Jumpstarter Global Competition, the Grand Award at Hong Kong ICT Startup Awards, and Forbes 100 to Watch. Gense is collaborating with healthcare providers in Hong Kong and globally to set up local deployment pipeline, including primary healthcare, hospital network, clinic chains, elderly service, and multinational conglomerates.

Gentuity, LLC

Gentuity, LLC

142 North Road, Sudbury, Massachusetts, USA, 01776-1142

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

Gero

Gero

Singapore, Singapore

We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once. You can find our publications here: https://gero.ai/publications

Gestalt Diagnostics

Gestalt Diagnostics

Spokane, Washington, United States

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals

New York, United States

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

Ginkgo Bioworks

Ginkgo Bioworks

Boston, Massachusetts, United States

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Gladstone Institutes (UCSF)

Gladstone Institutes (UCSF)

San Francisco, California, United States

Our mission is to use visionary science and technology to overcome major unsolved diseases.

Glytec

Glytec

Waltham, Massachusetts, United States

Glytec's industry leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing readmissions, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by 106 patents and over 100 publications. The Glytec Glucommander® solution, with clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics, is supported by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home. We are on a mission, join us. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.

GNS Healthcare

GNS Healthcare

Somerville, Massachusetts, United States

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

Gnubiotics

Gnubiotics

Epalinges, Switzerland

❌❓ THE CHALLENGE: Glycans hide the tumor in disguise. ➡ Typical cancer-specific Tumor Glycocodes render the tumor invisible to the immune system, they stay ‘cold’. Intelligently, glycans from that Tumor Glycocode are not present on neighbouring healthy tissue, rendering it a perfect target for eradication & potential use as biomarker for patient selection and treatment response. ➡ So far, efforts to break that code for therapeutic benefits have been unsuccessful. One reason for this is the dynamic shape & motion of glycans, and the inability to manufacture them ex vivo. ⭕❗ THE SOLUTION: Conjugated Glycopeptides. Gnubiotics’ proprietary technology conjugates O-glycans with short protein parts - peptides - ex vivo to form novel glycopeptides that are druggable targets amenable to mass production. 🔜 Breaking the Tumor Glycocode. Since 2019, multiple preclinical models have demonstrated proof of concept for the lead compound GNU101 to be orally bioavailable, resisting degradation, and surviving enzyme proteolysis. The preclinical body of evidence has demonstrated proof-of-concept that the GENESIS platform based glycopeptides are able to turn 'cold' into 'hot' tumors, breaking through I/O resistance and inducing tumor cell killing. 💡 THE TEAM: We are a highly specialized team of Founders, Scientists and Entrepreneurs pursuing the transition from a large basis of preclinical evidence into IND-readiness and the clinics with First-in-human clinical phase 1 study for colorectal cancer patients in 2024/2025. 📥 Curious to learn more? Check out our new website and contacts 🌐 https://gnubiotics.com/

Google

Google

Seattle, Washington, United States

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Google - Cloud LIfe Sciences

Google - Cloud LIfe Sciences

Mountain View, California, United States

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Gradiant Bioconvergence

Gradiant Bioconvergence

Seoul, KR

GRAIL

GRAIL

Redwood City, California, United States

Graph Therapeutics

Graph Therapeutics

Vienna, AT

Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.

Great Bay Bio

Great Bay Bio

Unit 518 of the 5th Floor of Building 11W, Phase Two, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, China

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Disruptive Revolution of Biologics Development. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

Greenstone Biosciences

Greenstone Biosciences

Palo Alto, California, United States

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Grey Matter Neurosciences

Grey Matter Neurosciences

Toronto, Ontario, Canada

Based on world-leading technology, we are developing a unique ultrasound helmet that is as portable as it is precise. Our first disease target: Alzheimer’s disease.

Gritstone Bio

Gritstone Bio

Emeryville, California, United States of America

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Grove AI

Grove AI

548 Market St, San Francisco, California 94105, US

Automate and scale your participant recruitment and engagement with the Grove AI Assistant and PRM™. Our AI assistant is available 24/7 and adapts to every trial, ensuring the right participants are connected to the best clinical trials.

Grove Biopharma, Inc.

Grove Biopharma, Inc.

1375 west fulton street, chicago, illinois, united states

Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Precision-Linked Proteomimetic therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.

Gryphon Scientific

Gryphon Scientific

Takoma Park, Maryland, United States

In April 2024, Deloitte acquired substantially all of the assets of Gryphon Scientific LLC. The team, comprised of life scientists and health researchers who apply rigorous scientific analysis to problems of global health and homeland security, is now part of the Deloitte GPS Federal Health sector. Our projects drive policy changes in security, preparedness, and science policy at the highest levels of US government.

GSK

GSK

Brentford, United Kingdom

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Guided Therapeutics

Guided Therapeutics

Norcross, Georgia, United States

Guided is a Georgia-based medical technology company that develops and commercializes non-invasive medical devices for early detection of cancer.

Harbinger Health

Harbinger Health

Cambridge, Massachusetts, United States

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

Harter Secrest and Emery LLP

Harter Secrest and Emery LLP

Rochester, New York, United States

Harter Secrest & Emery LLP is a full-service business law firm providing legal services to clients ranging from individuals and family-owned businesses to Fortune 100 companies and major regional institutions. With offices in Buffalo, Rochester, Albany, Corning, and New York City, New York, the firm is a recognized leader in litigation, corporate, employee benefits, environmental and land use, health care, higher education, immigration, intellectual property, labor and employment, real estate, and trusts and estates law. The firm and its attorneys are consistently recognized by the industry's leading law firm and attorney ranking programs, including Chambers and Partners, Best Law Firms® and The Best Lawyers in America®.

hc1

hc1

6100 Technology Center Drive, Building K, Indianapolis, IN 46278, US

hc1 + Accumen, together, unlock the vast potential of actionable lab data to transform labs into a strategic asset. Health system executives often face challenges in improving patient care and financial performance. By partnering with hc1 + Accumen, health systems can gain profitable new growth and improve patient outcomes. Our solutions use advanced data management, analytics, and workflow automation powered by AI to uncover actionable insights and hidden risk signals, delivering innovation, operational and clinical excellence, and revenue growth across the entire care continuum. With over a decade of experience and thousands of health systems and labs leveraging our technology and consultative services to care for nearly 100 million patients, we provide the expertise needed to unlock the strategic value of your lab data, improving patient outcomes and boosting financial performance. Healthcare Progress Starts Here.™ With hc1 + Accumen.

Health Technology Innovations, Inc.

Health Technology Innovations, Inc.

4640 SW Macadam Avenue, Suite 200D, Portland, Oregon 97239, US

HTI accelerates drug discovery for Biotech and Pharma companies by providing structure determination services using cryogenic-electron microscopy (cryo-EM) and machine learning based image processing software. As a member of the Oregon Bioscience Incubator, HTI is partnering with leading research institutions and cryo-EM centers.

Healx

Healx

Cambridge, United Kingdom

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

HeartBeam Inc. (NASDAQ: BEAT)

HeartBeam Inc. (NASDAQ: BEAT)

2118 Walsh Ave, Suite 210, Santa Clara , CA 95050, US

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

Heartflow

Heartflow

Redwood City, California, United States

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.

HeartVista

HeartVista

Menlo Park, California, United States

Vista.ai is harnessing the power of artificial intelligence (AI) to offer clinicians an easy, cost-effective and stress-free way to conduct MRI studies. The company's FDA 510(k) cleared MRI CoPilot™ software-only solution automates and dramatically simplifies a CMR exam, enabling any MRI tech to perform a CMR in a standard mixed-use scanner time slot. Available for use on Siemens Healthineers and GE Healthcare MRI scanners, MRI CoPilot™ • Eliminates the need for specialized CMR technologist • Allows CMRs to fit into your mixed-use scanner standard time slot • Makes scans less stressful for the technologist • Gives patients greater comfort and convenience Vista.ai is funded by Khosla Ventures, and the National Institute of Health's Small Business Innovation Research program.

Heinrich Heine University Düsseldorf

Heinrich Heine University Düsseldorf

Düsseldorf, DE

Heinrich Heine University Düsseldorf is a Higher Education institution that offers a wide range of academic programs and research opportunities.

HelixNano

HelixNano

700 Main St, Cambridge, Massachusetts 02139, US

HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology

Hengrui Therapeutics (Jiangsu Hengrui Pharmaceuticals Co., Ltd.)

Hengrui Therapeutics (Jiangsu Hengrui Pharmaceuticals Co., Ltd.)

Princeton, New Jersey, United States

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals

Hepion Pharmaceuticals

Edison, New Jersey, United States of America

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Hera Health Solutions

Hera Health Solutions

88 Union Ave, 200, Memphis, Tennessee 38103, US

Imagine your drug’s effect lasting for months, after one single dose, and with fewer side effects—Hera Health Solutions is turning this vision into reality. Pharma companies can rapidly turn their promising APIs into long-acting, precise, and profitable therapeutics. How? Through our proprietary, cutting-edge nanotechnology-based drug delivery platform. The best part? The platform is: ♻️ Biodegradable: Resorbs into the body. 💊 Versatile: Delivers your API through implants, pellets, patches, and more. ⏳ Long-acting: Lasting up to 48 months! We are focused on significant healthcare and industry challenges. Our mission is to revolutionize drug delivery and transform patient care. 💭 Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential. Or visit: https://www.herahealthsolutions.com/contact

Hexagon Bio

Hexagon Bio

Menlo Park, California, United States

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

HiFiBiO Therapeutics

HiFiBiO Therapeutics

Cambridge, Massachusetts, United States

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.

Hilo by Aktiia

Hilo by Aktiia

Neuchatel, Switzerland

Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. Hilo is transforming blood pressure monitoring with cuffless, AI-powered technology that delivers continuous, accessible insights for individuals and healthcare professionals. Our foundation model is trained on billions of optical signals and hundreds of millions of readings from over 120,000 users—one of the largest datasets in the field. Backed by a multidisciplinary team with deep expertise in biomedical signal processing, Hilo has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, we’re expanding globally to redefine how blood pressure is measured and managed.

Hippocratic AI

Hippocratic AI

Palo Alto, California, United States

Hippocratic AI’s mission is to develop the first safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Washington University in St. Louis, Stanford, Google, Microsoft, Meta and NVIDIA. Hippocratic AI has received a total of $137 million in funding and is backed by leading investors, including General Catalyst, Andreessen Horowitz, Premji Invest, SV Angel, NVentures (Nvidia Venture Capital), and Greycroft.

HistoIndex

HistoIndex

20 Science Park Road, #01-26, Singapore, Singapore 117674, SG

HistoIndex is a digital pathology company based in Singapore, founded in 2010. It specializes in AI-driven, stain-free tissue analysis, focusing on disease assessment, particularly for fibrosis and liver-related conditions. The company utilizes its proprietary Second Harmonic Generation (SHG) imaging technology to provide high-resolution visualization of collagen and other structural proteins, enhancing the accuracy of pathology assessments. HistoIndex offers stain-free digital pathology services that detect and quantify fibrosis, inflammation, and other biomarkers in tissues such as the liver, kidney, and skin. Its AI image-analysis platforms support reproducible quantification of morphological features, which is beneficial for clinical trials and diagnostics. The company collaborates with research institutions and pharmaceutical companies to evaluate drug efficacy in various diseases, including metabolic dysfunction-associated liver conditions. With a global presence, HistoIndex operates imaging centers and maintains partnerships across multiple countries, including the US, UK, and India.

HistoWiz

HistoWiz

Brooklyn, New York, US

Hologic

Hologic

Marlborough, Massachusetts, United States

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Honeywell International

Honeywell International

Morris Plains, New Jersey, United States

Honeywell is a Fortune 500 company that invents and manufactures technologies to address tough challenges linked to global macrotrends such as safety, security, and energy. With approximately 110,000 employees worldwide, including more than 19,000 engineers and scientists, we have an unrelenting focus on quality, delivery, value, and technology in everything we make and do. For additional information on how Honeywell processes your personal information please visit https://www.honeywell.com/privacy-statement.

Horizon Surgical Systems

Horizon Surgical Systems

malibu, california, united states

The Future of Microsurgery is Robotics and AI. Horizon Surgical Systems, founded in 2021 by experts in ophthalmology and medical robotics, is at the forefront of innovation in microsurgery. Our groundbreaking product, Polaris, leverages state-of-the-art robotics, advanced medical imaging, and AI to extend the capabilities of surgeons beyond their current limitations. With a foundation rooted in academic excellence and a vision for the future, Horizon is committed to revolutionize global healthcare through technological innovation, bringing a new era of precision, enhanced outcomes, and safety to eye care.

Horizon Therapeutics

Horizon Therapeutics

Dublin, Ireland

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

HotSpot Therapeutics

HotSpot Therapeutics

Boston, Massachusetts, United States

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

HT BioImaging (HTVet)

HT BioImaging (HTVet)

hod hasharon, center district, israel

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

Hua Medicine

Hua Medicine

275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, Shanghai, Shanghai CN

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

Hummingbird Bioscience

Hummingbird Bioscience

Singapore, Singapore

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Hummingbird Diagnostics

Hummingbird Diagnostics

Heidelberg, Germany

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

Hyperfine, Inc.

Hyperfine, Inc.

531A New Whitfield St, Guilford, Connecticut 06437, US

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

Iambic Therapeutics

Iambic Therapeutics

San Diego, California, United States

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

iBio Inc.

iBio Inc.

Bryan, Texas, United States

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

iCAD

iCAD

Nashua, New Hampshire, United States

At iCAD, we believe that is possible to create a world where cancer can't hide. Leveraging the power of artificial intellegence (AI), we empower healthcare providers to more accurately, reliably, and quickly detect disease and improve outcomes. The ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation providing certainty and peace of mind - Optimizing every patient's opportunity to live better, longer lives! To learn more, visit www.icadmed.com.

Icahn School of Medicine

Icahn School of Medicine

New York, US

ICON plc

ICON plc

San Diego, California, United States

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

iCura

iCura

Malvern, Pennsylvania, United States

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

Identifai-Genetics

Identifai-Genetics

Tel Aviv, Israel

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IFOWONCO

IFOWONCO

Vancouver, Canada

IFOWONCO uses advanced computational modelling techniques coupled with state of the art machine learning to rapidly identify and optimize drug candidates.

Ignota Labs

Ignota Labs

London, United Kingdom

More than half of all clinical trials fail due to safety issues. Discovering drugs that show therapeutic potential is difficult, time-consuming, and expensive. But of those found, it is harder still to find those drugs which do not also have severe side effects and can pass through clinical trials. Most of these drugs are shelved and never reach patients. Safety issues are tough to fix without weakening the therapeutic effect, involving a mix of chemistry, biology, and knowledge of how humans will respond. Our proprietary AI model, SAFEPATH©, applies deep learning to our combined bioinformatics and cheminformatics datasets to solve drug safety issues. SAFEPATH© utilises the latest deep learning approaches to identify the mechanism of toxicity, predict its effects on the human body, and balance that with therapeutic effectiveness. We are building at speed a robust pipeline of matured assets. We look at historically failed clinical trials to identify the most promising targets as well as internal projects that were abandoned. By focusing on safety problems that occur in Preclinical, Phase 1, or Phase 2 trials, we are able to identify the most promising drugs therapeutically, turn them around quickly, and get them to patients faster than starting drug discovery from scratch. Our mission is to bring more treatments to patients, faster. Thousands of life-changing drugs fall at the last hurdle and never reach patients. We’re here to change that.

Ikonopedia

Ikonopedia

Richardson, Texas, United States

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

Iktos

Iktos

Paris, France

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity. Please visit our webpage to know more about our products and offerings https://iktos.ai/products/

illumicell AI

illumicell AI

Boston, MA, US

AI-powered fertility care

Immunai

Immunai

New York, New York, United States

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Immune IQ

Immune IQ

1000 westgate dr, saint paul, minnesota, united states

Immune IQ has developed, in collaboration with Honeywell, the Immune Reveal platform. It reads disease information from a patient's immune system in 5 minutes to rapidly identify critical diseases, many not detectable today. Our powerful diagnostic approach has a much lower cost-per-test, a greater range of disease identification, and a shorter time to results than other cellular- and mRNA-based approaches. Immune IQ's initial focus is sepsis, one of the world's greatest healthcare challenges.

ImmunoMind.

ImmunoMind.

2150 Shattuck Ave, Penthouse, Suite 1300, Berkeley, California 94704, US

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

ImmunoPrecise Antibodies

ImmunoPrecise Antibodies

4837 Amber Valley Pkwy, Suite 11, Fargo, ND 58104, US

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

ImmunoScape

ImmunoScape

San Diego, California, United States

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.

IMU Biosciences

IMU Biosciences

London, GB

IMU Biosciences is a UK-based techbio company that is revolutionizing immune powered precision medicine by mapping the immune system in unprecedented detail and scale. Their CytAtlas platform combines systems-level immunophenotyping with an AI platform to gain a new understanding of the immune system across health and disease.

INanoBio

INanoBio

Menlo Park, California, United States

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Inari

Inari

Cambridge, Massachusetts, United States

Inari is the SEEDesign™ company, using new breeding technology to push the boundaries of what is possible by designing nature-positive seeds for a more sustainable global food system. A combination of AI-powered predictive design and a pioneered multiplex gene editing toolbox enables us to unlock the full potential of seed and advance critical solutions with broad applications for growing more food with fewer resources.

InBiome

InBiome

Amsterdam, Netherlands

By combining machine learning with advanced chemistry, inBiome enables microbiology labs over the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable- and antibiotics treated species are detected. Current applications include replacing traditional culture in ICU’s for more accurate, same day results, infection control, gut flora analysis and various r&d applications for healthcare, pharmacy and food industies. Promising new applications currently undergoing clinical trials include IBD and Sepsis dagnostics and preventive screening.

Inceptive

Inceptive

3440 Hillview Ave, D100, Palo Alto, California 94304, US

Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning life's languages to improve the lives of billions of people around the world, please visit our website.

Indiana University

Indiana University

Bloomington, Indiana, US

Indiana University is a Higher Education institution that provides academic programs and conducts research.

Indica Labs

Indica Labs

Corrales, New Mexico, United States

Indica Labs is a digital pathology company that specializes in advanced software solutions for medical imaging and analysis in the field of healthcare technology.

Inductive Bio

Inductive Bio

708 3rd avenue, new york, new york, united states

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

InduPro

InduPro

Seattle, Washington

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

IndyGeneUS AI

IndyGeneUS AI

Washington, United States

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

Infinitopes

Infinitopes

696 Roosevelt Drive

Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, developing vaccines for the treatment of cancer.

Inflammatix

Inflammatix

Burlingame, California, United States

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

InfoBionic

InfoBionic

Lowell, Massachusetts, United States

InfoBionic.Ai's MoMe® ARC system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

Innodem Neurosciences

Innodem Neurosciences

6666 St Urbain St, Montreal, Quebec, CA, H2S 3H1

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

Innophore

Innophore

Am Eisernen Tor 3, c/o Humboldtstraße 50/III, Graz, 8010, AT

Innophore is a biotechnology company based in Graz, Austria, founded in 2017. It specializes in drug and enzyme discovery, primarily serving the biotech and pharmaceutical industries. As a spin-off of acib GmbH and the University of Graz, Innophore is supported by strategic investor EOSS Industries GmbH. The company focuses on developing high-value industrial and therapeutic enzymes, as well as environmentally friendly chemical production processes. Innophore employs an AI-guided platform that utilizes advanced 3D point-cloud technology to analyze protein structures, enhancing the identification and optimization of protein candidates. Its Catalophore platform improves traditional methods, enabling more effective drug repurposing and side-effect prediction. With access to high-performance supercomputing resources, Innophore can analyze extensive protein structure databases, accelerating research and development in the biotech sector. The company collaborates with a diverse team of experts and has established partnerships with leading global companies, including Merck and Henkel.

InnovaFeed

InnovaFeed

Paris, France

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

Innovimmune Biotherapeutics

Innovimmune Biotherapeutics

New York, United States

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Insamo

Insamo

2630 Bancroft Way, Berkeley, California, United States

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding.

Inscripta

Inscripta

5720 Stoneridge Drive, Suite 300, Pleasanton, California 94588, US

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Insightful Science

Insightful Science

San Diego, California, United States

Buys life science software companies.

Insight Medbotics

Insight Medbotics

Greater Toronto Area, Ontario, CA

Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot inside an MRI, Insight Medbotics is now advancing the technology to improve the standard of care for prostate cancer. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.

InsightRX

InsightRX

San Francisco, California, United States

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

Insilico Medicine

Insilico Medicine

1000 Massachusetts Ave, Boston, Massachusetts 02138, US

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

insitro

insitro

South San Francisco, California, United States

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

Insmed Incorporated

Insmed Incorporated

Bridgewater, New Jersey, United States

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Integrated Biosciences

Integrated Biosciences

San Carlos, California, United States

We combine synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics.

Integro Theranostics

Integro Theranostics

16052 Swingley Ridge Rd, 300, St. Louis, Missouri 63017, US

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Intelerad Medical Systems

Intelerad Medical Systems

Montreal, Canada

Improving healthcare through innovative technology is at the core of Intelerad’s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We’re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations. For more information, visit www.intelerad.com. L'amélioration des soins de santé grâce à des technologies innovantes est au cœur du travail d’Intelerad. Notre plateforme d'imagerie médicale évolutive connecte les cliniciens à un écosystème d’images puissant, rapide et intelligent qui exploite les données dont ils ont besoin, peu importe leur emplacement. Nous concentrons nos efforts pour offrir la meilleure solution de gestion d'images médicales de l’industrie, qui augmente l'efficacité des fournisseurs, qui réduit le coût des soins de santé et qui améliore la santé globale des populations. Pour plus d'information, visitez www.intelerad.com/fr.

Inteliquet, an IQVIA business

Inteliquet, an IQVIA business

3500 south dupont highway, dover, delaware, united states

Inteliquet, an IQVIA business, Inteliquet is a leading provider of innovative technology and comprehensive support services for cancer clinical researchers. We bridge sponsors, patients and cancer centers nationwide for the ultimate purpose of increasing patient access to cancer trial treatment options. From trial selection to patient matching, Inteliquet enables a streamlined and more accurate journey to patient enrollment. To learn more about Inteliquet, visit https://inteliquet.com/

InterAx Biotech

InterAx Biotech

Villigen, Switzerland

InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. The company is specialized in GPCR drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan. InterAx Biotech is a Swiss drug discovery company that focuses on developing drugs targeting disease-specific GPCR heterodimers. The company is pioneering computational pharmacology for drug discovery and has entered into R&D agreements with other organizations for drug development. InterAx Biotech also announced the appointment of seasoned pharmaceutical executive, Mark Levick, MD, Ph.D., as a new board director.

InterVenn BioSciences

InterVenn BioSciences

Redwood City, California, United States

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Intus Bio

Intus Bio

Farmington, Massachusetts, United States

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Invasight AG

Invasight AG

zürich, zurich, switzerland

We are a Swiss-based early-clinical stage biotech start-up. Using our breakthrough technology, ACINDA, we develop first-in-class, protein-protein interaction antagonists against invasive cancers.  Invasight's precise therapies will make a positive difference in the lives of patients with invasive cancers. 

InveniAI

InveniAI

Branford, Connecticut, United States

InveniAI is pioneering AI and machine learning to map and identify breakthrough innovation across industries. Our platform, AlphaMeld, is an Artificial Intelligence (AI) based system that monitors millions of data points every day to identify signals for breakthrough events and provides a first mover advantage in detecting early signals of innovation. It combines human ingenuity and experience, with ceaseless, comprehensive and efficient machine learning that ensures no data point is missed in the pursuit of Alpha signals. AlphaMeld monitors developments daily across industries and rank orders them on their breakthrough potential. Visit www.inveniai.com for more details. Connect with us on Twitter: @Inveni_AI Careers: We are always on the lookout for talent to join our team at our US headquarters in Guilford, CT USA. We are not hiring at present. Please check back or contact us at +1 203 643 8002. Important Note on Our Hiring Process at InveniAI (inveniai) At InveniAI, we are committed to upholding the highest standards of transparency and integrity in everything we do. As part of our dedication to providing a fair and genuine hiring process, we would like to address a crucial matter. It has come to our attention that some individuals may be receiving fraudulent claims requesting money or personal information under the guise of being associated with InveniAI's hiring process. These unauthorized and fraudulent individuals are sending emails from domain names which are similar to our official domain name ‘inveniai.com’. When the recipient clicks on the domain name provided by the fraudulent individuals, they may be redirected to our website (www.inveniai.com). All individuals are requested not to communicate with any email id other than our official email id(s) that end with ‘@inveniai.com’. We want to make it clear that this is not how we operate, and we take this matter very seriously. Our Policy: No Course Registration: We want to emphasize that

Invenio Imaging

Invenio Imaging

2310 Walsh Ave, Santa Clara, California 95051, US

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

InvenireX

InvenireX

Milburn House, Dean Street; Newcastle Upon Tyne NE1 1LE

InvenireX is a biotechnology company developing real-time, ultra-sensitive Nucleic-acid detection instrumentation powered by the latest AI neural networks.

inviCRO

inviCRO

Boston, Massachusetts, United States

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

INVI MindHealth

INVI MindHealth

Denver, Colorado, United States

INVI MindHealth was founded at the University of Oxford and leverages learnings from the Health Pillar of The SEAL Future Foundation, a 501(c)3 co-founded by Jonathan. INVI combines the power of biometrics, deep learning analytics, and human networks to provide personalized mental health support.

InVirtuoLabs

InVirtuoLabs

Lugano, Switzerland

InVirtuoLabs is a new-generation laboratory for drug discovery. We design novel drugs by combining advanced machine learning techniques with physics-based simulations to rapidly identify and optimize promising drug candidates.

Invitrocue

Invitrocue

51 Science Park Rd, , #01-11/13 The Aries, Singapore Science Park II, , Singapore , Singapore 117586, US

Invitrocue Limited is a biotechnology company based in Singapore, founded in 2012. The company specializes in advanced 3D cell-based models and personalized oncology solutions, operating globally with a presence in Australia, China, Hong Kong, and Germany. Invitrocue offers a range of services, including the Onco Patient-Derived Organoid (PDO) Test, which uses patient-derived tumor cells to tailor cancer treatments. Their 3D CelluSponge Technology provides a scaffold-based system for drug metabolism studies, toxicology assessments, and infectious disease modeling. Additionally, they offer customized services for disease modeling and assays, focusing on respiratory diseases and liver infections, as well as digital pathology and medical imaging to support drug testing and organoid analysis. The company collaborates with industry networks to develop preclinical models, enhancing drug discovery and therapeutic outcomes.

ioGenetics, LLC

ioGenetics, LLC

3591 Anderson Street Suite 218, Madison, Wisconsin 53704, US

ioGenetics

IONpath

IONpath

Menlo Park, California, United States

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

IPA (ImmunoPrecise Antibodies)

IPA (ImmunoPrecise Antibodies)

4837 Amber Valley Pkwy, Suite 11, Fargo, ND 58104, US

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

IQVIA

IQVIA

Durham, North Carolina, United States

IQVIA applies data science to the continuous advancement of human science to make health care decisions more precise, relevant, and even creative.

iRhythm Technologies, Inc.

iRhythm Technologies, Inc.

650 Townsend St., Ste. 500, San Francisco, CA 94103, US

iRhythm Technologies, Inc. is a digital healthcare company focused on cardiac arrhythmia detection and management using AI-driven wearable technology. The company combines wearable biosensors, cloud-based analytics, and proprietary AI algorithms to analyze heart rhythm data, having served over 8 million patients and analyzed more than 1.5 billion hours of heartbeat data. The flagship product, Zio by iRhythm, is a comprehensive cardiac monitoring platform that includes discreet, long-term ECG monitors and cloud-based analytics that produce clinically actionable reports. iRhythm also offers end-to-end monitoring services for healthcare providers, streamlining the arrhythmia detection process. The company targets cardiologists and primary care physicians, as well as patients needing long-term cardiac monitoring, particularly those at risk of undiagnosed arrhythmias. Under the leadership of CEO Quentin Blackford, iRhythm aims to enhance patient care and reduce healthcare costs through early detection and personalized solutions.

IR-Med

IR-Med

20 Yahalom Street, Rosh Pinna, North District, IL, 1210002

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

Irvine Scientific

Irvine Scientific

Santa Ana, California, United States

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

Isogenica

Isogenica

Little Chesterford, United Kingdom

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Isomorphic Labs

Isomorphic Labs

100 new bridge street, london, greater london, united kingdom

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we're working at the cutting edge in the new era of ‘digital biology'. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.

iSono

iSono

South San Francisco, California, United States

The iSono Health has developed the world’s first AI-driven platform with an automated, portable, and wearable ultrasound to empower women and their physicians with early breast cancer detection and monitoring. Our patented compact ultrasound scanner captures 3D images by automatically scanning the whole breast volume in 2 minutes. The device connects to a smartphone/tablet/laptop. The data is transferred to a secure cloud for image processing and storage. Our machine-learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expand ultrasound use in point-of-care diagnostics and monitoring of breast health at radiology centers, walk-in, and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

Isospec Analytics

Isospec Analytics

Lausanne, Vaud, Switzerland

Isospec Analytics is a life science company that aims at simplifying molecular identification. They provide high detection sensitivity suitable for bioanalytical applications and offer next-level molecular intelligence to empower biotechnology. Their technology takes the guesswork out of biomolecular analysis and they have raised $1.9m for their breakthrough biomolecular analysis technology.

IUPUI

IUPUI

Indianapolis, Indiana, US

IUPUI is a Higher Education institution that offers a wide range of academic programs and research opportunities.

IVBH Bio

IVBH Bio

Newport Beach, California, United States

We are on a mission to create the next century’s worth of impact on human health, starting with early detection. Since our founding in 2018, we have been operating at the convergence of artificial intelligence, transcriptomics and liquid biopsy — applying the most advanced compute to the most fundamental language of the human cell to create the world’s most advanced early detection blood tests. Our disease-agnostic platform is revolutionizing healthcare diagnostics, providing a reliable and scalable approach to solving real-world problems for pandemic diseases, from oncology to metabolic health. To date, our brain trust of visionary entrepreneurs and world-class scientists and technologists have conceived, created and scaled three pioneering early detection companies — @mammogen, @liquidlung & @hepgene — leveraging our novel end-to-end AI-powered platform to usher in a new era of clinical assays capable of detecting early-stage disease with unprecedented accuracy, affordability and accessibility. To learn more about us visit IVBH.studio or send us a note at info@IVBH.studio.

iVis Technologies S.r.l.

iVis Technologies S.r.l.

Via Luigi Corsi, 50, Taranto, TA 74121, IT

We, at iVis Technologies, are considered as the pioneers and innovative thinkers in corneal eye surgery since 1996, the year we launched CIPTA®, our dedicated software for corneal surgery customization, while the majority of refractive surgeries were executed as standard ablations worldwide. Since then, we also considered low invasiveness treatments and patients' wellbeing as the fundamental driving concepts in our R&D activities and thus we developed cTen™, our exclusive no-touch one-step procedure for refractive and therapeutic corneal surgery as the ultimate alternative to LASIK and patient's safety. Nowadays, we are offering the 4D iVis Suite™. the most advanced corneal surgery platform, which includes a comprehensive refractive products portfolio of medical devices. Our iVis Suite™ gives Surgeons the ultimate capability to execute customized refractive treatments correcting wide range of corneal refractive errors with outstanding clinical results and with the lowest possible invasiveness. iVis' R&D activities, along with our mindset for continuous innovation, are the core of our care. Core is Care. Recently, we have introduced the second generation of Precisio™, the world's most advanced High Resolution Tomographer, able to detect the whole anterior corneal segment, incorporating highly detailed epithelial maps and uniquely using a voice driven full automated exam acquisition, for corneal pathology diagnosis and corneal surgery.

IXICO

IXICO

15 Long Lane, London, EC1A 9PN, GB

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

JADBio

JADBio

Los Angeles, California, United States

JADBio’s purpose-built AutoML platform provides leading-edge AI tools and automation capabilities enabling life-science professionals to build and deploy accurate and interpretable predictive models with speed and ease, even if they have no data science expertise. For life-science professionals, knowledge discovery is fundamental and sets the requirements apart when it comes to data analysis. JADBio can analyze small sample sizes or very large feature sets, focusing on feature selection and interpretation of the predictive model.

Jan Medical

Jan Medical

Mountain View, California, United States

Jan Medical is a medical device start-up company dedicated to providing physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technology, BrainPulse, uses accelerometers on a non-invasive headset to detect skull motion resulting from pulsatile blood flow into the brain. The BrainPulse system is an FDA cleared device for cranial motion measurement currently under research for a variety of neurological conditions. Jan Medical has developed clinical experience and collected valuable clinical data with the BrainPulse device in a variety of indications such as concussion, stroke, aneurysm, AVM, and vasospasm detection. Visit us at www.janmedical.com to better understand our company, our technology and our people.

Janssen Pharmaceuticals

Janssen Pharmaceuticals

1000 U.S. 202, Raritan, NJ 08869, United States

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

Javelin Biotech

Javelin Biotech

Woburn, Massachusetts, United States

Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing. The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery.

JaxBio

JaxBio

Tel Aviv, Israel

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

JD Bioscience

JD Bioscience

Gwangju, Kwangju-jikhalsi, South Korea

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

Jeeva Clinical Trials Inc.

Jeeva Clinical Trials Inc.

10432 Balls Ford Rd Suite 300, MANASSAS, VA 20109, US

Jeeva Clinical Trials Inc. specializes in decentralized clinical trial solutions, offering a unified SaaS platform that enhances global patient engagement and streamlines trial operations. The company utilizes AI-powered tools and modular technology to support efficient trial management, allowing sponsors and medical centers to conduct studies under a single login. Their services include decentralized and hybrid trial solutions, patient recruitment and retention tools, and comprehensive clinical data management. Jeeva's platform features a next-generation Clinical Trial Management System (CTMS) for real-time oversight and protocol adjustments. The company prioritizes security and compliance, adhering to HIPAA, GDPR, and other regulatory standards. Jeeva has successfully implemented its solutions in oncology trials, achieving significant improvements in patient enrollment and data accuracy. They also support academic research, reducing costs and administrative burdens for campus-based studies. With a focus on scalability and workflow standardization, Jeeva provides a patient-centric approach to modern clinical trials.

JOGO Health

JOGO Health

991 US Highway 22 West, Suite 200, Bridgewater, NJ 08807

JOGO Health uses wearable sensors and AI to treat chronic pain, migraine, post-stroke, and pelvic floor disorders using the foundational science of digital therapeutics.

Johns Hopkins University

Johns Hopkins University

Baltimore, Maryland, US

Johns Hopkins University is a higher education institution known for its research initiatives and academic programs.

Journey Biosciences

Journey Biosciences

15473 Neo Pkwy, Cleveland, Ohio 44128, US

✨ Journey Biosciences is on a mission to shift the future of care. 🧬 Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass™, to offer up to 12 years of advanced diabetes-related kidney disease (DKD) detection, plus tailored intervention strategies to slow or prevent progression. 🎯 This approach improves patient outcomes, optimizes resource allocation, and reduces costs. 🔍 Discover more about our transformative approach at journeybio.life.

JuneBrain Inc.

JuneBrain Inc.

101 W Dickman St, Suite 703, Baltimore, Maryland 21230, US

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

Junevity

Junevity

135 mississippi street, san francisco, california, united states

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Juvena Therapeutics

Juvena Therapeutics

Palo Alto, California, United States

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Juvenescence

Juvenescence

Dublin, County Dublin, Ireland

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.

Kadence Bio

Kadence Bio

15 Southampton Place, London, England WC1A 2AJ, GB

We are a clinical stage company developing novel therapeutics inspired by kanna, or Sceletium tortuosum. Kanna is a medicinal succulent traditionally used by the San hunter-gatherers of South Africa.

Kailera Therapeutics

Kailera Therapeutics

Waltham, MA; San Diego, CA

Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Kailos Genetics

Kailos Genetics

601 Genome Way, Huntsville, AL 35806, US

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

Kainos Medicine Usa

Kainos Medicine Usa

institut pasteur korea, 4th floor, 16, 712 beon-gil, daewangpangyo-ro, bundang-gu, seongnam-si, ca, korea, republic of

치료 약물이 없는 뇌퇴행성 질환과 암 질환을 타겟으로 한 혁신 신약 개발 전문기업

Kapoose Creek Bio

Kapoose Creek Bio

vancouver, british columbia, canada

Kapoose Creek Bio is a Canadian biotech company using AI technologies to uncover small molecule medicines from nature with unprecedented speed and scale. Our R&D efforts are supported by off-grid research facilities in the hunt for undiscovered chemistry in environments of unique biodiversity. We have developed a platform – unEarth Rx – that integrates phenotypic screening with advanced machine and deep learning to accelerate the identification of high-quality drug leads and simultaneously determine their mechanism of action. The result is a comprehensive, data-rich, functional map of nature's chemistry for accelerated discovery and development of new small molecule medicines. We are building a diversified portfolio of stakes in the next generation of critical medicines, focusing our platform on neuroscience, cancer and infectious disease. Currently our development pipeline is concentrated on lead assets with exciting potential in neurological indications.

Karius

Karius

Redwood City, California, United States

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

Karolinska Institute

Karolinska Institute

Stockholm, Sweden

The Karolinska Institute is a research-led medical university in Solna within the Stockholm urban area of Sweden. It covers areas such as biochemistry, genetics, pharmacology, pathology, anatomy, physiology and medical microbiology, among others.The Institute is developing aDNA vaccine against COVID-19with electroporation delivery in partnership with Cobra Biologics as part of the OPENCORONA Project.

Kerna Labs

Kerna Labs

San Francisco, California, United States

Kerna Labs is unlocking the full potential of mRNA as the universal toolkit for genetic medicine.

Kernal Biologics

Kernal Biologics

Cambridge, Massachusetts, United States

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Kimia Therapeutics

Kimia Therapeutics

Berkeley, California, United States

Kimia Therapeutics is generating a chemical atlas for treating human disease. Kimia's ATLAS is the key to druggable space, unlocking the potential of generative chemistry. The company is focused on drug discovery and developing disease-modifying therapies for metabolic diseases.

Kingston Health Sciences Centre

Kingston Health Sciences Centre

Kingston, CA

Kingston Health Sciences Centre is a healthcare provider that offers a range of medical services and healthcare solutions.

Kiragen Bio

Kiragen Bio

Boston, Massachusetts, United States

KiraGen Bio is pioneering the next wave of cancer treatment through AI-driven, multiplex gene-edited CAR-T cell therapies, targeting the challenging realm of solid tumors. Despite the transformative success of cell therapies in hematologic cancers, solid tumors — which constitute the majority of cancer cases — have remained elusive to current treatments due to their complex tumor microenvironment (TME). Our mission is to breach this final frontier, leveraging our proprietary AI platform and combinatorial gene editing to design CAR-T cells capable of overcoming the immunosuppressive barriers of the TME. Founded on the belief that every cancer patient deserves a chance at a cure, KiraGen Bio combines the latest in biotechnology and computational science to bring innovative therapies from the lab to the clinic. Our team, comprised of experts in oncology, immunology, gene editing, and artificial intelligence, is dedicated to creating effective, durable treatments for solid tumors. KiraGen Bio stands at the intersection of innovation and hope, where cutting-edge science meets the urgent need for more effective cancer treatments. Our integrated approach spans from discovery through clinical development, embodying a commitment to excellence, patient-centricity, and the relentless pursuit of curing cancer. Join us as we work to transform the landscape of cancer therapy and bring new hope to millions of patients worldwide.

Kiromic Biopharma

Kiromic Biopharma

Houston, Texas, United States

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

KisoJi Biotechnology

KisoJi Biotechnology

Montreal, Quebec, Canada

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology.

Kleiner Device Labs

Kleiner Device Labs

999 Driver Way, Incline Village, Nevada 89451, US

Kleiner Device Labs - Advancing Minimally Invasive Spinal Surgery™ During 25 years of active spinal surgical practice and over 6,000 surgeries, Dr. Jeffrey Kleiner became increasingly aware that instrument design and quality played a significant role in the clinical outcome of spinal surgery. He recognized key gaps in the instrumentation available to spinal surgeons and this led him to develop a series of innovative solutions. In 2013, Dr. Kleiner established Kleiner Device Labs to build and sell innovative spinal surgical products. These novel and advanced tools deliver improvements in efficiency and safety for patients and enable surgeons to perform more effective and less complicated fusion surgery. Kleiner Device Lab's first product, a Bi-Directional Graft Funnel (KG™1), works with any flowable biologic graft material, provides a more efficient and safer delivery vehicle for bone graft extenders, facilitates grafting in front of or alongside all types of interbody cages and can eliminate or reduce surgeon dependency on BMP. Building on the underlying philosophy behind the KG™1, Kleiner Device Labs developed the KG™2 Surge™ Flow-Thru Interbody Implant in 2021. No other device integrates implant positioning and graft delivery like the KG™2 Surge™. The system not only maximizes successful outcomes for patients (while simplifying the procedure for surgeons) but reduces costs for healthcare providers and insurers as well. Kleiner Device Labs has a broad patent portfolio and a runway of innovative minimally invasive spinal surgical products. These strategies are equally effective in open theater surgical technique as well.

Kobiolabs

Kobiolabs

Gyeonggi, South Korea

KoBioLabs is recognized for its international level of microbiome therapeutic technologies. In particular, our researchers have a distinctive position in the microbiology field globally with their presence in the ongoing International Human Microbiome Consortium [IHMC].

Koidra

Koidra

Seattle, Washington, United States

Koidra is an intelligent automation company, dedicated to modernizing the automation of manufacturing facilities, with the high-tech greenhouse industry being the core market. Our tiered products deliver a comprehensive solution that enhances industrial efficiency.

Koios Medical

Koios Medical

Piscataway, New Jersey, United States

Koios DS™ is a Smart Ultrasound™ solution for radiologists diagnosing cancer. Using AI algorithms trained on tens of thousands of images combined with data from pathology results, Koios DS™ is clinical decision support for a new era of diagnostic excellence. Smart Ultrasound™ redefines what radiology professionals can discern in the radiology suite. Our proprietary technology and patented methods provide an invaluable “second opinion” that is already being adopted by leading healthcare institutions to improve diagnostic accuracy, speed clinical decision making, and elevate the quality of care. Our software is FDA cleared for use in the USA. Koios DS. We put the AI in ultrasound.

Koliber Biosciences

Koliber Biosciences

Lakeside, California, United States

Koliber Biosciences is a biotechnology company that accelerates biomedical discoveries using machine learning and artificial intelligence.

Koning Health

Koning Health

Norcross, Georgia, United States

Koning Corporation develops and manufactures advanced medical imaging systems for breast cancer detection using cone-beam computed tomography technology. This revolutionary technology provides true 3D images for early breast cancer detection, providing a significantly more accurate and effective test than mammography and tomosynthesis. Koning's vision is to fundamentally change breast cancer is detected and diagnosed, with earlier detection, increased patient comfort and lower costs. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications. Our hope is to be able to improve survival rates and outcomes for millions of patients. Koning Corporation's core technologies are protected by over 80 patents globally, and has received regulatory approval in the US (FDA), Europe (CE-Mark), China (CFDA), Australia (TPG), and Canada (Health Canada). Koning has been the beneficiary of over $17 M in venture funding and over $20 M in government grants to bring this exciting technology to market. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body.

Korea University

Korea University

Seoul, KR

Korea University is a higher education institution that offers academic programs and conducts research.

Korro Bio, Inc.

Korro Bio, Inc.

Cambridge, Massachusetts, United States of America

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

KOTAI Biotechnologies, Inc.

KOTAI Biotechnologies, Inc.

Suita, Osaka 565-0871, JP

KOTAI Biotechnologies, Inc. (KOTAI, Osaka, Japan) is a spinout from Osaka University's world leading research center, Immunology Frontier Research Center launched in 2016. Our unique and sophisticated bioinformatics based on deep structure understandings has enabled us to analyze high throughput sequencing data of the immune systems such as Immune repertoire (BCR, TCR, antibodies, etc) and RNA-seq data. KOTAI is working on discoveries of new biomarkers and therapeutic compounds through the repertoire analysis.

Küleon Bioscience

Küleon Bioscience

SEATTLE, Washington

Küleon is a drug discovery company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!

kyron.bio

kyron.bio

Labby

Labby

Cambridge, Massachusetts, United States

We are building next-generation products to transform how food testing is done, providing fast, accurate, and affordable testing solutions for consumers and businesses so they can test anytime and anywhere. At its core, Labby is an AI-powered spectrometer. It is portable and super versatile. It combines the power of optical sensing and machine learning so it can be used in many industrial applications beyond food.

LabGenius

LabGenius

201.3 Building B, Biscuit Factory, 100 Drummond Road, London SE16 4DG, England, United Kingdom

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics.

Labvantage

Labvantage

Somerset, New Jersey, United States

Headquartered in Somerset, NJ with offices around the world, LabVantage Solutions, Inc. provides laboratories with a comprehensive portfolio of informatics products and services, including LIMS (Laboratory Information Management System), integrated electronic laboratory notebook (ELN) and business intelligence. Our industry-leading solutions and services are the result of 35+ years of experience in laboratory informatics. We leverage that knowledge with state-of-the-art technology to help organizations redefine and optimize the way their laboratories conduct business. LabVantage has a solid track record of delivering return on investment to laboratories of all sizes. Our capabilities extend to legacy system migration, global laboratory harmonization, and laboratory business intelligence derived from disparate sites and systems. LabVantage delivers the best technical and domain expertise available to help you drive the success of your business. To find out more, visit us at: http://www.labvantage.com.

Lantern Pharma

Lantern Pharma

Dallas, Texas, United States

Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Latent Labs

Latent Labs

We are making biology programmable to transform health and sustainability for the benefit of all. We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizing existing enzymes, and advancing genetic engineering. Contact us to work with us today.

LatentSpace Therapeutics

LatentSpace Therapeutics

At LatentSpace Therapeutics, we are at the forefront of a medical revolution. Leveraging advanced AI technology, we are pioneering the development of groundbreaking medicines for some of the most challenging cancers and complex diseases. Our innovative approach harnesses the power of an AI-driven virtual drug company to conduct comprehensive in-silico testing for retrosynthesis, toxicity, and most importantly, efficacy -- dramatically accelerating the discovery process. Our unique platform enables us to identify promising therapeutic candidates at an unprecedented pace, significantly reducing both the time and cost associated with traditional drug development. This efficiency does not come at the expense of quality; our rigorous in-silico testing ensures that only the most effective and safe compounds move forward in the development pipeline. We are committed to delivering new hope to patients battling difficult-to-treat cancers. By streamlining the path from discovery to development, we aim to bring novel, life-saving treatments to market faster than ever before. Join us as we transform the future of drug development, one breakthrough at a time.

Lattice Automation

Lattice Automation

Boston, Massachusetts, United States

Lattice Automation provides complete solutions to fundamentally change the way that biological designs are conceived, designed, physically created, and managed. Our technology builds upon state-of-the-art techniques in computer science, electrical engineering, and bioengineering. We're hiring!

Layer Health

Layer Health

Boston, Massachusetts, United States

Layer Health is a healthcare AI company spun out of MIT and backed by GV (Google Ventures), General Catalyst, MultiCare Health System and Froedtert Health. We are solving the information problem in healthcare.

Laza Medical

Laza Medical

los gatos, california, united states

Laza Medical is a healthcare technology company based in California, founded in 2020. As a portfolio company of Shifamed, it focuses on developing innovative solutions for cardiovascular interventions. The company specializes in AI-powered robotic assistance technology, which enhances medical imaging and procedures. Laza Medical's main offering is an advanced imaging solution that supports cardiovascular interventions. This solution utilizes AI and robotic technology to provide navigation tools for structural heart and electrophysiology procedures in cath labs. The company aims to improve the precision and efficiency of these medical procedures through its technology. In December 2023, Laza Medical raised $36 million in a Series A funding round, led by The Capital Partnership, with participation from investors like Unorthodox Ventures and GE Healthcare Financial Services. With its innovative approach and strong funding support, Laza Medical is positioned to make a notable impact in the medical technology field.

LBT Innovations

LBT Innovations

Adelaide, Australia

LBT Innovations is a medical technology company that utilizes artificial intelligence to deliver automation in healthcare through a patent-protected machine learning and intelligent imaging platform.

Leanbio

Leanbio

Av. Dr. Marañón 8, Barcelona, Cataluña 08028, ES

Leanbio is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Barcelona, founded in June 2014. The company specializes in the development and manufacturing of biologics, focusing on accelerating the time-to-market for New Biological Entities (NBEs) and biosimilars. Leanbio adheres to Quality-by-Design (QbD) principles and maintains regulatory compliance throughout its processes. The company offers comprehensive services across the biopharmaceutical product lifecycle, including feasibility studies, process development, analytical development, and manufacturing. Leanbio's capabilities encompass the production of therapeutic molecules such as antibodies and enzymes, as well as nucleic acids like mRNA and plasmid DNA. Their facilities include a 4,000 sqm GMP site in Barcelona, equipped for both microbial and mammalian production, and they have the capacity to handle high-potency products. Leanbio serves a diverse range of sectors, including pharmaceuticals, biotechnology, cosmetics, and agro-food, having supported over 100 therapeutic candidates in various stages of development. Their flexible platforms and regulatory expertise enable them to provide tailored solutions while minimizing intellectual property constraints for their clients.

Leash Bio

Leash Bio

48 South Rio Grande Street, Salt Lake City, Utah, 84101

Leash Bio is a biotechnology company that is transforming drug design with a rich dataset built by screening millions of compounds against thousands of proteins to generate billions of data. They are pioneering AI-driven medicinal chemistry and unleashing machine learning to solve medicinal chemistry.

Leica Biosystems

Leica Biosystems

Buffalo Grove, Illinois, United States

Leica Biosystems is proud to be part of Danaher. Danaher's science and technology leadership puts Leica Biosystems' solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems' Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.

Leica Microsystems

Leica Microsystems

Buffalo Grove, Illinois, United States

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Ever since the company started as a family business in the nineteenth century, its instruments have been widely recognized for their optical precision and innovative technology. It is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes. Leica Microsystems has seven major plants and product development sites around the world. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany. Leica Microsystems is proud to be part of Danaher Danaher's science and technology leadership puts solutions from Leica Microsystems at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Leman Bio

Leman Bio

Futian District International

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

Leman Biotech

Leman Biotech

Lausanne, Switzerland

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

Leuko

Leuko

8 St Marys St, Boston, Massachusetts 02215, US

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Life Adapt

Life Adapt

Los Angeles, California

LifeAdapt is at the forefront of AI technologies that promote healthy living.

Lifebit

Lifebit

Hackney, United Kingdom

At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.

Life & Brain

Life & Brain

Bonn, Germany

Your partner for nucleic acid extraction, biobanking, genotyping, epigenetics, transcriptomics, NGS, proteomics and bioinformatics.

Life Chemicals

Life Chemicals

Niagara-on-the-Lake, Canada

Life Chemicals Inc. Niagara-on-the-Lake, Canada, specializes in state-of-the-art organic synthesis for high-throughput screening: - Drug-like and lead-like screening compounds; - Carefully designed targeted libraries; - Building blocks and intermediates; - Custom synthesis projects. As an advanced synthetic laboratory Life Chemicals employs the high skills and research abilities of more than 80 qualified professionals. It also takes advantage of its co-operation with 14 leading Universities, Academic and industrial laboratories and is the largest exporter of their HTS compounds. Life Chemicals operates worldwide and in addition to its main office in Niagara-on-the-Lake, Canada, it has a US office in Orange, CT, and a European office in Munich, Germany. The production site is located in Kyiv, Ukraine. The Company sells its products and services to more than 1000 customers, with its sales volume steadily growing. Keeping pace with market demands, Life Chemicals does offer mutually beneficial terms and very competitive prices, thus making the ratio of product quality and its cost most attractive for our customers.

Lifecode

Lifecode

Foster City, California, United States

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

LifeMap Sciences

LifeMap Sciences

Alameda, California, United States

LifeMap Sciences offers a leading integrated biomedical knowledgebase for empowered life sciences research and precision medicine, and a powerful advertising products for research reagents. Our products are used by more than 5 million researchers from both academia and the biopharma industry. GeneCards (www.genecards.org) is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. The knowledgebase automatically integrates gene-centric data from ~150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information. MalaCards (www.malacards.org) is an integrated database of human maladies and their annotations, modelled on the architecture and richness of the popular GeneCards database of human genes. Today, it offers information about 22,060 disease entries, consolidated from 74 sources

LifeNome

LifeNome

New York, New York, United States

LifeNome's AI algorithm looks at 9000+ genetic variations holistically (rather than other companies that look at single gene associations)to assess your overall predispositions for nutrition, fitness, skin care and many more wellness traits.​

Lifespin

Lifespin

Regensburg, Germany

Lifespin GmbH, a deep data company developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples. Our platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin's health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.

Ligandal

Ligandal

San Francisco, California, United States

Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.

Ligence

Ligence

T. Kosčiuškos g. 24, 104, Vilnius, Vilniaus 01100, LT

Cardiac ultrasound is a safe and inexpensive test for monitoring and preventing heart disease. Manual work (e.g. measuring, writing report) takes 50-85% of test time. We make cardiac ultrasound more accessible, cheaper and less human reliant by automating the analysis.

Lila Sciences

Lila Sciences

Cambridge, Massachusetts, United States

Lila is a technology company pioneering the application of artificial intelligence to transform every aspect of the scientific method.

Lindus Health

Lindus Health

New York, New York, United States

Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations.To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp.

Linguamatics

Linguamatics

Cambridge, United Kingdom

Founded in 2001, Linguamaticsusesnatural language processing (NLP)-based text mining for high-value knowledge discovery and decision support.

LinkGevity

LinkGevity

Cambridge, GB

Based at the Babraham Research Campus in Cambridge, LinkGevity is a pioneering drug discovery company founded on ground-breaking research in longevity science. Our goal is to change the paradigm of ageing, paving the way for people to live healthier lives for longer.

Livongo

Livongo

Mountain View, California, United States

Livongo is now a part of Teladoc Health. Teladoc Health is transforming the healthcare experience and empowering people everywhere to live healthier lives. Recognized as the world leader in whole person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person's health journey. In more than 175 countries and ranked Best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Liying Biotechnology (Shenzhen Liying Biotechnology Co., Ltd.)

Liying Biotechnology (Shenzhen Liying Biotechnology Co., Ltd.)

Shenzhen, China

Shenzhen Liying Biotechnology Co., Ltd. is a synthetic biology company based on the foundation of structural biology and cutting-edge artificial intelligence computation. We specialize in protein design and modification, providing high-quality and efficient research and development services for various protein applications, as well as the synthesis of protein materials. The company’s core technology founders and team members have over a decade of experience studying in the UK, with deep expertise in protein structure and function cultivated at top international universities and research institutions such as the University of Oxford, the University of Cambridge, and the Francis Crick Institution. They possess comprehensive technical workflows for advanced protein performance optimization and design that is internationally recognized. We have assembled a scientific advisory team at the Nobel Prize and Royal Academy Fellow level, as well as experts of high caliber from both domestic and overseas talent pools. Additionally, they have established extensive connections in industry, policy, and resources through the Chinese Central Organization Department’s Thousand Talents Program.

Lockheed Martin Corporation

Lockheed Martin Corporation

Bethesda, Maryland, United States

We connect customers with integrated solutions & predictive technologies to ensure they stay ahead of emerging threats. Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Locus Biosciences

Locus Biosciences

Morrisville, North Carolina, United States

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

LTZ Therapeutics

LTZ Therapeutics

1100 Island Dr., Redwood City, California, USA, 94065

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

Lumibird Medical - Quantel Medical, Ellex & Optotek

Lumibird Medical - Quantel Medical, Ellex & Optotek

1, Rue du Bois Joli, Cournon-d'Auvergne, Auvergne-Rhône-Alpes 63800, FR

Lumibird Medical is the medical division of the Lumibird Group, an expert in fiber lasers, solid lasers, laser diodes, and medical equipment. Formed from the 2020 merger of three entities – Quantel Medical, Ellex and Optotek – specializing in diagnostic and treatment devices for ophthalmology and other medical fields, our company is recognized for its commitment to innovation and stands out as a world leader in ophthalmic equipment. Our mission is to improve the comfort of patients worldwide by optimizing the standard of care with innovative diagnostic and treatment solutions dedicated to the medical sector. More information in our website!

LungLife AI

LungLife AI

Thousand Oaks, California, United States

LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time. The Company's core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB® test may have additional utilities, the most significant of which is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. The Company has completed a 149 subject pilot study to evaluate the LungLB® test, which showed a well-balanced performance and a Positive Predictive Value of 89 per cent. The Company is now gearing up to proceed to a larger, multi-centre validation study to garner regulatory and reimbursement support and facilitate commercialisation.

Lunit

Lunit

Seoul, South Korea

Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.

Lyssn

Lyssn

Seattle, Washington, United States

For organizations committed to providing the best behavioral health, human services, or wellness care, Lyssn's AI is the modern evidence-based quality improvement and training solution that provides visibility into human interactions and integrates expert-developed best practices so organizations can measure, train, and improve evidence-based practice at scale while meeting regulatory requirements. And, Lyssn requires dramatically less labor than current approaches with superior results at lower cost.

MaaT Pharma

MaaT Pharma

Lyon, France

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Machine Medicine

Machine Medicine

London, United Kingdom

We are a team based in London, that develops a platform to help assess people with Parkinson's disease better. Motor assessment in Parkinson's disease is plagued by issues of subjectivity and reproducibility – not to mention systematic biases such as rater drift. To counter this, we are developing a platform, called Kelvin, that can be used from any device (e.g. smartphones or tablets). Named after the famous physicist so beloved of precise measurement, the platform allows researchers to record, score, store and analyse video of Parkinson's patients during motor assessment. Once captured and organised, the platform uses a cutting-edge computer vision technique, called pose estimation, to objectively track the movement of the patients down to the fingertip level and deliver objective metrics of core symptoms, such as tremor and bradykinesia.

Mammoth Biosciences

Mammoth Biosciences

Brisbane, California, US

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mana.bio

Mana.bio

san francisco, california, united states

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

Manas AI

Manas AI

New York, United States

Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.

Manifold Bio

Manifold Bio

Boston, Massachusetts

Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

Mapmygenome

Mapmygenome

Hyderabad, India

Mapmygenome™ uses genomics to personalize health and well-being. Our at-home DNA tests and diagnostic genomic tests provide DNA-based insights that enable consumers, physicians, and health service providers to create a personalized health journey. Established in 2013, Mapmygenome™ has a vision to “Touch 100 million lives and save a million lives by 2030. Some of the preventive genomic tests that Mapmygenome™ offers are Genomepatri, BeautyMap, MyFitGene, Cardiomap, MedicaMap, and MapmyBiome. MapMyGenome also helps people discover their ethnic roots with Genomepatri Heritage.

Massachusetts General Hospital

Massachusetts General Hospital

Boston, Massachusetts, United States

Guided by the needs of our patients and their families, Massachusetts General Hospital aims to deliver the very best health care in a safe, compassionate environment; to advance that care through innovative research and education; and, to improve the health and well-being of the diverse communities we serve. Visit our careers page! http://www.mghcareers.org

Massive Bio

Massive Bio

New York, New York, United States

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Matchpoint Therapeutics

Matchpoint Therapeutics

Cambridge, Massachusetts, United States

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.

Mateon Therapeutics (Merge with Oncotelic)

Mateon Therapeutics (Merge with Oncotelic)

South San Francisco, California, United States

Mateon Therapeutics is developing OXi4503 for the treatment of acute myeloid leukemia. OXi4503 has a unique dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.The company is also using artificial intelligence to develop treatments for coronavirus.

Max Planck Society

Max Planck Society

Munich, Germany

The Max Planck Institute of Quantum Optics is a forefront research organizations in the fields of quantum physics and photonics, with light-matter interaction at its core. In five different research areas excellent scientists from all corners of the world are working together in an open and diverse environment, breaking the ground to what could become another revolution in science. Our laboratories are amongst the best equipped in the world and our scientific culture and spirit is based on freedom and trust, both allowing our scientists to reach the most ambitious objectives.

MDI Therapeutics, Inc.

MDI Therapeutics, Inc.

46430 Peary Ct., Novi, MI 48377, US

Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.

MedCognetics

MedCognetics

Dallas, Texas, United States

MedCognetics provides an advanced AI software platform which integrates into the radiology workflow. The AI platform is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating more predictable medical outcomes and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com.

Meddenovo Drug Design

Meddenovo Drug Design

Lyon, 69100, FR

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

Medeloop

Medeloop

menlo park, california, united states

Medeloop accelerates breakthrough discoveries through novel deep AI model explainability techniques built on top of a comprehensive data linkage infrastructure. Medeloop is a one of a kind platform that seamlessly links, harmonizes, and analyzes massive amounts of health data. We are pioneering AI techniques that find biomarkers for clinical researchers, helping break down barriers to save lives. For Researchers: Our platform shortens the clinical research process using advanced AI techniques that provide research hypotheses for even the most understudied diseases. All of your data, all in one place. Cleaned, organized and analyzed. Medeloop transforms the research approach, enabling researchers to publish more and publish faster. For Research Participants: Our patient-facing app encourages the public to take control of their health and contribute to life-changing medical research. You always have access to view your health information and how it is being utilized.

Median Technologies

Median Technologies

Les Deux Arcs B, 1800 route des Cretes, Valbonne, Provence-Alpes-Côte-d'Azur, FR, 06560

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

Medmain Inc.

Medmain Inc.

東京都港区南青山2-10-11 A青山ビル2F, Ark Hills South Tower 16F, 港区, 東京都 107-0062, JP

Medmain Inc. is a company to develop and provide "PidPort", a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." "PidPort" is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product "PidPort", we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.

Mednet

Mednet

650 Carlson Pkwy, Minnetonka, Minnesota 55305, US

Mednet is a leading healthcare technology company specializing in eClinical solutions designed for the global life sciences community. Pharmaceutical, medical device, biotechnology, academic institutions, and Contract Research Organizations (CROs) around the world have trusted Mednet for over 23 years to deliver the technology innovation, experience and reliability they need for success. Mednet's comprehensive, EDC-centric eClinical platform, iMednet, optimizes clinical studies of all types and sizes – accelerating research with exceptional flexibility, ease-of-use, robust functionality, affordability, and stellar support. iMednet is feature-rich and uniquely designed to help sponsors and CROs get studies up and running quickly and to see them through with a full suite of native capabilities, including: randomization, trial supply management, adjudication, ePRO, payments, DICOM Imaging, and eConsent. All backed by a highly tenured and experienced support team, ensuring quality, compliance and easy onboarding of the entire research team and clinical trials sites. For more information, visit mednetsolutions.com. Mednet Solutions, Inc.

MedTek21

MedTek21

West Chester, Pennsylvania, United States

Patient populations and their medications are continuously moving. MedTek21 ensures your entire patient base is continuously monitored for potential drug/gene interaction risks, allowing you to focus your care.

Medtronic

Medtronic

710 Medtronic Parkway

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Dublin, Ireland. Medtronic operates in more than 140 countries and employs over 90,000 people worldwide. The company is the world's largest standalone medical technology development company.

MegaRobo Technologies Co.,Ltd.

MegaRobo Technologies Co.,Ltd.

6 Raffles Quay, Singapore, 048580, SG

Founded in 2016, MegaRobo is a national high-tech enterprise, headquartered in Beijing, with branches in Shenzhen, Shanghai, and Suzhou; the team size is over 300 persons, with R&D personnel accounting for 60%. Focusing on R&D and the application of robot and intelligent Internet of things, MegaRobo has a number of core technologies that are competitive in the world and has applied for over 200 invention patents, which have passed the IOS9001 Quality Management System Certification. Based in China and facing the world, MegaRobo unremittingly provides industry-leading, efficient, and reliable automation solutions for the life sciences, smart retail, and lightweight manufacturing.

Melio

Melio

Santa Clara, California, United States

Melio is developing a clinically actionable fast and comprehensive test for all common infections

MeMed, Ltd.

MeMed, Ltd.

Andover, Massachusetts, United States

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

MemVerge

MemVerge

Milpitas, California, United States

MemVerge is a pioneering developer of software for Big Memory Computing. In the cloud or on-premises, data-intensive workloads run faster, cost less, and recover automatically with the company’s award-winning Memory Machine™ products. Memory Machine X is poised to revolutionize how CXL® memory will be used in the future, while Memory Machine Cloud stands out with its ability to continuously right size cloud cost and performance. Learn more about MemVerge and its Memory Machine software at www.memverge.com.

Mendel

Mendel

San Jose, California, United States

Mendel AI is the only clinical AI platform that performs clinical reasoning to supercharge clinical data workflows. Powered by coupling large language models with a clinical Hypergraph, Mendel's AI copilots, known as Hypercubes, offer clinically trustworthy and explainable insights, streamlining tasks like cohort building, chart review, and data discovery. Mendel's solutions cater to biopharma, providers, and diagnostics, integrating seamlessly with existing tools and delivering proven results We strive for excellency, to be authentic and original, and to make a difference by greeting our challenges head on. Please visit our website, mendel.ai, to learn more about our company, goals, and values.

Mesh Bio

Mesh Bio

Singapore, Singapore

Multidimensional Health Intelligence Platform for digital powered care delivery Mesh Bio is a fast growing digital health startup focused on addressing the growing challenges in care delivery. Mesh Bio develops AI powered clinical decision support, analytics and automation solutions for healthcare providers to transform healthcare delivery with digital solutions. At Mesh Bio, we actively build an environment for personal excellence and career growth. We encourage diversity of experiences/backgrounds and want team members to thrive in their domain of professional expertise.

Metafora Biosystems

Metafora Biosystems

Paris, France

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

Metagenomi

Metagenomi

Emeryville, California, United States

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Metis Therapeutics

Metis Therapeutics

Cambridge, Massachusetts, United States

The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.

Metofico

Metofico

London, England

At Metofico, we specialise in developing no-code data analysis software tailored specifically for life science research. We are dedicated to making powerful tools accessible to all researchers—regardless of coding expertise. Our mission is to enhance the efficiency, reliability, and reproducibility of data analysis, empowering scientists to focus on advancing scientific discoveries instead of spending time on tedious data processing. Our suite of tools—ranging from Fiber photometry analysis to AI-driven rodent tracking and automated behaviour quantification—is designed to streamline preclinical research. Additionally, we provide custom software and hardware solutions tailored to the unique needs of each research project. We uphold the highest scientific standards and continuously refine our offerings based on valuable feedback from the research community.

Micrographia Bio

Micrographia Bio

London, United Kingdom

Micrographia Bio (MGB) has developed a new approach which uses spatial proteomics for stunningly sensitive and high-throughput assessment of the true molecular effects of drug candidates.

Microsoft

Microsoft

Redmond, Washington, United States

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Micro Systems Engineering, Inc.

Micro Systems Engineering, Inc.

6024 Jean Road, Lake Oswego, Oregon 97035, US

Micro Systems Engineering, Inc. (MSEI), with its main office in Lake Oswego, Oregon, is is a pioneer in developing innovative implantable medical device technologies and devices that save and enhance the quality of life for millions of patients across the globe. With more than 40 years of experience in design and manufacturing active implantable medical devices, our continuing success is based on our company's core values – innovation, quality, reliability, integrity, teamwork, and undisputed expertise – thus enabling us to inspire confidence and trust in physicians and patients worldwide. MSEI has two main divisions, Operations and System Design & Development. With over 400 technical staff including physicists, electrical, software, biomedical and materials engineers, MSEI employs an elite team of the brightest minds in the medical technology industry. The Operations division is a specialist in medical microelectronics manufacturing including development, design, testing, supply chain and system integration for medical technology, in particular for active implants in the area of CRM (cardiac rhythm management) and other medical applications. The Operations division is dedicated to the innovative design and quality construction of electronic modules used in implantable medical devices. System Design & Development is the innovation center for next generation class III active implants. This includes full system design, clinical research, hardware and software, as well as the design and test of application-specific integrated circuits (ASICs). The resulting products deliver life-saving therapies to patients accurately and reliably across the globe.

Mid-Atlantic BioTherapeutics

Mid-Atlantic BioTherapeutics

Doylestown, Pennsylvania, United States

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

Milu Labs

Milu Labs

New York, New York, United States

Focus on women's heatlh

Mindera Health

Mindera Health

South SF, California, United States

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

Mindpeak

Mindpeak

Hamburg, Germany

Mindpeak's mission is to enable personalised cancer treatment through AI tissue diagnostics Our partners are leading pathology and university labs. Our team consists of world-class industry experts in machine learning and company building. Mindpeak's Impact The demand for medical image analysis is growing rapidly but the number of cancer experts remains the same - this results in growing workloads per specialist. We help cancer experts meet this challenge. We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable.

MintNeuro

MintNeuro

london, england, united kingdom

We are pioneering the use of semiconductor technology for next-generation neural implants. Our mission is to provide the best possible outcomes for patients with neurological conditions by delivering the highest performance with the least invasive surgery. Our team brings together world-class experts in neuroscience, microtechnology, and implantable neural interfaces — augmented with medtech industry pedigree and clinical experience.

Mirador Therapeutics

Mirador Therapeutics

San Diego, CA, United States

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

Mirai Bio

Mirai Bio

601 Gateway Blvd, South San Francisco, California, USA, 94080

We're Mirai Bio, biotech's first open end-to-end development platform company for co-creation of optimized #GeneticMedicines. Learn more at MiraiBio.com.

MIT Lincoln Laboratory

MIT Lincoln Laboratory

Lexington, Massachusetts, United States

The Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts. MIT is devoted to the advancement of knowledge and education of students in areas that contribute to or prosper in an environment of science and technology.

MNDL Bio

MNDL Bio

TEL AVIV, IL

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression. Proud winner of the "Coller Startup Competition" for Edition 2023.

Model Medicines

Model Medicines

1268 Prospect Street, La Jolla, CA 92037, US

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.

Modicus Prime

Modicus Prime

La Porte, Indiana 46350, US

Modicus Prime's Self-Service software places cutting-edge AI where it belongs: in the hands of biotechnology experts. Our computer vision solution, mpVision, provides intelligent image analysis to monitor biologics at any scale. mpVision has been tested by scientists in a Top 10 Pharma company supporting our mission to eliminate contamination from the pharmaceutical industry. These contaminations cost 100’s of millions of dollars per incident as illustrated by the recent Covid vaccine 60 M incident experienced by J&J/AstraZeneca/Emergent. Such unmet needs of the Life Sciences industry, including real-time product quality assurance, full agency compliance, faster go-to-market, and reduced operating costs, are being met with Modicus Prime’s Self-Service AI solution.

Modulo Bio

Modulo Bio

San Diego, California, United States

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune system mapping platform is designed to identify potential treatments for neurodegenerative diseases such as ALS and FTD.

Moichor

Moichor

Oakland, California, United States

We are a tech-centered, animal diagnostics company on a mission to help veterinarians lengthen the lives of their patients by applying deep learning to the diagnostics they use daily.

Moirai Biodesign

Moirai Biodesign

Carrer de Baldiri Reixac, Lab CL02C75. Cluster II Building. Barcelona Scientific Park., Barcelona, Catalonia 08028, ES

Moirai Biodesign is a pioneering RNA design company developing a novel RNA-based diagnostics platform. Our initial investigation and development aims to diagnose the cause of sepsis in the fastest, most reliable and affordable way. We are working on providing the asset which patients need the most: time.

Molecular Connections

Molecular Connections

Basavanagudi, India

With over two decades of experience in Big Data and Data Science Solutions, Molecular Connections (MC) has been using AI-powered proprietary models to help customers achieve digital transformation. We have been able to successfully build a data-driven decision-making strategy for our customer’s digital transformational journey. MC leverages AI, ML and the Linked Data Store to build efficiencies in various verticals and generate new revenue streams for its customers. MC’s decades of industry presence and a strong focus on innovation have led us to work with the world’s leading pharma and STEM industries to offer end-to-end software development and data insights powered by proprietary workflows and platforms, enabling content engineering across multiple domains. With over 70% of its workforce being women, MC is ranked among the top 15 best companies for women to work for in India. Subsidiary Companies: 1. Molecular Connections Analytics Pvt. Ltd. | URL: https://mcanalytics.co.in/ 2. Molecular Connections Research Pvt. Ltd. | URL: https://mcresearch.co.in/

Molecular Devices

Molecular Devices

San Jose, California, United States

Moma Therapeutics

Moma Therapeutics

Cambridge, Massachusetts, United States

MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.

Monte Rosa Therapeutics

Monte Rosa Therapeutics

Boston, Massachusetts, United States of America

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

Moonwalk Biosciences

Moonwalk Biosciences

South San Francisco, California, United States

Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.

Morgridge Institute for Research

Morgridge Institute for Research

Madison, Wisconsin, US

Morgridge Institute for Research is a scientific research institution that focuses on biomedical research and innovation.

Morphoceuticals

Morphoceuticals

Oklahoma City, Oklahoma, United States

Morphoceuticals is pioneering the bioelectric reprogramming of biology. They are focused on organogenesis and organ regeneration without transplantation. The company has successfully achieved limb regeneration in adult frogs using a novel drug combination.

Mount Sinai Health System

Mount Sinai Health System

New York, US

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. WHO WE ARE We are compassionate collaborators—38,000 strong—working to heal, teach, and advance medicine in New York City and throughout the world. WHAT WE BELIEVE We believe in challenging the status quo. Forging a new pathway in clinical excellence is only possible by putting the patient at the center of the experience. WHY WORK WITH US Here, innovation is valued and collaboration is integral. Mount Sinai is full of friendly, helpful people who share a common devotion to delivering exceptional patient care. Yet we’re as diverse as the city we call home—culturally, ethnically, in outlook and lifestyle. When you join us, you become part of Mount Sinai’s unrivaled record of achievement, education, and advancement as we revolutionize healthcare together.

MSAID

MSAID

Garching bei München, Germany

MSAID transforms the way scientists analyze proteomics data. MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany and is located at the high-tech-center gate, which is part of the TUM campus in Garching. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The team has an exceptionally strong track record and long-standing expertise in the acquisition, analysis, and interpretation of proteomic data. Our ambition is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data. Legal Notice: https://www.msaid.de/legal-notice

MSInsight

MSInsight

Paris, France

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

MultiOmic Health

MultiOmic Health

London, United Kingdom

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

MyBiotics

MyBiotics

Rehovot, Israel

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

MYND Life Sciences

MYND Life Sciences

Kelowna, British Columbia, Canada

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Nabla Bio

Nabla Bio

Nabla Bio, Boston, Massachusetts, United States

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.

Nanite

Nanite

6 Liberty Square #6128, Boston, Massachusetts, 02109

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.

NanoLive

NanoLive

Ecublens, Switzerland

#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

Nanostics Inc.

Nanostics Inc.

129 ave nw, edmonton, alberta, canada

Nanostics develops and commercializes novel, non-invasive diagnostic tests for cancer. Our core technology is an advanced liquid biopsy platform that can accurately diagnose cancer from a single drop of blood. Our lead product, ClarityDx Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer. Go to https://www.nanosticsdx.com/clarity-dx-prostate/ to order ClarityDX Prostate today.

Nanox

Nanox

Nave Ilan, Israel

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

National Institute of Standards and Technology

National Institute of Standards and Technology

Gaithersburg, Maryland, US

National Institute of Standards and Technology is a government agency that sets standards, conducts research, and promotes innovation in technology and measurement.

NeoCura

NeoCura

生命园路, 29号1幢3层, 北京, 102206, CN

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

Neogap Therapeutics

Neogap Therapeutics

Stockholm, Sweden

NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.

Nephrogen

Nephrogen

New York, New York, United States

Nephrogen is a therapeutics company developing transformative medicines for kidney disease. Their initial focus is on gene therapy for autosomal dominant polycystic kidney disease (ADPKD).

Nerai Bio

Nerai Bio

Zurich, Switzerland

Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships.

Nereid Therapeutics

Nereid Therapeutics

Cambridge, Massachusetts, United States

Nereid starts with approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with cell biology and medicinal chemistry. Nereid’s platform uses physics to discover therapeutics that can modify the phase behavior of livingcells.

Nested Therapeutics

Nested Therapeutics

Cambridge, Massachusetts, United States

We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection, we’re determined to dramatically expand the reach of precision medicine and make first- and best-in-class precision oncology treatments available to a larger population.

NetraMark

NetraMark

Toronto, Ontario, Canada

NetraMark combines proprietary QML/ML algorithms with cross-domain expertise to bring ML commercialization into reality, starting with the pharmaceutical space in drug development where we utilize large and small data in order to help pharmaceutical companies understand their patient populations better. Our technology allows for the utilization of phase II data in order to optimize phase III trials from the vantage of their specific patient population.

Netri

Netri

Lyon, France

NETRI is a technology enabling company that provides human cell based smart assays for high throughput preclinical data acquisition for the neurological Pharma & Cosmetics industries. We provide organs-on-chip solutions & interoperable in vitro models designed to deeply accelerate drug discovery and preclinical trials by mimicking in vivo neural connectivity.

Neuroelectrics

Neuroelectrics

Avinguda Tibidado, 47 Bis, Barcelona, 08035, ES

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Neuroglee Health

Neuroglee Health

33 Arch St, FL 17, Boston, Massachusetts 02110, US

While our healthcare system has increasingly embraced virtual health in many areas to accelerate access to care, in-person care for patients with cognitive conditions remains the status quo - but Neuroglee Health is making virtual cognitive care a reality. We partner with medical groups to serve as your practice's virtual cognitive care extension – enabling you to provide immediate access to evidence-based care for patients with cognitive disorders and highly coordinated, guided support for the caregivers they rely on. Through our virtual care model, which we developed in collaboration with Mayo Clinic, Neuroglee Health is leaning in to disrupt the status quo. Our partners gain timely access to our team of expert multidisciplinary specialists and powerful, award-winning digital tools: a patient app, care partner app, and clinician dashboard, which optimize patient and caregiver engagement, deliver actionable data-driven insights, and enable coordination across the patient's extended care team. When combined, Neuroglee Health helps patients improve cognition, enhance quality of life, and prolong patient independence, while reducing provider and caregiver burnout. We are on a mission to improve the lives of individuals with cognitive conditions and their loved ones. Join us at www.neuroglee.com.

NeuroKaire

NeuroKaire

Tel Aviv, Israel

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Neuron23

Neuron23

South San Francisco, California, United States

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

NeuShen Therapeutics

NeuShen Therapeutics

Shanghai, China

A global biotech company commited to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need. We design novel CNS-tropic AAV capsids and innovative gene expression cassettes to achieve efficient, effective, and safe gene therapies for severe CNS disorders.

Neuvotion, Inc.

Neuvotion, Inc.

2 Leeds Ln, Darien, Connecticut 06820, US

Neuvotion is developing breakthrough solutions for facilitating and restoring movement. Our approach combines targeted neurostimulation and AI (artificial intelligence) to deliver unparalleled therapeutic value for patients with a movement disorder or impairment from stroke or injury. Neuvotion products allow doctors and therapists to leverage state-of-the-art technology, while monitoring patient progress in-person or remotely.

Newdel Biotech

Newdel Biotech

Shenzhen, China

NewDEL Biotech is a biotechnology company based in Shenzhen, China, established in 2021. The company focuses on the research and development of new drugs, with a particular emphasis on innovative drugs designed for tumors. NewDEL Biotech utilizes DNA Encoded Library technology to significantly improve the success rate of drug development.

NewLimit

NewLimit

South San Francisco, California, United States

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

New Wave Biotech

New Wave Biotech

Better Space, 127 Farringdon Road, London, GB

For those creating a more sustainable future with biotechnology, we use AI and computational modelling to help precision fermentation alt protein companies optimise their downstream processing, so they can de-risk their ventures, speed up R&D and reduce costs.

Nexilico, Inc.

Nexilico, Inc.

danville, virginia, united states

Nexilico is an early-stage biotechnology startup that employs the power of computational biology and AI to address challenging problems in medicine and biotechnology. As a pioneer in the next generation in silico microbiome technologies, Nexilico advances scientific understanding about the role of microbiomes in health and disease and leverages that information to develop novel microbiome-based technologies

Nexstem

Nexstem

4th floor, 19, KHB Colony, Koramangala 8th Block, Bengaluru North, Karnataka 560095, IN

We are Nexstem. We create Brain-Computer Interface (BCI) solutions that help people interact with technology using their brain signals. Founded in 2020, by Siddhant and Deepansh - engineers with a passion for neuroscience and technology, we've been pushing the boundaries of what's possible in neurotech since our first product, the Nexstem V1 in 2022. At Nexstem, we specialize in non-invasive BCI devices, like our 19-channel headset, Instinct, which comes with a full software ecosystem to decode brain signals. Our goal is to make BCI technology accessible, empowering researchers, clinicians, and developers to innovate and explore new frontiers in brain-computer interaction. Nexstem's technology is recognised by many stalwarts of the industries includes Mircrosoft for Startups, NASSCOM, VIVA tech Paris, YourStory and many more. We have got support from some of the finest neuroscientists and doctors to build accessible tech for the neurotech. We strongly believe in creating value for people and NeuroTech Pulse is our monthly news letter that highlights a news round-up of neurotech industry across the globe, events, case studies and individual spotlights for notable achievers in the field. Do join us on substack - nexstem.substack.com

NextGen Jane

NextGen Jane

Oakland, California, United States

At NextGen Jane, we believe in enriching your Quality of Life, expanding your Agency, and enabling your Pursuit of Data. All good revolutions are anchored in coherent philosophies championed by an impassioned base. This is our revolution, to empower women with the information needed to make smart decisions and take true health ownership. Armed with our SmartTampon platform that serves as a sentinel system for your reproductive health, we hope to impact how you manage your health, from menarche to post-menopause. If you dig it, join us. It is hard to create new ways of engaging with our health in rigid systems within a complex care system, but not impossible. Help us re-engineer our future, in our image.

Nference

Nference

Cambridge, Massachusetts, United States

nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.

Nikon Instruments Europe BV

Nikon Instruments Europe BV

Amsterdam, Netherlands

ニコンは、100年の歴史で培ってきた「光利用技術」と「精密技術」をもとに、多彩な技術・製品・サービスをグローバルに展開しています。 映像の可能性の追求から、スマートデバイスやバイオサイエンスの進化、高度なものづくり、さらに数十億光年彼方の宇宙を捉える挑戦まで。世界中の人々の暮らしを、未来を開く最先端産業を、そして人類の挑戦を、ニコンはこれからも支え続けます。 At Nikon, we use opto-electronics and precision technologies cultivated during our 100-year history to provide a wide range of products and services globally. Our activities extend from exploring the possibilities of imaging, to advancing bioscience and smart devices, refining our high-level manufacturing processes, and capturing views of stars that are billions of light years away. Nikon will continue to enrich lives, support cutting-edge industries that are shaping the future, and confront challenges around the world.

Nimble Therapeutics

Nimble Therapeutics

Madison, Wisconsin, United States

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods.

NImmune Biopharma

NImmune Biopharma

Blacksburg, VA

NImmune is a late-stage precision immunology biopharmaceutical company that develops best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by advanced computational modeling and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. NImmune’s clinical development pipeline includes omilancor, a Phase 3-ready lead clinical candidate targeting LANCL2, an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023.

Nintx

Nintx

Avenida das Nações Unidas 18801,, 18801, São Paulo, SP 04757025 , BR

Originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants and microorganisms) into novel therapies, Nintx (Next Innovative Therapeutics) believes plant-based natural products bear huge potential to serve as a superb platform to modulate human biological targets and the microbiome concomitantly, affording therapies for multifactorial diseases (multi-target therapies). Nintx was founded by two experienced PhD scientists, Dr. Miller Freitas (CEO) and Dr. Cristiano Guimarães (CSO), who are the main executives of the company, and Mr. Stephani Saverio, MBA, a healthcare veteran who has been acting as a Non-Executive Board Member for the startup. Nintx is a startup with innovation as core business, right at the center of the strategy, heavily based on advanced technologies, coupled with the Brazilian biodiversity, the most biologically diverse in the world, to develop the next generation of therapies. Some of Nintx's proprietary technologies include xGIbiomics®, which closely emulates the human gastrointestinal digestive system and microbiome, and GAIApath®, an artificial intelligence and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome concomitantly. Nintx's cutting-edge technologies and concepts will be key in the future development of multi-target therapies.

Noah Labs

Noah Labs

lohmuehlenstrasse, berlin, berlin, germany

Noah Labs develops AI-based software solutions for medical care and research to facilitate diagnosis, manage conditions, and guide intervention.

Noah Medical

Noah Medical

San Carlos, San Carlos, California 94070, US

Noah Medical is a medical technology company based in San Carlos, California, founded in 2018. The company specializes in developing advanced medical robotics aimed at enhancing diagnostic procedures in pulmonology. Its flagship product, the Galaxy System, is a robotic platform that integrates real-time navigation, augmented fluoroscopy, and tomosynthesis to improve the accuracy of lesion localization, which is vital for early lung cancer diagnosis and treatment. With a team of over 150 engineers and industry experts, Noah Medical leverages extensive experience from leading healthcare companies. The company's mission focuses on saving lives through early diagnosis and treatment, particularly in robotic navigated bronchoscopy. Noah Medical has received recognition as a "Fierce 15" company of 2023 and has raised $150 million in funding to support its innovative approach. Its technology is designed to enhance procedural efficiency and diagnostic accuracy in healthcare facilities, particularly in pulmonology and oncology.

Nobias Therapeutics

Nobias Therapeutics

144 s whisman rd, mountain view, california, united states

Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications.

NOETIK

NOETIK

2 Tower Pl, South San Francisco, California 94080-1826, US

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

North Carolina State University

North Carolina State University

Raleigh, North Carolina, United States

Northrop Grumman

Northrop Grumman

San Diego, California, United States

Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 95,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services.

Nosis Bio

Nosis Bio

Nosis Biosciences delivers breakthrough receptor-targeted RNA medicines with cutting-edge physics-aware deep learning, single cell biology, and high-throughput chemistry

Nostics

Nostics

Delft, Netherlands

By applying nanotechnology, photonics and machine learning, Nostics brings a new type of diagnostics to a world desperately in need for 21st century solutions. We believe that a good life starts with good health. We believe that accessible and affordable diagnostics should be a given for our entire human family. Improvements in healthcare can only start when we know what’s going on. By providing instant and affordable testing at any location, Nostics wants to contribute to a better safer and healthier world.

Nostos Genomics

Nostos Genomics

Berlin, Germany

At Nostos Genomics, we partner with genetic testing labs to turn data into genomic insights and give more people with genetic diseases a fast and clear diagnosis. Over 300 million people live with a rare genetic disease and for most, the journey from the first symptoms to a diagnosis takes more than 5 years. Even after that, diagnoses are often incorrect, and many people end up not being diagnosed at all. Now, new technology is allowing millions to benefit from genetic testing for diagnosis, while at the same time targeted therapies for previously untreatable disorders are being developed. But the last step in genetic testing – interpreting mutations – remains laborious and costly. It can take a genetic testing lab weeks to interpret data from a single patient. Because of limited understanding of the consequences of mutations, the test results are often inconclusive and leave 70% of people undergoing a genetic test without diagnosis. Our CE-certified platform leverages a unique combination of machine learning and synthetic biology to characterize mutations at scale and automate the interpretation. By offering it to labs, we enable them to diagnose more people in a fraction of the time.

Notable Labs

Notable Labs

San Francisco, California, United States

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

Novaccess Global

Novaccess Global

Chesterland, Ohio, United States

NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

Nova In Silico

Nova In Silico

1 Place Giovanni da Verrazzano, Lyon, Rhône 69009, FR

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Nova Signal

Nova Signal

Los Angeles, California, United States

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company's FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Novigenix SA

Novigenix SA

Route de la Corniche 3, Lausanne, VD 1066, CH

Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for early detection of disease, development of novel therapeutics, and drug target discovery. The Novigenix proprietary LITOSeek™ platform is an AI-enabled RNA analytic platform optimized for mapping the response of the immune system to onset and progression of disease. Our analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to provide actionable insights and precision solutions. Our liquid biopsy products and services include a suite of biopharma solutions for clinical development of novel therapies, drug target discovery, and early detection of Colorectal Cancer. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOSeek™ data analytics and patient clinical data platform to deliver previously unknown insights into heterogeneity of patient response and development of actionable biomarkers for optimization of new therapeutic modalities. Specialties Precision Medicine solutions in oncology and immunology, ImmunoTranscriptomics, Machine Learning and Artificial Intelligence, clinical development of multi-omics biomarkers, standardized RNAseq platform and analytic pipelines, product development for In-vitro Diagnostics and Liquid Biopsy solutions.

Novopyxis

Novopyxis

Boston, Massachusetts, United States

Novopyxis is a biotechnology company that specializes in the development of therapeutics and medical devices using proprietary mathematical algorithms for drug validation across various models.

Novorex

Novorex

240 Pangyoyeok-ro, #302 Samhwan HIPEX A, Bundang-gu, Seongnam-si, Gyeonggi-do, KR

Novorex is specialized company in the development of new small molecule drugs targeting mostly oncology and neurology diseases using FBDD and artificial intelligence with pharmaceutical experts. Seamless Drug Discovery is performed using cutting-edge technology that considers the entire process of new drug development. We aim to develop high-efficiency new drugs through drug design that combines biophysical analysis and in vitro/in vivo assay.

Novus Diagnostics

Novus Diagnostics

Dublin, Ireland

When a patient is critically ill, giving their doctor the right information at the right time can mean the difference between life and death. At Novus Diagnostics, we are developing ground-breaking diagnostics technologies to provide rapid answers right at the patient’s bedside. Our first product, SepTec, will help tackle the global challenge of sepsis which kills more than 11 million people every year. Our technology platform brings together novel electrochemical sensors, centrifugal microfluidics and automated sample processing and analysis to diagnose and characterise a blood stream infection within 15 minutes; enabling earlier lifesaving targeted treatment. We are a young, driven company working to solve a major global health challenge. We are building a team of people who are excited by this challenge and committed to making a real difference through their work.

Noze

Noze

7171 Rue Frederick Banting, Montreal, Quebec H4S 1Z9, CA

Noze is the global leader in digital odor perception (often hailed as the digital equivalent of the sense of smell). We have developed the world's most advanced digital nose, capable of detecting and identifying odors in real-world settings with unparalleled accuracy. Leveraging cutting-edge machine intelligence and a sensor developed with exclusively licensed NASA technology, Noze is committed to enhancing human health and wellbeing. Our mission is to improve patient outcomes by enabling real-time disease detection at any point-of-care by using our technology to target breath-based odor biomarkers.

Nth Analytics

Nth Analytics

12 Crimson King Trail, Flemington, NJ 08822, US

Nth Analytics pharmaceuticals consultants: CDISC SDTM/ADaM, biostatistics, and SAS programming.

Numares Health

Numares Health

Boston, Massachusetts, United States

Develops a diagnostics platform.

NuMedii

NuMedii

Palo Alto, California, United States

NuMedii is a biopharmaceutical company that discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success.

Nutshell Therapeutics

Nutshell Therapeutics

Shanghai, China

Nutshell Therapeutics Inc. Inventing small molecule in the realm of drug discovery fostered by protein dynamics. Leveraging our cutting-edge technology based on protein dynamics, Nutshell

nView medical

nView medical

2681 E Parleys Way, Suite 107, Salt Lake City, Utah 84109, US

nView medical, based in Salt Lake City, UT, is a startup whose mission is to make surgery safer, faster, and consistently accurate. nView develops imaging technology — bringing breakthrough AI solutions for image creation, image processing, and image visualization to surgery and interventional radiology. nView medical backers include the National Science Foundation (NSF), the National Institutes of Health (NIH), the State Of Utah, the National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, HealthTech Arkansas, Dr. Kevin Foley, M.D., and Fusion Fund (Palo Alto, CA). Its founder, Cristian Atria, has had a progressive career with GE Healthcare in positions that range from development engineer to general manager with P&L responsibility. He has successfully assisted start-up and public companies with technology transfers, licensing, product development, regulatory approvals, and commercialization.

Objective Biotechnology

Objective Biotechnology

Minneapolis, Minnesota, United States

Objective Biotechnology's mission is to develop high-impact technologies that enable comprehensive measurement and manipulation of biological systems at multiple scales, unlocking new research capabilities.

Ocean Genomics

Ocean Genomics

Pittsburgh, Pennsylvania, United States

Ocean Genomics works with biopharma, academic researchers and advocacy to empower discovery and development. We provide our advanced computing platforms for gene expression analysis, and biomarker and target discovery, and our vast and fast-growing gene expression database. We also provide integrated programs ranging from single experiment analyses to multi-milestone efforts that include computational biologists, and use of all of our platforms, AI models and data assets.

Oceanit

Oceanit

Honolulu, Hawaii, United States

At Oceanit, a rule-breaking practice of Intellectual Anarchy™ produces disruptive innovation, as we consistently discover the edges of thinking and create breakthroughs in science, engineering, and technology to change the world. Our teams create innovative solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research. Empowering our teams to practice transdisciplinary thinking allows for extraordinary problem-solving across disciplinary boundaries. Our teams morph together and apart, aligning the best experts in each discipline to solve some of the world’s toughest problems Here at Oceanit, our mission is to create value from... Innovation through engineering and scientific excellence... produced in an environment where elements of such work and play are indistinguishable. We are proud of what we’ve created and what lies ahead. We are Oceanit.

Ochre Bio

Ochre Bio

Oxford, England, United Kingdom

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Octagos Health

Octagos Health

13325 Hargrave Road, Suite 281, Houston

Octagos Health is a dynamic and rapidly growing healthcare technology company dedicated to improving patient outcomes through AI-driven solutions. Octagos provides a cloud-based platform that aggregates remote and in-person device interrogations for all cardiac rhythm management (CRM) manufacturers, wearables (Holter, MCT, etc.) and remote physiologic monitoring (RPM).

Octant

Octant

Emeryville, California, United States

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

Odimma Therapeutics

Odimma Therapeutics

Grandest, France

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers. Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic

Odyssey Therapeutics

Odyssey Therapeutics

Boston, MA

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

Ofni Systems

Ofni Systems

808 103 Salem Woods Drive, Raleigh, North Carolina, USA, 27615

Ofni Systems is an industry leader for 21 CFR Part 11 compliance and validation services. Their products for Part 11 compliant databases and spreadsheets are used by pharmaceutical, biotech and medical device companies across the globe, while its products for computer validation, auditing and FDA submissions ensure that their clients meet every requirement for electronic records and electronic signatures. The company provides live desktop support for superior customer support and training, and has been providing solutions to their clients since 1999. For more information, call (919) 844-2494 or visit http://www.OfniSystems.com.

Okeiro (ex Predict4Health)

Okeiro (ex Predict4Health)

130, Rue de Lourmel, Paris, Île-de-France 75015, FR

AI in the service of precision medicine. We don't perform miracles, just create the tools that enable them. At Okeiro, we develop medical AI solutions that transform the monitoring of transplant patients and those with chronic conditions. Our predictive algorithms, scientifically validated digital biomarkers, convert complex medical data into information directly usable by healthcare teams. This technology allows us to: - Detect early signals of complications or graft rejection - Personalize each treatment for truly proactive care - Intervene before critical symptoms appear Our goal is clear: to tangibly improve patients' lives by equipping healthcare professionals with innovative tools that make a daily difference. In close collaboration with healthcare professionals and pharmaceutical companies, we accelerate the clinical validation of therapeutic innovations to make new treatments more quickly accessible to the patients who need them!

Olaris

Olaris

Waltham, Massachusetts, United States

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

Olio Labs

Olio Labs

-, San Francisco, California, USA, 94139

Olio labs uses AI and ML to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. The only way to build and test the number of combinations required to find a better treatment is to automate as much of the therapeutic discovery and development pipeline as possible. We are a new type of scientist that is comfortable working at the bench and in the code base. Our custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one. We are currently backed by the amazing investors at SciFounders and YCombinator.

Olive Diagnostics

Olive Diagnostics

149 Avraham Elmalich, Jerusalem, IL

Olive Diagnostics is a health technology startup founded in 2019 and based in Jerusalem, Israel. The company focuses on developing innovative, non-invasive health monitoring technologies aimed at empowering individuals with continuous insights into their health data. This approach supports healthier lifestyles and improved healthcare outcomes. The company specializes in digital diagnostics, particularly with its non-invasive urinalysis sensor, the Olive KG. This device mounts to any toilet and utilizes optics, IoT technology, AI, and data analysis to provide real-time health alerts and disease detection. It is designed for early disease detection and chronic disease management by continuously collecting and analyzing health data, offering users historical insights and proactive health tips. Olive Diagnostics has a multidisciplinary team with expertise in various fields, including biochemistry and data analytics. The company is in the final stages of research and development and plans to launch its product by the end of 2024, positioning itself for growth in the digital diagnostics market.

Omega Therapeutics

Omega Therapeutics

Cambridge, Massachusetts, United States of America

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature’s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OmicaBio

OmicaBio

Mexico City, Mexico

OmicaBio is a population genomics startup focused on diversity genomic research in Latin America,

Omics Edge

Omics Edge

Miami, Florida, United States

Omics Edge is a bioinformatics company that integrates AI with bioinformatics to yield portable Polygenic Risk Scores that work across ancestries and ethnicities.

Omiqa Bioinformatics

Omiqa Bioinformatics

berlin, berlin, germany

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

OmniAb

OmniAb

Emeryville, California, United States

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

OmniGuide

OmniGuide

43 Manning Rd, Billerica, MA 01821, US

OmniGuide's corporate culture has grown from the roots of an innovative idea from MIT to a global company that has successfully adapted to changes in the market. INSPIRATION Our purpose is to help reduce complications, every day. We achieve this with our creative energy and enthusiasm for fresh ideas. Our motivation is to continually remind ourselves that when we get up in the morning, patients who need our therapies are counting on us. EXCELLENCE The pursuit of excellence lies at the heart of everything we do. We are builders, redefining what it means to support great outcomes. We have the courage to think different and will ensure that OmniGuide remains committed to ideas that benefit patients and their outcomes.

OmniTier

OmniTier

Milpitas, California, United States

OmniTier Inc. develops easy to use, end-to-end, genomic analysis on-premise and cloud based systems that achieve greater accuracy and faster run-times than competing offerings.

Onc.AI

Onc.AI

232 Windsor Drive, San Carlos, California, USA, 94070

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Oncimmune

Oncimmune

1 Park Row, Leeds, Yorkshire LS1 5AB, GB

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.

Oncobit AG

Oncobit AG

Rütistrasse 16, Schlieren, Zurich 8952, CH

Oncobit is a medtech UZH Spin-off, enabling personalized cancer care by matching patients to the best cancer treatment available. We are developing cancer-specific genomic fingerprinting and personalized monitoring tests and provide therapy decision support.

Oncobox

Oncobox

San Francisco, California, US

Oncobox is transforming cancer care with precision medicine by leveraging the power of artificial intelligence and systems biology. Through the integration of deep molecular profiling—which includes analysis of not only DNA mutations (exome) but also RNA gene expression (transcriptome)—and comprehensive data analytics, we achieve unmatched precision in identifying the most effective treatment strategies, markedly improving outcomes for patients battling late-stage cancers. The effectiveness of Oncobox's technology is backed by both prospective and retrospective studies. This approach has shown remarkable success, leading to a twofold decrease in disease progression and a significant increase in progression-free survival (PFS). Oncobox's innovative use of deep molecular profiling is setting new standards in the precision and efficacy of cancer treatment.

ONCOCROSS Co., Ltd.

ONCOCROSS Co., Ltd.

15F, Gongdeok B/D, 11,, Mapo-gu, Seoul Teugbyeolsi, KR, 04168

We are an AI biotech specializing in drug development based on transcriptomic database. We strive to develop treatments for intractable and rare disease both in oncology and non-oncology space. We partner with pharmaceutical companies and i) identify the optimal indications of NCE under development, ii) identify the proper indications for clinical stage failed compounds, iii) screen combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) identifying the primary site for carcinoma of unknown primary. While our AI technology offers platform to minimize cost, time, and risk of clinical failure for drug candidates, our desire to provide alternative cost competitive treatments for patients with rare and intractable disease are embedded in everyone at ONCOCROSS. Accelerate Drug Development with ONCOCROSS.

Oncodesign Precision Medicine

Oncodesign Precision Medicine

Dijon, France

OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com

OncoHost

OncoHost

Binyamina, Israel

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

One Biosciences

One Biosciences

Paris, France

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences.

OneCell Diagnostics Inc.

OneCell Diagnostics Inc.

209, B Wing, GO Square,, Aundh-Hinjewadi Road, Wakad, Pune , Maharashtra 411057, IN

OneCell Diagnostics, Inc. is a Precision Oncology Liquid Biopsy Diagnostics Company focused on developing the 1st-in-Class, Circulating Tumor Cell (CTC)-based, Single-Cell Multi-omics Lab Developed Tests for applications in clinical cancer care & early-stage clinical trials for Biotech/Pharma companies. ​ OneCell Diagnostics, Inc. is a joint venture between two companies with innovative technologies: Actorius Innovations and Research Pvt Ltd, a leading provider of CTC Tests in India, and Indx.ai, a Silicon Valley based innovative software company specialising in Multi-omics Biomarker Data Analytics.

Onena Medicines

Onena Medicines

Basel, Switzerland

Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.

Ophiomics

Ophiomics

Lisboa, Portugal

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

Optalysys

Optalysys

Wakefield, United Kingdom

🔒 Enabling a world of secure computing. Harnessing the power of light, we push the boundaries of what is possible in data security by bringing speed to always-encrypted data technology. Through optical computing, we accelerate Fully Homomorphic Encryption (FHE) beyond the capabilities of electrical computing, making secure data sharing and collaboration a reality for everyone, everywhere. To find out more, visit www.optalysys.com ✅ Join our unique community hub, the Innovation Lab, to develop your FHE skills with expert training, market insights, exclusive content and events. https://optalysys.com/register-for-innovation-lab/ 🔗 We are committed to building a home for exceptional talent. Keep an eye on our job vacancies https://optalysys.com/careers/ if you're interested in joining the team.

Optibrium

Optibrium

Cambridge, United Kingdom

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

Optithera

Optithera

Montreal, Canada

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

OptraHealth

OptraHealth

San Jose, California, United States

OptraHEALTH® is at the forefront of healthcare innovation, leveraging cutting-edge Artificial Intelligence to transform patient care and streamline operations for providers and payors alike. At the heart of this revolution is our flagship AI platform, HealthFAX™. HealthFAX™ isn't just another healthcare tool—it's a comprehensive AI ecosystem designed to redefine the entire patient journey. From the moment a patient considers seeking care to long after their visit, HealthFAX™ is there, invisibly orchestrating a seamless, efficient, and patient-centric experience. Imagine a healthcare world where: * Digital front doors welcome patients with personalized, AI-driven guidance * Intake processes are streamlined, reducing wait times and frustration * Intelligent triage ensures patients receive the right care at the right time * Accurate cost estimates eliminate billing surprises * AI-powered patient counseling provides round-the-clock support * Insurance information is clarified with ease, reducing administrative burdens But HealthFAX™ doesn't stop there. Post-visit, our AI continues to work tirelessly: * Automating report analysis for faster, more accurate diagnoses * Managing follow-ups to ensure no patient falls through the cracks * Providing actionable insights to continuously improve care quality In the age of value-based care and the No Surprises Act, HealthFAX™ is more than a technological advancement—it's a strategic imperative. By automating complex processes, ensuring regulatory compliance, and enhancing communication at every touchpoint, HealthFAX™ allows healthcare organizations to focus on what truly matters: delivering exceptional patient care. Join the AI-driven healthcare revolution with OptraHEALTH®. Together, we're not just improving healthcare—we're reimagining it.

OptraSCAN

OptraSCAN

100 Century Ct., San Jose, CA 95112, US

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

Ora Biomedical

Ora Biomedical

Seattle, Washington, United States

Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

Orakl Oncology

Orakl Oncology

1, Parvis Notre-Dame, Hotel-Dieu, Paris, Île-de-France 75004, FR

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

OrbiMed

OrbiMed

New York,, New York, United States

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed's team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Orbis Medicine

Orbis Medicine

Route de la Corniche 6, 1066 Epalinges, Switzerland

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo. The company is focused on macrocycle drugs, described as a family of compounds with a platform to discover, develop.

Orbital Therapeutics

Orbital Therapeutics

Cambridge, Massachusetts, United States

Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans.

Ordaos Bio

Ordaos Bio

New York, New York, United States

Ordaos is a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins. Their mission is to help biopharma partners deliver life-saving treatments by creating bespoke mini-proteins to aid drug hunters.

Origenis

Origenis

Bavaria, Germany

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

Orthogonal

Orthogonal

222 West Merchandise Mart Plaza, Suite 1230, Chicago, IL 60654, US

Orthogonal is a product development and consulting firm that creates software for medical hardware such as smartphone apps talking to devices that operate directly on the human body to treat sickness and injury. Our solutions take on some of the toughest healthcare problems facing our loved ones, healthcare system, and society. Working at Orthogonal, you will immediately be exposed to projects designed to: •Revolutionize the rapid detection of COVID-19 and other infectious diseases. •Improve the minute-by-minute lives of millions of people suffering from the lifetime affliction of diabetes by managing the delivery of insulin. •Transform the early diagnosis of Alzheimer's disease. •Give patients an at-home means to stimulate specific nerves to treat chronic conditions that drag down their quality of everyday life. •Power the next generation of omics-based cancer-detection systems. Specifically, Orthogonal develops Software as a Medical Device (SaMD), digital therapeutics (DTx), and other types of connected medical devices. We accelerate the product innovation pipeline at medical device, diagnostics, and pharmaceutical manufacturers to modernize patient care and gain competitive advantage. Orthogonal's industry-leading experience with SaMD enables us to rapidly develop, launch, and continuously improve connected, compliant products – and we offer this innovative approach to clients, so they can build their own SaMD product development workflows. Over the last decade, we've worked with partners ranging from startups to Fortune 500 firms to develop and bring their connected devices to market in a highly regulated space.

Orthogon Therapeutics

Orthogon Therapeutics

Canton, Massachusetts, United States

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

Otologic Technologies

Otologic Technologies

887 North High Point Road, Madison, Wisconsin, USA, 53717

Health tech startup developing artificial intelligence tools for ear exams.

Otraces

Otraces

Sykesville, Maryland, United States

OTraces has developed a blood-based disease testing platform that uses math- and physics-based noise suppression techniques never before employed in human disease testing, and has thereby achieved 90%+ accuracy in the detection of cancer tumors as measured by predictive power.

Outpace Bio

Outpace Bio

Seattle, Washington, United States

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Overjet

Overjet

Boston, Massachusetts, United States

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

Ovizio Imaging Systems

Ovizio Imaging Systems

Brussels, BE

Ovizio Imaging Systems, founded in 2009, is a Belgian company that provides the bioprocessing industry with a unique PAT for gathering insight into their cell culture process. The Ovizio platform utilizes label-free, non-destructive, holographic microscopy to detect changes in cell morphology, which is recorded by the microscope and interpreted by AI into meaningful data. The bio-connect, a single-use disposable, allows for closed-loop travel of the cells between the bioreactor and the instrument for analysis. Some applications of interest include cell density and viability metrics, cell counting of cells on microcarriers, transduction or transfection efficiency, cell subtype differentiation, cell activation, and early stage bacterial or fungi contamination. Ovizio’s flagship instrument, the iLineF Pro, is GMP qualified and is commonly used in the cell & gene therapy industry where it is deployed in manufacturing, as well as process development.

Owkin

Owkin

New York, New York, United States

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Owl Therapeutics

Owl Therapeutics

san antonio, texas, united states

Owl Therapeutics, a spin-out of Gryphon Bio, is a clinical-stage biopharmaceutical company created to develop best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health. The company has rapidly built a promising, diversified pipeline of small and large molecule medicines poised to address the highly unmet needs of patients with neurodegenerative disease. Owl is led by a proven, cohesive, interdisciplinary, and internationally recognized team with deep scientific, clinical, and business experience in drug development and commercialization.

Oxford Cancer Analytics

Oxford Cancer Analytics

Oxford, England, United Kingdom

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Oxford Drug Design

Oxford Drug Design

Oxford, United Kingdom

Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action.

Oxitone Medical

Oxitone Medical

Kfar Saba, Israel

Oxitone is a leading wearables and digital health company helping providers deliver continuous remote care for people with severe chronic and complex conditions and ensure the best clinical outcomes. MAXIMIZE VALUE AT LOW COST The top 5% of people with severe chronic conditions account for 50% of care spending. Practicing fragmented care doesn't deliver help in time. Oxitone generates continuous remote measurements of multiple physiological parameters and their derivatives, so any critical deviations could be flagged and notified in a timely manner. Oxitone continuous monitoring solution helps to maximize care for patients while significantly reduce cost. VitalsTone™ AI-POWERED ANALYTICS ENGINE At the core of Oxitone is the VitalsTone™ exceptionally accurate personalized data analytics engine integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. It passively collects and analyses multiple critical physiological parameters and their derivatives (hospital-grade) in real time and guides personalized therapeutic decision-making ULNAR BONE FlexSense™ CONTINUOUS MONITORING TECHNOLOGY Oxitone 1000M is the first FDA-cleared wrist medical monitor that works without a bulky fingertip probe. Oxitone's elastics sensors gently embrace wrist ulnar bone, do not affect local blood flow and provide superior accuracy, comfort and monitoring continuity. The technology was intensively validated through FDA clearance and numerous clinical applications. Oxitone is spotlighted on The New York Times, MobiHealthNews, MedCityNews, and Digital Health Global 100. Won awards from Cleveland Clinic, NODE.Health, Tech Tour, and Hello Tomorrow. Oxitone was a part of StartUp Health and TEDMED Hive 2014.

Ozette Technologies

Ozette Technologies

Seattle, Washington, United States

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

Pacific Northwest National Laboratory

Pacific Northwest National Laboratory

Richland, Washington, US

Pacific Northwest National Laboratory advances the frontiers of knowledge, taking on some of the world’s greatest science and technology challenges. PNNL is a U.S. Department of Energy national lab with distinctive strengths in chemistry, Earth sciences, biology, and data science that are central to our scientific discovery mission. PNNL’s research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in its fundamental research and with industry to transition technologies to market.

Paige

Paige

New York, New York, United States

Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists' workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options. Learn more about Paige: https://www.paige.ai

Palisade Bio

Palisade Bio

Carlsbad, CA, United States

Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.

Panacea Technology Co.,Ltd.

Panacea Technology Co.,Ltd.

901, Block B, Building G3, Hefei Innovation Industrial Park, Shushan District, Hefei City, Anhui Province

About Us As a contract research organization (CRO) in pharmaceutical R&D and clinical studies, Panacro Pharmaceutical Technology Co., Ltd. is committed to providing overall solutions for clinical studies & IND and NDA of chemical & biological drugs and vaccines. Since its establishment in 2004, Panacro has provided professional technical services to hundreds of customers at home and abroad in 20+ major therapeutic fields. In addition, it established offices in 20 major provinces or cities in China. With complete and detailed standard operating procedures (SOPs), and a professional team operating in accordance with international standards (ICH-GCP), it has built close cooperation with 80% study sites in China. Panacro focuses on providing customers with quality and efficient professional services, in order to shorten the product marketing cycle, and facilitate the product marketization. By virtue of a professional technical team and an operation team operating in strict accordance with relevant standards, as well as professional and efficient quality service, we provide customers with highly customized solutions in a rigorous and pragmatic way based on the principle of sincere cooperation and honest operation.

PanGenomic Health

PanGenomic Health

Vancouver, Canada

PanGenomic is a healthtech company on a mission to offer effective and accessible tools that transform the status quo in the world of mental and physical health. With a special focus on alternative and holistic care, brands like NARA, Mindleap, and MUJN are filling gaps left by conventional practices — and offering natural solutions that are safe, accessible, and backed by the latest science. By leveraging proprietary AI, and the latest tech, the PanGenomic family of products is poised to transform the experience of individuals, practitioners, teams, and the communities that surround them. PanGenomic Health is one of Canada's first public benefit corporations.

Panome Bio

Panome Bio

4340 duncan avenue, st. louis, missouri, united states

Panome Bio can help you profile and discover biomarkers with our Next-Generation Metabolomics capabilities, comprehensive workflows and personalized data analysis reports. Our Next-Generation Metabolomics platform is making major advancements in the metabolism field by going beyond pairwise comparisons and making complex experiments with large and complicated datasets possible. Cutting-edge technology and computational methods are used to extract only the biologically-relevant chemical compounds to give you a clearer view of phenotype. We provide a global and unbiased view of the metabolome through a suite of complementary LC/MS assays that captures the breadth of diverse metabolites in biological systems. We have the ability to complement your metabolomics data with proteomics to better understand pathways and metabolism through our partnership with Somalogic. Somalogic's SomaScan® 7K Assay is a high-throughput proteomics assay that screens 7,000 proteins per sample simultaneously.

Panorama Medicine

Panorama Medicine

3675 Market St, 7th Floor, Philadelphia, Pennsylvania 19104, US

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

Parabricks (Nvidia)

Parabricks (Nvidia)

Ann Arbor, Michigan, United States

Since its founding in 1993, NVIDIA (NASDAQ: NVDA) has been a pioneer in accelerated computing. The company’s invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined computer graphics, ignited the era of modern AI and is fueling the creation of the metaverse. NVIDIA is now a full-stack computing company with data-center-scale offerings that are reshaping industry.

Paradigm

Paradigm

New York, New York, United States

Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.

Paradromics

Paradromics

Austin, Texas, United States

CONNECTING THE HUMAN BRAIN What if we could restore or enhance function using the power of AI and advanced technology? Our direct data interface enables this connection. MISSION We are building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. Our first clinical application will help severely motor-impaired people communicate, enabling social connection and restoring independence. ABOUT Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.

Paragon 28

Paragon 28

14445 Grasslands Dr, Englewood, Colorado 80112, US

Paragon 28 was established in 2010 as an orthopedic foot and ankle company. The name "Paragon 28" was chosen to show that we are exclusively a foot and ankle company, with the "28" representing the number of bones in the foot. We will remain true to that vision. Paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. Our mission is to strategically build a company around the core principles that drive innovation and quality. Relentlessly working to advance the science behind foot and ankle surgery, Paragon 28 is passionate about and committed to: - Creation and Innovation: Blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - A Focus on Service: A customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - Efficient Practices: Meeting the needs of increasing pricing pressures and reimbursement while continuing to develop cutting-edge surgical implants. - Practical and Comprehensive Solutions: Creating complete surgeon-centric systems, specialty instruments, and next generation implants to solve real world issues faced by foot and ankle surgeons. - Research Motivated: Improving clinical outcomes through meaningful and unbiased research. We are ready to embrace research data regardless of marketing impact. Motivation, competition and the desire to learn are unique characteristics that are incredibly valuable to our success. Paragon 28's work environment is modern and exciting. We are seeking experienced and energetic individuals to join our team in areas of Quality, Engineering, Marketing, Sales, Administration and Accounting.

Parallel Bio

Parallel Bio

Los Angeles, California, United States

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.

Parallel Health

Parallel Health

San Francisco, California, United States

Parallel is a next-generation skin health company providing effective, targeted solutions powered by microbiome science, genomics, and machine learning. At Parallel, everything we do is grounded in science and innovation. We believe that the future is precision medicine and we believe that what we’re building is vital to that vision. Here, consumers and patients can access best-in-class expertise and clinical guidance, a personalized genomic assessment to understand their skin microbiome, as well as personalized, targeted microbiome skincare products and prescriptions (if needed). With one of the largest data sets in the world on the skin microbiome, a 10,000-deep bacterial library, and patents pending, Parallel was just honored by Fast Company as a "World Changing Idea."

Pathos AI

Pathos AI

Chicago, Illinois, United States

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Pattern BioSciences

Pattern BioSciences

Austin, Texas, United States

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

Pattern Computer

Pattern Computer

Friday Harbor, Washington, United States

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major pattern discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. Highlights: • Innovative / Proprietary Technology • Pattern Discovery Engine™ discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Pattern produces exceptionally valuable assets within some of the most fiercely competitive domains … and commercializes them • Multiple high-growth markets: immediate focus most daunting yet immediate promise for life-changing & life-saving contributions to society including: • Life Sciences • XAI • Commercial Journey along with us as we move from creating our high-value assets to capitalization/commercialization of them- taking AI by storm with our focus on Third Wave AI.

Pepticom Ltd.

Pepticom Ltd.

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem, Israel 9139002 , IL

Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom's disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being. Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.

Peptilogics

Peptilogics

Pittsburgh, Pennsylvania, United States

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

Pera Labs

Pera Labs

3675 Market St, 200, Philadelphia, Pennsylvania 19104, US

At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg cells all the way to newborn screening, our innovative platform technology can provide more efficient and affordable fertility treatment strategies. We are looking for investors, distribution and implementation partners. Join us for making fertility journey affordable and efficient.

PERCAYAI

PERCAYAI

saint louis, missouri, united states

We're PercayAI, an AI venture providing fundamentally different augmented intelligence software across a variety of healthcare applications, including a variety of healthcare applications, including life sciences, drug discovery, payment integrity, and medical claims. Founded in 2019, PercayAI is made up of an interdisciplinary team with expertise across life sciences, technology and enterprise business who think differently about technology and its impact on our life.

Perceptive Inc.

Perceptive Inc.

58 Grosvenor Street, London, W1K 3JB, GB

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.

Perimeter Medical Imaging AI

Perimeter Medical Imaging AI

8585 N Stemmons Fwy, 106N, Dallas, Texas 75247, US

Perimeter Medical Imaging AI is a pioneering medical technology company driven to transform cancer surgery with advanced imaging tools. We can't imagine how frustrating it is for surgeons to do everything they can and still have to make the "dreaded call" to the patient. That's why we developed our OCT technology that provides 10x the resolution of X-ray and ultrasound at 2mm imaging depth for real-time insight, so surgeons can act in the moment with greater certainty. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further our mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Persephone Biosciences

Persephone Biosciences

3210 Merryfield Row, San Diego, California 92121, US

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

PhageLab

PhageLab

Vicuña Mackenna 4860, Santiago, Chile

We are PhageLab, a global biotech company with over 10 years of experience partnering with poultry and livestock producers to develop tailor-made antibacterial solutions. We target and eliminate specific bacterial pathogens through an AI-powered streamlined sample protocol. We ensure long-term farm health by providing fast, precise diagnosis and solution development. Backed by one of the largest global bacteriophage repositories and unmatched data-gathering capabilities, we stand at the forefront of science and technology, committed to the principles of One Health. Our HQ is in Santiago, Chile. We also have offices in Brazil and Spain. #ScienceWorks PhageLab® is registered as a trademark in Chile, Brazil, Peru, Mexico, Europe, the United Kingdom, Argentina and the United States. Copyright © 2010 - 2024, PhageLab Chile SpA or its affiliates. All rights reserved for its own use.

Phantom Neuro

Phantom Neuro

Austin, Texas, United States

Phantom Neuro is creating the first minimally invasive peripheral neural interface, the Phantom X. Our technology allows complex electronic systems, like prosthetic limbs, to operate like natural extensions of the human body. We are a group of forward thinking individuals on a mission to help people with function-limiting injuries.

PHARMA Inventor

PHARMA Inventor

Vancouver, Canada

Pharma Inventor Inc. is a Canadian Chemistry R&D and Analytical Services company established to serve the needs of pharmaceutical, biotech and agrochemical industries as well as research institutes/academic research groups in North America to support their innovative R&D/Analytical testing activities. Reach out to us for Custom Organic Synthesis / Medicinal Chemistry / Analytical Services / Process Chemistry Works / IP Consultation.

Pharmanest

Pharmanest

Princeton, New Jersey, United States

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

PharmCADD

PharmCADD

17, APEC-ro, U-dong, Haeundae-gu, 221, 222 Ho, Busan, 48060, KR

PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.

Pharos iBio

Pharos iBio

south korea

PhaseV

PhaseV

Boston, Massachusetts, United States

PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.

Phenaros Pharmaceuticals

Phenaros Pharmaceuticals

uppsala, uppsala county, sweden

Phenaros is a spin-off drug discovery company from Uppsala University. We use phenomics (large scale cell morphological profiling) combined with automation and governed by AI for the discovery of new and repurposing drugs for rare diseases. Apart from pursuing an in-house drug discovery pipeline, we also establish partnerships where we provide access to our discovery platform. We are an AI-first drug discovery company. This means that AI is central to everything we do, and that wet-lab experiments are carried out to support the models and confirm hypotheses. Human diseases are complex, and AI can accelerate our understanding of complex biology and bridge over to drug discovery. But AI depends fundamentally on access to sufficient but also high-quality data. In Phenaros, we automate the collection of data and treat it as a central asset that we continuously expand, and our AI learns. This leads to faster, safer, and more efficient drug discovery.

Phenome Health

Phenome Health

Seattle, Washington, United States

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

Phenomic AI

Phenomic AI

Toronto, Ontario, Canada

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.

Phenomics Health

Phenomics Health

Ann Arbor, Michigan, United States

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

Phenomix Sciences

Phenomix Sciences

1000 Westgate Dr. 1003

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

Phesi

Phesi

East Lyme, Connecticut, United States

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools to help trial sponsors make quick and informed decisions to expedite drug development. Our distinguished team works side-by-side with its clients to analyze data, answer questions, and offer informed solutions to benefit study sponsors, investigators, and ultimately patients. Phesi has been applying its innovative technology and deep expertise to help life sciences companies for over 10 years. Our experts work with study sponsors to drive solutions from clinical development planning through trial implementation to optimize protocol designs, select the best investigator sites, shorten enrollment cycle times, select and manage CROs, and much more.

Phio Pharmaceuticals

Phio Pharmaceuticals

Marlborough, Massachusetts, United States

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology

PhiTech Bioinformatics

PhiTech Bioinformatics

Kocaeli, Gebze

PhiTech Bioinformatics translates genome-wide molecular data (Genomics, Transcriptomics, Epigenomics, Microbiomics, etc.) into biotechnology solutions primarily for use in precision medicine. We are moving beyond genomics by applying cutting-edge algorithms to extract information critical for diagnostic decision making. We are currently focusing on development of RNA-based diagnostics. Follow us on Twitter @PhiTech_Bioinfo

PhoreMost

PhoreMost

Cambridge, Cambridgeshire, United Kingdom

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Photocure

Photocure

Oslo, Norway

About Photocure Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com On this account Photocure posts about uro-oncology and company activity. All information presented on this account is for informational purposes only and is not intended as a substitute for informed medical advice or recommendations from healthcare professionals. Please consult a healthcare professional for more information about your condition and medicinal products.

Photon Biosciences

Photon Biosciences

Spokane, Washington, United States

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

PhotoSound Technologies

PhotoSound Technologies

Houston, Texas, United States

PhotoSound Technologies, Inc. was founded in September 2015 in Houston, Texas USA to develop and commercialize new biomedical imaging technologies based on optics and photoacoustics. Photoacoustic tomography (PAT) is a biomedical imaging modality combining the molecular sensitivity of optical probes with the spatial resolution of ultrasound that is ideal for a multitude of applications that can be used for pre-clinical research.

Phylex Biosciences

Phylex Biosciences

Del Mar,USA

Neutralizing Antibody Discovery

Phythera Therapeutics

Phythera Therapeutics

San Leandro, California, United States

Phythera Therapeutics, Inc. was started to test, develop and improve promising small molecule-based drugs for oncology and inflammation markets. Many small bioactive phyto-molecules used in biomedicine have been derived from plants (hence –Phythera Therapeutics). The cocktail of drugs is expected to be better than one molecule for managing complex diseases with no available treatments. The only medicine which can manage HIV is a cocktail of drugs. We have something of the same magnitude but for oncology, which is viewed as “one drug- one IND” by US FDA. We see the potential of drugs carrying many small bioactive molecules to substantially improve the treatment of cancer, either as an auxiliary or even as the main treatment method. The same is true for inflammation. Optimizing and improving these small molecules to maximize their efficacy to combat metastatic cancers, and converting them into potent and robust treatments of untreatable conditions like metastatic cancer and persistent inflammation is Phythera’s main overarching goal. We leverage our expertise in 3D cell biology and transcriptomics to test the small molecule compounds to define and improve their efficacy in 3D tissue model systems, either as a single compound or as a combination of several most potent small molecule drugs. The team’s proven deep expertise in stem cell biology enables us to study the impact of our candidate molecules on the most elusive and most malignant cancer stem cells and develop drug combinations, optimized for a specific disease. Last but not least, our team has a strong interest in regenerative medicine approaches for inducing tissue regeneration and improving tissue homeostasis, the key to wellness and enduring health. Small molecule compounds derived from plants possess many of the properties promoting tissue regeneration and modulating homeostasis in tissue. Enhancing these properties and converting them into new treatments is Phythera’s 2nd overarching goal.

Piccolo Medical

Piccolo Medical

218 Mississippi St, San Francisco, California 94107, US

Solving unmet needs in vascular access care

PinkDx

PinkDx

2001 Junipero Serra Blvd, Daly City, California 94014, US

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

PINS Medical

PINS Medical

Building 19, No.79, Shuangying West Road, Zhongguancun Changping Science Park, Changping District, Beijing, 102200, CN

Founded in 2008, Beijing PINS Medical Co., Ltd., is an innovative medical company specializing in R&D, production, and sales of full-range neuromodulation products, including stimulators for deep brain, vagus nerve, spinal cord, and sacral nerve. PINS Medical devotes itself to providing cutting-edge treatments for patients who suffer from neurological disorders such as Parkinson's disease, epilepsy, chronic pain, and uroclepsia. The name of PINS is derived from "Programmable Implanted Neuromodulation Stimulator" and is also an acronym of "patient is no. 1, always." This speaks to the goals of PINS Medical, which are to enhance patient well-being and restore hope, with a focus that goes beyond business to improving society for all citizens. As the incidence of neuropsychiatric disorders continues to rise, placing an increased burden on societies worldwide, PINS Medical, together with research centers, companies, and top academic scientists, will continue to develop the latest cutting-edge therapies and bring them to patients as rapidly and affordably as possible.

Piramidal

Piramidal

San Fransisco, United States

2024 marks 100 years since Hans Berger made the first EEG recording of the brain. Despite a century having passed, we still do not fully understand what brainwaves are telling us. From diagnostics to wellbeing, we are building technology that bridges the gap between research and real-world EEG applications. Foundation Model for the Brain.

PLAIO

PLAIO

Bjargargötu 1, Reykjavík, 102, IS

PLAIO is a revolutionary visual planning tool for the pharmaceutical industry. The PLAIO platform uses prediction and artificial intelligence to assist planners and supply managers optimise future manufacturing needs.

Polares Medical

Polares Medical

1070 E Meadow Circle, Palo Alto, California 94303, US

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Polaris Genomics

Polaris Genomics

Gaithersburg, Maryland

The scope of experience of Polaris’s executive team spans nine decades & several fields, including military service, medicine, & federal research & development. These experiences have allowed the team to cultivate timely knowledge of pandemic-era mental health needs, & develop deeply unique qualifications to address these needs. The team has garnered numerous awards, ranks, titles, & accomplishments, ranging from captain to engineer, Purple Heart recipient to medical doctor, virologist & immunologist, 9/11 responder to Iraq War veteran, & PhD to Homeland Security Public Health Officer amid the threats of SARS & anthrax. In 2017, inspired by their work at the Defense & Veterans Brain Injury Center & the US Department of Veterans Affairs, a veteran & a scientist coalesced their visions seeded in service around the urgent need for 21st-century innovation in behavioral healthcare. Drawing upon decades of experience in biomedical technology, public health, & molecular biology, they founded a company to take aim at the mental health crisis that results in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018. As a veteran-owned business, our roots remain in our founding mission to improve the lives of US military service members & veterans living with behavioral health conditions, such as post-traumatic stress disorder (PTSD). In 2020, global public health events & an evolving behavioral health landscape revealed that the number of people standing to benefit from advances in diagnostics & treatment is broadening by the day. Guided by a calling to serve, we expanded our mission to encompass: - Veterans & active-duty US military service members, - First responders, frontline workers, & individuals in high-risk occupations, & - Trauma-exposed communities at large.

Polybiomics

Polybiomics

Oakland, California, United States

Polybiomics is a biotechnology company that revolutionizes the analysis of live cells by enabling simultaneous measurements of multiple cellular features from the same sample in real-time, connecting data types to create actionable knowledge.

Poolbeg Pharma

Poolbeg Pharma

London

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

PopVax

PopVax

hyderabad, telangana, india

PopVax is an Indian biotechnology company based in Hyderabad building a novel thermostable, low-cost, and safe second-generation mRNA platform for rationally-designed broadly-protective multi-epitope vaccines. We're starting with an open-source 4-8 °C refrigerator-stable booster candidate that is intended to protect against the entire sarbecovirus sub-family, including current and future strains of SARS-CoV-2 (the virus which causes COVID-19), and some other beta-coronaviruses such as MERS-CoV. PopVax's work has been funded primarily via collaboration with the Bill & Melinda Gates Foundation (India) and Vitalik Buterin's Balvi. Our India-based team of 30 researchers and senior manufacturing leaders includes experts in antigen design, mRNA sequence optimization and synthesis, and nucleic acid delivery from top Indian and North American research institutions, including CCMB, CDFD, IIT Delhi, IAVI, Harvard, Scripps, and UBC, as well as vaccine & biologics production veterans from companies including Sanofi, Biocon, Panacea Biotec and Biological E. The smaller scientific team for our US-based subsidiary, PopVax North America, is led by Moderna's first Director of Chemistry, and includes several leading practitioners of de novo computationally-driven rational protein design for novel vaccine immunogens.

Praedicare Inc

Praedicare Inc

14830 Venture Drive, Dallas, TX 75234, US

Praedicare Inc. is a System of Systems based end-to-end drug development company [from drug discovery to phase IV trials] that uses preclinical wet lab models mathematically mapped to patients for quantitative prediction of clinical trial outcomes, significantly reducing clients' risk, time, and costs of developing safe and effective new drugs. Praedicare is headquartered in Dallas, Texas, but has international offices and has clients from around the globe.

Praesidia Biotherapeutics

Praesidia Biotherapeutics

1167 Massachusetts Avenue

Praesidia Biotherapeutics is built with the vision of being a patient focused and clinician driven drug development company championing unmet clinical needs. Praesidia's proprietary first in class Tunable Linker Technology is revolutionizing the ways to maximize.

Pramana

Pramana

Cambridge, Massachusetts, United States

Pramana, Inc., is a health technology company reimagining digital pathology through its autonomous AI-enabled whole-slide imaging solutions. Built upon extensive industry experience and patented technological innovation, Pramana enables pathologists and physicians to accelerate precise diagnosis with reduced manual intervention, minimizing human errors and improving operational efficiency. Pramana is headquartered in Cambridge, Mass., with R&D and manufacturing sites in Bangalore, India; Rochester, Minn.; and Toronto, Canada.

Prantae Solutions

Prantae Solutions

Zone B, Sector A, S-3/35, Mancheswar Industrial Estate, Bhubaneswar, Odisha, India

Prantae is the vision of what lies beyond the boundaries of human imagination. It is a leap-of-faith into 'tomorrow of connected technologies' that empowers each one of the human kind to take control his own health and well-being. It is the canvas of every creative scientist, engineer and doctor who desire to change the face of humanity for better wherever in the galaxy humans ever venture to

Precede Biosciences

Precede Biosciences

1 Design Center Place, Boston, Massachusetts, USA, 02210

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we're working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.

PreciseDx

PreciseDx

Mount Sinai, PreciseDX, 1 Gustave L Levy Place, New York, NY 10029, US

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PrecisionLife

PrecisionLife

Cambridge, Massachusetts, United States

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Precision Neuroscience

Precision Neuroscience

Manhattan, New York, United States

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data.

Precision Therapeutics(Predictive Oncology)

Precision Therapeutics(Predictive Oncology)

Eagan, Minnesota, United States

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

PreComb

PreComb

Garstligweg 8, Hombrechtikon, Zurich 8634, CH

PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It's automated microtumor-based 3DTwin™ technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome.

Predicine

Predicine

Hayward, California, United States

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.

Predicta Biosciences

Predicta Biosciences

Boston, MA

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

Predictive Oncology

Predictive Oncology

Pittsburgh, Pennsylvania

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

PredxBio

PredxBio

100 S Jackson Ave, Pittsburgh, Pennsylvania 15202, US

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

Prellis Biologics

Prellis Biologics

San Francisco Bay Area, California, United States

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.

Prenosis

Prenosis

Chicago, Illinois, United States

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

Prevencio

Prevencio

Kirkland, Washington, United States

Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.   Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com

Prime Discoveries

Prime Discoveries

New York, New York, United States

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Prime leverages multiple patented advanced technologies in microbial diagnostics including RT-LAMP, Rapid PCR, and mNGS (Next generation sequencing) to enable samples to result in under 1 hour with minimal lab infrastructure and technical expertise. Prime's products are best in class for Covid, Influenza, Sexually Transmitted Infections and new drug resistant microbes. All of Prime's assays are locally developed in the United States and can serve millions of people. Founded in NYC in 2017, Prime's scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and Esther Dyson. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar, BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others.

Proactive Diagnostics

Proactive Diagnostics

Carlsbad, California, United States

Harnessing the Power of Cytokine Monitoring and Host-Response Understanding to Transform Healthcare Cytokines, pivotal biomarkers of inflammation, are essential in tracking the progression of infections, helping physicians tailor more effective treatments. Annually, over 10 million patients in the U.S. are diagnosed with infections, and the post-COVID-19 era has highlighted the value of cytokine monitoring. However, the current methodologies are costly and slow, undermining its potential. Our solution introduces point-of-care cytokine testing that matches central lab accuracy, completed in just 5-10 minutes, and at a significantly lower cost. This enables continuous, real-time monitoring, offering timely, actionable insights to both physicians and patients exactly when needed. Proactive Diagnostics is transforming how infections are assessed and managed, to improve care in several critical areas: - Enhancing clinical outcomes - Minimizing unnecessary antibiotic use - Shortening hospital stays - Reducing patient readmissions Our AI-driven, cloud-connected platform leverages unique data collection capabilities to deepen our understanding of individual host responses to various inflammatory stimuli. Such capabilities can also play a critical role in other important clinical areas such as the treatment of Autoimmune Diseases, where monitoring host response can inform therapy adjustments and drastically improve lives; or in the treatment of Cancer, where Cytokine levels can help optimize the administration of groundbreaking immunotherapies and adjust treatments to harness the immune system's power more effectively against tumor cells. This transformation in cytokine monitoring could be the key to a new era of personalized, predictive, and preventative medicine, where each patient's treatment is as unique as their response to disease.

Profluent Bio

Profluent Bio

Emeryville, CA

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

ProFound Therapeutics

ProFound Therapeutics

Cambridge, Massachusetts, United States

ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Prognos

Prognos

New York, New York, United States

Prognos Health is a real-world data (RWD) company that unlocks the power of data to improve health. Prognos offers the leading managed RWD marketplace, accelerating the development and delivery of innovative therapies and improving health outcomes by offering fully integrated and harmonized lab and health records on more than 325 million de-identified patients. Prognos Health's platform provides a comprehensive and integrated view of patient health, enabling researchers, payers, and providers to make better decisions about care.

Prologue Medicines

Prologue Medicines

55 Cambridge Parkway, Cambridge, MA 02142

Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.

Promaxo

Promaxo

70 Washington Street Suite # 407

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Promise Bio

Promise Bio

Tel Aviv, Israel

Utilizing a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data

Proscia

Proscia

1700 Market St 23rd Floor

Proscia is a software company accelerating pathology's transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and AI-powered computational pathology software are redefining the pathology laboratory and enhancing cancer diagnosis.

Protai

Protai

Tel-Aviv, Israel

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

ProteinLogic

ProteinLogic

Cambridge, United Kingdom

ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning.

ProteinQure

ProteinQure

119 Spadina Ave, 304, Toronto, Ontario M5V 2L1, CA

ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.

Protillion Biosciences

Protillion Biosciences

Burlingame, California, United States

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Prozomix

Prozomix

Northumberland, United Kingdom

Prozomix Limited is an enzyme discovery and manufacturing company located in Haltwhistle, Northumberland, United Kingdom.

Prudentia Sciences

Prudentia Sciences

Cambridge, Massachusetts, United States

Prudentia Sciences, a Cambridge based technology company, is dedicated to accelerating drug pipelines and maximizing return on investment, envisioning a future where healthcare innovations reach their full potential. Prudentia’s platform enables comprehensive due diligence and valuation of drug assets.

PsychoGenics

PsychoGenics

Paramus, New York, United States

PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.

Psyomics

Psyomics

Beech House, 4a Newmarket Road, Cambridge CB5 8DT

At Psyomics, we’re helping people get the mental health support they need, sooner. Led by CEO Dr Melinda Rees, Psyomics aims to revolutionise the way we assess, diagnose, triage, and treat mental health. Cambridge University Biotech spinout turned Healthtech, Psyomics was founded by Professor Sabine Bahn, Laboratory Director at the Cambridge Centre for Neuropsychiatric Research. Following more than six years of research and development, our product — CENSEO — is a digital platform that significantly reduces clinical triage and assessment time through dynamic patient-reported information capture. CENSEO was commercially launched in late 2022 for the assessment and triage of 15+ mental health conditions, used by more than 6,500 patients to date.

PulmoSIM Therapeutics

PulmoSIM Therapeutics

San Francisco, CA 94104, US

PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need of combination therapies. PulmoSIM Therapeutics' pipeline includes 2 drug assets. PT001 is a U.S. Food & Drug Administration designated Orphan Drug and has successfully completed preclinical study. PT001 has demonstrated positive efficacy with key disease-reversal data for the treatment of PAH. The monotherapy differs significantly from current PAH combination therapies by targeting the disease's underlying biology. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to rapidly transition the program to clinical studies. PT002 is undergoing advanced preclinical study for the treatment of IPF. We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform to accelerate our drug development by bridging the translational gap between preclinical and clinical phases. Learn more about BIOiSIM at www.verisimlife.com. Get in touch if you are interested in learning more about our programs and working with us.

PulseMedica

PulseMedica

10235 101st NW, Edmonton, Alberta, CA, T5J 3E8

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure. PulseMedica is a company based out of Edmonton, AB, Canada.

Purdue University

Purdue University

West Lafayette, Indiana, US

Purdue University is an academic institution that offers a wide range of educational services and conducts research.

Q Bio

Q Bio

Redwood City, California, United States

Q uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history.

Qitan Technology

Qitan Technology

T1-3101, Office Building, Raffles City, Chengdu, No. 3, Section 4, Renmin South Road, Wuhou District, Chengdu, Sichuan 610041

Qitan Technology is a developer of genome sequencing technology, specializing in nanopore sequencing. The company has released datasets and publications related to its technology and has made significant technological achievements in the field of genetic code information.

Q-State Biosciences

Q-State Biosciences

Cambridge, Massachusetts, United States

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

QT Imaging Holdings

QT Imaging Holdings

Novato, California, United States

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

Quantori

Quantori

Cambridge, Massachusetts, United States

Quantori is the end-to-end data, technology, and digital services partner of choice for leading biopharma and healthcare organizations across the globe. We develop cutting-edge data and technology systems, applications, and infrastructures for biotech, pharmaceutical, and healthcare companies to accelerate drug discovery and improve patient outcomes. Our innovative approach harnesses the power of data engineering and informatics, machine learning, emerging technologies, and cloud expertise to bridge the gap between meaningful data and patient success, supporting every phase of the drug development process. Quantori also boasts a growing healthcare business that helps organizations optimize volumes of complex data sets to drive data to knowledge, knowledge to actionable insights, and insights to value. Quantori’s data scientists and informaticians understand the nature of data at a granular level, which is required for powering the future of precision medicine. • 20+ Years Serving the Life Science & Healthcare Sectors • Deep Domain Expertise • Over 800 experts including scientists, software engineers, data scientists • Blue-Chip Roster of Biopharma Clients • 1,500+ Digital IT Projects Contact Quantori today to learn how we can help accelerate your innovation pipeline through the power of data and digital IT. Website: www.quantori.com Email: contact@quantori.com Twitter: @Quantori_USA

Quantum Sky Inc

Quantum Sky Inc

750 main st, cambridge, massachusetts, united states

Quibim

Quibim

Valencia, Spain

At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Qure.ai

Qure.ai

6th Floor, Wing E, Times Square, Andheri-Kurla Road, Marol, Andheri (East), Mumbai - 400059, Maharashtra

Qure.ai is a breakthrough Artificial Intelligence (AI) solution provider that is disrupting the radiology 'status quo' by enhancing imaging accuracy and providing AI assistance for Accelerated Healthcare. The company uses deep learning and AI to make healthcare more accessible and equitable for patients. Qure AI also provides automated interpretation of radiology exams and ultrasound scans, and has raised a total funding of $56M over 5 rounds from healthcare investors.

qurebio

qurebio

Shanghai

启愈生物技术(上海)有限公司

Quris AI

Quris AI

Boston, Massachusetts, United States

Quris-AI is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. Quris-AI is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

Qynapse

Qynapse

130 rue de Lourmel, Paris, 75015, FR

Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions. Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.

Rad AI

Rad AI

548 Market St, PMB 49792, San Francisco, California 94104-5401, US

Our mission is to empower physicians with Al - saving physicians time, reducing burnout, and improving the quality of patient care.

Radiomics

Radiomics

Liège, Belgium

Radiomics.bio is a next generation Liege-based imaging research organization built upon the unparallel experience of its founders, pioneers of the radiomics science. Radiomics.bio focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images. Our final goal is to support insight-based decision making for optimizing pharmaceutical and biotech companies' clinical trials and drug development studies and for providing clinicians with a patient-centered approach based on personalized medicine. With this aim, Radiomics.bio's R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.

RADLogics Inc.

RADLogics Inc.

11 Times Square, Floor 37, New York, NY 10036, US

A healthcare software company developing artificial intelligence (AI)-powered solutions, RADLogics provides machine learning image analysis solutions to improve radiologists' productivity while enhancing patient outcomes. Based in New York, NY, US, and Tel Aviv, Israel, RADLogics is one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data from CTs, MRIs, PET scans, and X-rays to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. The company's patented AI medical image analysis platform enables rapid development of AI algorithms, and provides seamless integration into existing radiology workflow.

Raidium

Raidium

paris, île-de-france, france

Build the first Radiological Foundation Model Bring the radiological image to GPT Share the world's top medical expertise through AI Bring the best specialist to every patient/researcher/company

Rakovina Therapeutics

Rakovina Therapeutics

8 Smithe Mews, Vancouver, BC V6B 0A5

Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on a novel series of small-molecule DNA-damage response inhibitors. The company focuses on utilizing Deep Docking™ AI to target DNA-damage response (DDR) for oncology-focused treatments. Their target markets include breast cancer, ovarian cancer, and prostate cancer.

Rancho BioSciences

Rancho BioSciences

San Diego, California, United States

Rancho BioSciences is a fee for service life science company leveraging open source tools and public domain data in Pharma, non-profit foundations and academia.

RapidAI

RapidAI

Menlo Park, California, United States

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI — where AI meets patient care.

Ras Labs

Ras Labs

Quincy, Massachusetts, United States

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

Ravata Solutions

Ravata Solutions

Davis, California, United States

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

RaySearch Laboratories

RaySearch Laboratories

Eugeniavägen 18 C, Stockholm, 113 68, SE

ADVANCING CANCER TREATMENT RaySearch is advancing cancer treatment through pioneering software. Software has unlimited potential, and we believe it is now the driving force for innovation in oncology. Medical science never stands still, and neither does RaySearch. We work in close cooperation with leading cancer centers to bring scientific advancements faster to the clinical world. Today, our solutions support thousands of clinics worldwide in the fight against cancer. And this is just the beginning.

RealSeq Biosciences

RealSeq Biosciences

Santa Cruz, California, United States

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Real Time Genomics

Real Time Genomics

999 Bayhill Drive, Suite 101, San Bruno, CA 94066, US

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

Recursion Pharmaceuticals

Recursion Pharmaceuticals

Salt Lake City, Utah, United States

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Redefine Meat

Redefine Meat

Rehovot, Israel

Here at Redefine Meat, we believe the world deserves better meat – a new kind of meat that's good for the environment, kinder to animals, and of course, delicious. With cutting-edge technology, we've created plant-based ‘New Meat' that has the same flavor, texture, and versatility as animal meat. We offer a wide range of products suitable for any type of cuisine and cooking style.

Redesign Science

Redesign Science

180 Varick St, New York, US

Founded in 2017, Redesign Science is a platform biotech working at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery. We deploy our platform technology to develop first-in-class Protein Interaction Modulators against validated targets known to drive progression of multiple oncogenic and inflammatory diseases.

Reetoo Biotech

Reetoo Biotech

Room 406, Building F, Huafeng International Robot

Reetoo is a leading company for AI-driven IVD equipments in the world with revolutionary and innovative IVD equipments for blood, leucorrhea, sperm, urine, and tissues; All of our products are fully automatic in the whole process based on our AI-driven DeepCell engine,which can greatly improve doctors' efficiency and save a lot of time for doctors and patients.We are looking for distributors globally now,please contact us if you are interesting.

Rejuvenate Biomed

Rejuvenate Biomed

Heusden, Oost-Vlaanderen, Belgium

Rejuvenate Biomed is a clinical-stage company dedicated to the discovery and development of therapeutics to prevent or delay the onset of multiple age-related diseases. Founded in 2017, Rejuvenate Biomed is a privately-held platform and pipeline company developing safe and proprietary combination drugs that help people healthy for life. By using platform technologies, Rejuvenate Biomed identifies safe compounds that influence the aging process. Novel combination drugs are discovered that have the potential to prevent or delay the onset of multiple age-related diseases. Rejuvenate Biomed confirms prediction data in preclinical models and in clinical studies. Rejuvenate Biomed’s lead drug candidate RJx-01 is currently in Phase 1b for the treatment of sarcopenia, the progressive age-associated loss of muscle function and mass.

Relation Therapeutics

Relation Therapeutics

London, United Kingdom

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

Relay Therapeutics

Relay Therapeutics

Cambridge, Massachusetts, United States

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

Remmie

Remmie

Seattle, Washington, United States

Remmie Health is a digital health technology venture that delivers next-generation, AI-enabled, ear-nose-throat care for easier, accessible diagnosis, timely intervention, and exceptional patient care. Remmie is a patient-centric, primary care telemedicine/at-home examination device + API + AI system that enables patients/consumers to receive virtual/hybrid care from healthcare professionals, covering 22+ most commonly occurring respiratory conditions, causing over 120 million annual visits as the leading reason for ambulatory care, impacting every family 2-9 times a year. The winner of the Muse Innovation Fellowship, UCLA Knapp Venture Competition, and Rice Business Plan Competition, Remmie Health is a UnitedHealthcare Accelerator (powered by Techstars) and Plug and Play portfolio company. The company is based in Seattle, WA.

RenaissThera

RenaissThera

Bangalore, Karnataka, India

RenaissThera is a pharmaceutical company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in cardio-metabolic therapy including diabetes type 2 and obesity. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients. With a leadership team and scientific advisory board boasting extensive experience in global pharmaceutical product development, RenaissThera is committed to bringing innovative treatments to those in need around the world.

Renalytix

Renalytix

1460 Broadway, New York, 10036, US

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Reprieve Cardiovascular

Reprieve Cardiovascular

Milford, Massachusetts, United States

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

Resero Analytics

Resero Analytics

West 16th Street, Indianapolis, Indiana, USA, 46077

Resero Analytics creates software and data products to help Pharmaceutical companies, CROs, and Regulators to better manage their Data, to apply Analytics that will extract more value from their data, and to Report it more promptly and more accurately. Our primary focus is on Toxicology and its translation to human drug safety.

Reshape Biotech

Reshape Biotech

Copenhagen, Denmark

Reshape Biotech is building the next generation of lab automation robots. Our customers are biotech companies tackling the world’s biggest problems - be it alternative protein development or sustainable agriculture. Reshape Biotech is the scaling factor for these companies, as we let researchers collaborate globally on experiments and increase their throughput >500x. The team is highly multi-disciplinary, employing everything from PhD’s in biology to hardware and software engineers. We work closely together, and you will be exposed to a truly vertical team. We’re a fast growing startup with an incredibly ambitious team, dead-set on reinventing a 100 year old industry and becoming the standard infrastructure that the world of biotech relies on. Our customers already include global leaders in food, agriculture and biologicals. We’re backed by top tier investors from Y Combinator, CEOs from the industry and some of the biggest names you can find. At Reshape Biotech, you have the potential to influence how biotech research is done in the next 100 years.

Resilience

Resilience

San Diego, California, US

ResMed

ResMed

Poway, California, United States

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Restor3d

Restor3d

4001 E. NC 54 Highway, Suite 3160, Durham, North Carolina 27709, US

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

RetiSpec

RetiSpec

220 joicey blvd, toronto, ontario, canada

RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America. RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.

Revisto

Revisto

San Antonio, Texas, United States

Our mission is to optimize the release cycle, reduce cost, and eliminate compliance risk of releasing promotional materials in the pharmaceutical industry, while improving quality and consistency. ‍ We achieve this by applying deep industry knowledge in cutting-edge technology to automate the compliance requirements and best practices for our customers. We strive not only to uphold the highest standards of accuracy and compliance, but also to enable the generation of data-driven, personalized, and engaging content that results in positive patient outcomes. At the heart of our offerings is our AI-driven platform that learns from regulations, industry best practices, and our customers’ historical actions. Recommendations provided by our platform significantly reduce promotional material release time, and this level of efficiency has already earned us the trust of a Top 5 pharmaceutical company. At Revisto, we believe in transparency and understand that trust is earned through consistent performance and open communication. We are committed to delivering results for our customers and fostering relationships built on mutual respect and shared success.

ReviveMed

ReviveMed

Cambridge, Massachusetts, United States

ReviveMed is an MIT spinout AI-based metabolomics platform for precision medicine in oncology and cardiometabolic disease. Blood metabolites, e.g., glucose and cholesterol, are crucial direct readouts of drug response and have been associated with disease outcomes, yet under-explored, as <5% of them are characterized. Our patented AI platform characterizes 20 times more metabolites than current platforms, pioneering the development of blood-based metabolic tests of drug response and safety. The unprecedented amount of metabolomics data has enabled us, for the first time, to develop pre-trained foundation models for metabolomics to simulate treatment outcomes and pave the way for the future of precision medicine.

RevolKa Ltd.

RevolKa Ltd.

1-9-10 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo, JP

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

Rewire

Rewire

Portland, Oregon, United States

Rewire AI is a computer vision and machine learning company that specializes in biomedical imaging services, offering a cloud-based artificial intelligence inference engine for clinical and research applications.

Ribbon Biolabs

Ribbon Biolabs

Vienna, Austria

Let's write the future of DNA. Ribbon Biolabs is a biotech start-up working on developing the next technological wave of error-proof DNA synthesis. With its approach, company is developing a cost-efficient platform to produce long and complex DNA molecules, thereby enabling a new generation of biopharmaceutical processes and other synthetic biology products. Our international and highly motivated team located in Vienna is constantly looking for new talents who can join this exciting ride and take Ribbon Biolabs to the next level.

Rijk Zwaan

Rijk Zwaan

2678 KX De Lier, Netherlands

Rijk Zwaan develops vegetable varieties and sell the seeds produced from them to growers all over the world.

Rivanna Medical

Rivanna Medical

Charlottesville, Virginia, United States

RIVANNA® is elevating global standards of care through the development and commercialization of world-first imaging-based medical technologies, including BoneVision™ Multi-Probe Multi-Angle Image Acquisition, BoneEnhance® Multi-Frequency Image Reconstruction, and SpineNav3D™ AI-Enabled Spine Recognition. RIVANNA's complete clinician-assistance solutions improve decision-making, workflows, health outcomes, and patient satisfaction. Headquartered in Charlottesville, VA, RIVANNA is privately held and operates an FDA-registered and ISO 13485:2016 certified manufacturing facility. For more information, visit rivannamedical.com.

Rivus Pharmaceuticals

Rivus Pharmaceuticals

Charlottesville, VA

Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF).

RNAimmune

RNAimmune

Gaithersburg, Maryland, United States

At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. We collaborate with the world for the health of everyone.

Rubix LS

Rubix LS

60 Island St, Suite 236, Lawrence, Massachusetts 01840, US

Rubix LS: The Health Outcomes Architect At Rubix LS, we drive innovation in clinical research, drug development, and public health by combining cutting-edge science, real-world data, and inclusive patient engagement. Our work is structured around three core pillars: 🔹 Investigator-Led Research – We conduct our own research and develop targeted solutions to accelerate new therapies and improve health outcomes. 🔹 Clinical Research Services – We collaborate with biotech, pharma, and life sciences companies to manage clinical trials, support regulatory submissions, and enhance patient diversity in research. Our work is powered by 18M patient data sets and 369M patient data points. 🔹 Government & Public Health – We partner with federal agencies and public health organizations to develop policies, improve disease surveillance, and advance health equity through data-driven solutions. Leveraging Environmental & Geographic Insights To better understand health risks and intervention strategies, we integrate: ✅ DoE data to analyze long-term environmental exposures. ✅ USDA data to study the impact of food and nutrition on health. ✅ Heat Sink data to model cancer risk and environmental disease patterns. At Rubix LS, we don't just conduct research—we build pathways to better health by ensuring therapies are developed, tested, and delivered with precision, equity, and impact. 🔗 Learn more at our website.

RUMI Scientific

RUMI Scientific

310 E 67th Street, Suite 127

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

Ryght AI

Ryght AI

Saama

Saama

900 E Hamilton Avenue, Suite 200, Campbell, CA 95008, US

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

Sable Bio

Sable Bio

18 Clarendon Road, London W11 3AB, England, United Kingdom

Prevent target safety failures with unique data insights and cutting-edge approaches. ‍ Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities. Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

Sage Bionetworks

Sage Bionetworks

Seattle, Washington, United States

Sage Bionetworks is a trusted nonprofit leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. Our mission is to drive a new age of discovery through truly open science and radical collaboration. Better Science Together.

Sail Biomedicines

Sail Biomedicines

Somerville, Massachusetts, US

We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world.

Samsara Vision

Samsara Vision

27 US-202, Suites 8 & 9, Far Hills, New Jersey 07931, US

Samsara Vision, Inc. is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.

Sana Biotechnology

Sana Biotechnology

Seattle, Washington, United States

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

SandboxAQ

SandboxAQ

Tarrytown, New York, United States

SandboxAQ is harnessing the exponential power of AI + Quantum (AQ) technology. The inspiration for SandboxAQ and some of the team originated at Alphabet Inc., becoming an independent entity in 2022. Our mission is to develop commercial products for financial services, healthcare, telecommunications, public sector, and other computationally-intensive industries. Our team's unique approach enables cross-pollination across a diverse range of fields, from physics, computer science, neuroscience, mathematics, cryptography, natural sciences, and more! Our success comes from coalescing diverse talent to create an environment where experimental thinking and collaboration yield breakthrough physics + AI solutions. Join a culture where thought leadership, diverse talent, employee engagement, and technological impact will create the next tech uproar. We are deeply committed to education as a means to advance quantum solutions and computing initiatives. We invest in future talent through internship programs, research papers, developer tools, textbooks, educational talks/events, and partnerships with universities/talent hubs to attract multi-disciplinary talent. Our hope is to inspire people from all walks of life to be prepared for the quantum era and encourage a path in STEM.

Sanford Burnham Prebys Institute

Sanford Burnham Prebys Institute

La Jolla, California, United States

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding basic human biology and disease and advancing scientific discoveries to profoundly impact human health. Our track record of pioneering research spans more than 40 years and has produced breakthroughs in cancer, neuroscience, immunology and children's diseases and is anchored by our NCI-designated Cancer Center. Sanford Burnham Prebys' drug discovery center and global partnerships propel our prototype drugs and therapeutic strategies toward improving human health. A deep culture of collaboration and commitment to educating the next generation of scientists unites Sanford Burnham Prebys researchers, partners and philanthropists in a shared mission to improve human health.

Sanofi

Sanofi

Paris, France

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals

Shanghai, China

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

Sapere Bio, Inc.

Sapere Bio, Inc.

Research Triangle Park, North Carolina 27709, US

Sapere Bio is a longevity technology company. SapereX, a blood-based measure of cellular senescence and immune function, captures fundamental mechanisms of aging. SapereX allows clinicians and scientists to see early aging and monitor how interventions aimed to increase healthspan are working in individual patients. We are changing the way aging is measured and imagined, for longer healthspan and better lives. Sapere Bio was co-founded by Dr. Norman Sharpless, former Director of the NCI, and Dr Natalia Mitin, current CEO of Sapere Bio.

Sapio Sciences

Sapio Sciences

Baltimore, Maryland, United States

Sapio Sciences' mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions. Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.

SaponiQx

SaponiQx

3 Forbes Road, Lexington, MA 02421, US

SaponiQx is a cutting edge bio-pharmaceutical company with a vision of protecting the health of populations worldwide. We seek to enable the development of safe and effective vaccines through the expansion of access to saponin based adjuvants. Contact Us! communications@saponiqx.com

Sapphiros

Sapphiros

Boston, Massachusetts, United States

Sapphiros, backed by Neoenta and KKR, is a privately held consumer diagnostic portfolio company. The Sapphiros portfolio includes novel sample collection, next generation diagnostics, computational biology, and printed electronics to help consumers access important diagnostic results globally. Knowing Now Moves Us™ Knowledge empowers us to navigate through life's choices and decisions. With solutions that provide real-time, definitive results; at Sapphiros we work together to help global communities act on these insights with confidence.